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Background
Breast cancer is the most common cancer among women in developed and developing regions. 
Incidence varies from 19.3 per 100,000 women in Eastern Africa to 89.7 per 100,000 women 
in Western Europe.1  Early detection and adjuvant treatment led to decreased mortality rates 
in most western countries since the early 1990s. However, it is still the leading cause of 
cancer mortality in women. This thesis focuses on the genetics of breast cancer and its role 
in targeted therapy. 
Pathology and breast cancer subtypes
Breast cancer is a clinically heterogeneous disease and histopathological factors are used 
to categorize patients with breast cancer in order to assess prognosis and determine the 
appropriate therapy. Morphology, histological grade of the tumor, and the estrogen 
receptor (ER), progesteron receptor (PR), and HER2 (human epidermal receptor 2) status 
are routinely determined. These parameters are assessed by a pathologist using staining 
techniques and light microscopy. Using this approach, tumors that are ER positive and/
or PR positive, and HER2 negative are categorized as luminal A type, those that are ER 
positive and/or PR positive and HER2 negative, with a high Ki-67 staining (cellular marker 
for proliferation) are categorized as luminal B. Ki-67 expression helps to identify cancers in 
the luminal B group more precisely than does knowledge of the ER, PR, and HER2 status 
alone.2  Tumors with HER2 expression are mostly classified separately as the HER2 subtype 
(or ERBB2 subtype). Tumors without expression of ER, PR, and HER2 are categorized as 
triple negative (TN) breast cancer. If the presence of positive markers keratine CK5/6 and 
positive expression of the EGF receptor (EGFR) are added to this panel, the basal like tumors 
can be defined among the TN tumors.3  An even more precise classification of tumors can be 
made based on gene expression profiles and can accurately distinguish the different intrinsic 
subtypes (luminal A/B, HER2, and basal).4 Basal-like breast carcinomas express genes usually 
expressed in normal basal/myoepithelial cells of the breast. In the same way, ‘luminal’ refers 
to the luminal (duct) epithelial cells. The histological grade differentiates well differentiated 
(low grade), moderately differentiated (intermediate grade), and poorly differentiated (high 
grade) breast cancer tissue based on tubule formation, nuclear pleomorphism, and mitotic 
counts. Tumors with basal or HER2 subtype and/or high histological grade have a worse 
prognosis compared to other tumors. With respect to the morphology, three quarter of the 
invasive breast carcinomas are of the ductal type. Infiltrating lobular carcinomas are the second 
most common type of breast cancer (8-10%).5  Examples of other morphology types are 
tubular carcinoma, mucinous carcinoma, medullary carcinoma, and invasive micropapillary 
carcinoma. Micropapillary carcinoma is the most aggressive morphology type and even small 
lesions seem to metastasize to the lymph nodes.5  Beside invasive breast cancer also non-
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invasive precursor lesions in the breast epithelia occur, the so called breast carcinoma in situ. 
Ductal carcinoma in situ (DCIS) is considered a true (non-obligatory) cancer precursor, and 
its treatment is often similar to that for small invasive breast cancer. However, due to a high 
proportion of DCIS found in mammographic screening and low risk of progression, clinical 
trials are currently introduced to evaluate the option of avoiding surgical management. 6 
Lobular carcinoma in situ (LCIS), which is also known as lobular neoplasia, is primarily 
viewed as an indicator of increased breast cancer risk and not as a precursor lesion and patient 
surveillance is advised.7 8 
Staging and treatment of breast cancer 
Most patients with breast cancer have no evidence of metastatic disease. For treatment 
purpose, the disease is classified with the Tumor, Node, Metastases system (TNM system). 
With this system the disease can be divided into early stage, locally advanced breast cancer, 
and metastatic breast cancer (stage IV). In table 1 an overview of the TNM system is given. 
Patients with early stage breast cancer can either undergo breast conserving surgery in 
combination with radiotherapy or a mastectomy, depending on the size of the tumor and the 
breast and the preference of the patients. Twenty-year follow up of a large randomized clinical 
trial showed that breast conserving therapy (including radiotherapy) had similar survival rates 
and incidence of metastases compared to mastectomy (resection of complete breast).9  This 
shows that breast conserving therapy is a good alternative for mastectomy in early stage 
disease. Patients with a clinically negative axillary examination should also undergo a sentinel 
lymph node biopsy (SLNB) at the time of surgery. Patients with three or more pathologically 
involved sentinel nodes benefit from complete axillary node dissection or radiation of the 
axilla region because this reduces the risk of locoregional recurrence and improves survival.10  
Neo-adjuvant chemotherapy (chemotherapy before surgery) is increasingly being used to 
downstage the N1 axillary tumor status after which only adjuvant radiotherapy on the axilla 
is required (and not complete axillary node dissection), resulting in decreased morbidity.11  
Systemic therapy refers to the medical treatment of breast cancer using endocrine therapy, 
chemotherapy, and/or biologic therapy and has the purpose of reducing recurrences. The 
use of systemic therapy is guided by the patient’s clinical status and tumor characteristics. 
In patients with hormone receptor-positive breast cancer adjuvant endocrine therapy may 
be indicated. In addition, patients with HER2-positive breast cancer with an indication for 
adjuvant chemotherapy are also treated with a monthly infusion of trastuzumab (a monoclonal 
antibody directed against HER2) for one year. In the decision making whether or not to start 
adjuvant systemic chemotherapy several factors will be taken into account, such as tumor 
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histology, tumor size, nodal status, expression of estrogen (ER) and/or progesterone (PR) 
receptors, HER2 receptor status, age, comorbidity, and patient’s preferences. If the decision 
on conventional histological data is difficult novel genomic assays such as MammaPrint can 
be used to predict the risk of recurrence.12  Adjuvant chemotherapy gives an 25% relative 
risk reduction of breast cancer related mortality.13  The current advice is to treat patients 
with adjuvant chemotherapy, if the absolute risk reduction is at least 5%, which is the case 
in patients with a 10-years mortality rate of 20% or more. In general, the advice is to give 
adjuvant chemotherapy to patients with stage II/III disease or stage I disease with unfavorable 
prognostic factors like young age, high grade tumor, a negative hormone receptor negative 
status or positive HER2 receptor status of the tumor.14  Neo-adjuvant chemotherapy is used 
in patients with large tumors to improve the opportunity of breast conserving surgery and 
to reduce the need for axillary lymph-node dissection. In addition, the pathologic response 
rate after neoadjuvant chemotherapy can be assessed which may be of prognostic importance 
and is therefore increasingly used in clinical trials. In case of neo-adjuvant chemotherapy the 
sentinel node procedure is performed before the start of chemotherapy, because the sentinel 
node can be false-negative after chemotherapy.11  
In general, stage I and II breast cancer has a good prognosis with a 5 year survival between 
85 and 97%. The 5 year survival of stage III is approximately 75%.15 
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Table 1. The TNM staging system of breast cancer (6th edition).16  The staging system classifies cancers based on their T (tumor), 
N (lymph node), and M (metastasis) stages.
Stage  T  N  M 
0 Tis
Carcinoma in 
situ 
N0
No regional lymph node 
metastases
M0 No distant spread
IA T1b Tumors ≤ 20 mm
IB
T0
No evidence of 
primary tumor N1mi
Micrometastases (≤ 0,2 
cm) to ipsilateral lymph 
node(s)T1b
IIA
T0
No evidence of 
primary tumor
N1c
Both N1a (ipsilateral 
lymph node metastases) 
and N1b (Nmi in internal 
mammary lymph nodes 
with sentinal node biopsy)
T1b Tumors ≤ 20 mm
T2
Tumor >20 mm 
but ≤50 mm 
N0
No regional lymph node 
metastases
IIB
T2
Tumor >20 mm 
but ≤50 mm 
N1
1-3 axillary lymph 
nodes (n1a) and/or Nmi 
in internal mammary 
lymfnodes (n1b)
T3 Tumor >50 mm N0
No regional lymph node 
metastases
IIIA
T0
No evidence of 
primary tumor
N2 4-9 axillary lymph nodesT1b Tumors ≤ 20 mm
T2
Tumor >20 mm 
but ≤50 mm 
T3 Tumor >50 mm
N1 N1a and/or N1b
N2 4-9 axillary lymph nodes
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Table 1. The TNM staging system of breast cancer (6th edition).16  The staging system classifies cancers based on their T (tumor), 
N (lymph node), and M (metastasis) stages.
Stage  T  N  M 
IIIB T4
Extension to the 
chest wall and/or 
to the skin
N0
No regional lymph node 
metastases
M0 No distant spread
N1 N1a and/or N1b
N2 4-9 axillary lymph nodes
IIIC Any T N3
10 or more axillary lymph 
nodes, clavicular lymph 
nodes, internal mammary 
lymph nodes 
IV Any T Any N M1
Cancer has spread 
to distant organs
Metastatic breast cancer 
Approximately 5% of the breast cancer patients have overt metastasis at initial presentation. 
In addition, 20 to 30% of primary breast cancer patients will develop recurrent disease 
with metastases over time. The risk of recurrence is related to stage of the initial disease and 
prognostic factors like age, grade and subtype of breast cancer. Breast cancer mostly spreads 
to the lungs, liver, bones and brain. There are several standard therapies for the palliative 
treatment of metastatic breast cancer. Due to a variety of treatment options with hormonal 
therapy, systemic chemotherapy and, targeted agents, median overall survival for patients 
with metastatic breast cancer is still 2-3 years, although the range is wide.17  
Genetic susceptibility to breast cancer
Both genetic and non-genetic factors contribute to the etiology of breast cancer. Examples of 
non-genetic factors are: hormones, weight, and lifestyle. Women who had early menarche, 
late menopause, nulliparity, late first birth, or long use of oral contraceptives have an increased 
breast cancer risk. Also obesity, alcohol consumption and dietary fat intake are associated 
with breast cancer. Genetic factors are reflected in a family history of breast cancer, although 
shared life style factors might also be involved in this. Genetic factors can be classified as high 
penetrance mutations (relative risk 5 to >20 compared to the general population), moderate 
penetrance variants/mutations (relative risk between 1.5 and 5) and low-penetrance variants 
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(relative risk below 1.5).18  Linkage studies in the 1990s led to the discovery of BRCA1 and 
BRCA2 as high penetrance breast cancer genes. Families with multiple cases of breast cancer 
or breast and ovarian cancer were explained by mutations in the tumor suppressor genes 
BRCA1 and 2. BRCA1 and BRCA2 mutation carriers have a life time risk of 57-65% and 
45-55%, respectively, to develop breast cancer.19  BRCA1 and 2 are part of an important 
DNA repair pathway, the FA/BRCA pathway (see below) and subsequently other high and 
moderate penetrance breast cancer susceptibility genes were identified that operate in this 
pathway, such as PALB2 and RAD51C. 
Two other examples of moderate breast cancer susceptibility genes, CHEK2 and ATM, are 
involved in the DNA damage response. A truncating variant of CHEK2, CHEK2*1100delC 
was linked to hereditary breast cancer in a Dutch family and based on population studies it 
was calculated that the mutation resulted in a two-fold increased risk in breast cancer.20  ATM 
(Ataxia telangiectasia mutated) is involved in a rare human recessive disease characterized by 
cerebellar degeneration, extreme cellular sensitivity to radiation and a predisposition to cancer. 
On the basis of retrospective breast cancer incidence in families with ataxia-telangiectasia 
patients it is estimated that mutations in ATM, the upstream regulator of CHEK2, result in 
a two-fold increased breast cancer risk in heterozygous carriers. The effects of other missense 
variants, not already known to be associated with ataxia-telangiectasia, are more difficult to 
predict.21  
Mutations in the tumor suppressor gene TP53 lead to the Li-Fraumeni syndrome, a 
highly penetrant cancer predisposition syndrome with a life time cancer risk of 80-100%. 
Patients are predisposed to malignancies such as sarcoma, breast cancer, leukemia, and 
other solid cancers. Breast cancer is the most common tumor in women with Li-Fraumeni 
syndrome with a life time risk of 49% by age 60.22  Patients with Lynch syndrome (hereditary 
nonpolyposis colorectal cancer), due to heterozygous mutations in DNA mismatch repair 
genes are at high risk for colon and endometrial cancer, but also a moderate risk for breast 
cancer has been reported.23 
Genome wide association studies turned out to be a powerful technique that identify more 
than 90 single nucleotide polymorphisms each conferring a low risk to breast cancer.24  The 
relative risk conferred by these alleles is 1.3 or less and the underlying causative mechanism 
is mostly unknown.25  It is calculated that low, moderate and high risk alleles together explain 
approximately 35% of the familial breast cancer risk.18  It is thought that additional low and 
moderate risk alleles, explain the majority of the remaining familial breast cancer risk. Novel 
rare moderate risk variants may exist and therefore next generation sequencing techniques 
are currently being used to detect such variants in (familial) breast cancer cases. Exome and 
whole genome sequence studies have already suggested, FANCM, BLM, FANCC, and 
ERCC2 as new candidates, but significant evidence is lacking with respect to the association 
of these genes with breast cancer. Genotyping of a very large number of cases and controls is 
necessary to assess the risk and confirm these associations.26  
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All of the mentioned genes in the previous section are part of DNA damage response and 
DNA repair mechanisms and in the following two sections these mechanisms are described 
in more detail. In figure 1 an overview is given of the frequencies and risk distributions of 
currently known breast cancer alleles. Some very rare high-penetrance breast cancer genes are 
depicted, involving genes such as TP53, CDH1, PTEN, and STK11, associated with cancer 
syndromes such as Li–Fraumeni syndrome (TP53), Cowden syndrome (PTEN), and Peutz–
Jeghers syndrome (STK11).26 
Figure 1. The genetic landscape of breast cancer. Kindly provided by F. Hilbers. 26  This figure shows the allele frequencies and risk 
distributions for the currently known breast cancer alleles. Variants (or loci) represented by a filled diamond indicate a joint allele 
frequency, and an average risk associated with all observed mutations in this gene. Genes indicated by an open triangle represent a 
single variant for which associated breast cancer risk was derived from case-control studies. It has to be noted that recently a large 
systematic study concluded that there is no clear evidence for an association between BRIP1 and breast cancer risk.27 
The Fanconi Anemia/BRCA pathway and breast cancer
Fanconi Anemia (FA) is a rare recessive disorder first described by Guido Fanconi and 
characterized by hematological and congenital abnormalities. Patients frequently present 
at young age with hematological symptoms such as myelodysplastic syndrome, aplastic 
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anemia and acute myeloid leukemia. Other symptoms include hearing loss, congenital 
limb deformities, microcephaly, short stature, and skin hypo and hyper pigmentation. 
The extremely high risk for the FA-patients to develop cancer, in particular leukemia and 
squamous cell carcinoma of the head and neck region, can be attributed to the cellular 
phenotype of genomic instability. Cells of FA-patients are extremely sensitive to DNA-
damaging agents that create interstrand cross-links (ICLs), such as cisplatin, diepoxybutane 
and mitomycin C (MMC).28  Certain metabolites of alcohol, cigarette smoke and dietary 
fat, such as acetaldehyde and malondialdehyde, are now recognized as endogenous sources of 
ICLs.29  Until now, twenty-one FANC genes (FANCA-V) are known to be associated with 
Fanconi Anemia. Most Fanconi subtypes result from bi-allelic mutations in one of the FANC 
genes, two exceptions are FANCB in which the mutation occurs on the X chromosome and 
a reported mutation in FANCR in which the mutation has a dominant negative effect.30  
The gene products of the FANC genes are thought to collaborate in a pathway to repair 
DNA ICLs. ICLs are highly toxic for cells since these covalently link the two strands of the 
DNA double helix, inhibiting replication and transcription. The FANCM protein recognizes 
the ICL and activates the FA core complex that comprises FANCA, FANCB, FANCC, 
FANCE, FANCF, FANCG, FANCL and FANCT (UBE2T). The core complex is required 
for the monoubiquitination of the FANCI/FANCD2 heterodimer. This monoubiquitination 
somehow signals to nucleases, such as FANCP (SLX4) and FANCQ (XPF), and downstream 
repair factors that include FANCJ (BRIP1), FANCN (PALB2), FANCD1 (BRCA2), and 
FANCO (RAD51C).31  Nucleases are necessary to unhook the cross-links and downstream 
factors are involved in the repair of the subsequently generated double stranded break (DSB) 
by homologous recombination. 
Homologous recombination (HR) is the “error free” process of repair where the intact 
sister chromatid serves as template for repair. BRCA1 binds to DSBs through its association 
with the abraxas–RAP80 macro-complex, which associates with ubiquitylated histones at sites 
with DNA DSBs. Next, BRCA1 interacts with the CtIP/MRN complex and is involved in 
5’-end resection of the breaks and facilitation of HR-mediated repair. BRCA1 is also required 
for RAD51 recruit ment to the sites of DNA damage through its interactions with PALB2 
and BRCA2.32  RAD51 plays an essential role in HR and is loaded on the DNA and facilitates 
the search for the homologous sister chromatid, loop formation, and DNA synthesis.33  Most 
recently, REV7 (FANCV) has been discovered as a downstream FA protein.34  REV7 is 
involved in translesion synthesis, mitosis and cellular choice of DNA repair pathways during 
DNA double-strand break repair. It is not clear which of these functions are responsible for 
the FA phenotype (therefore it is not included in figure 2). In figure 2 a simplified model of 
the Fanconi anemia-BRCA pathway (FA/BRCA) is shown. 
Some downstream factors of the FA/BRCA pathway are involved in both FA and breast 
cancer predisposition. In 2001, the establishment of an initial connection between FA and 
the BRCA genes came from the following observation. In the tumors of BRCA1 and BRCA2 
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mutation carriers, the wild-type allele  is often   lost and these BRCA1 -/- and BRCA2 
-/- tumor cells exhibit MMC hypersensitivity and chromosome instability similar to FA-
deficient cells.35  To further investigate the relation between the BRCA genes and FA, BRCA1 
and 2 were sequenced in FA-patients and bi-allelic mutations in BRCA2 were detected in 
FA-D1 patients.36  This was the first link between FA and familial breast cancer. Specific 
BRCA2 mutations may vary in cancer risk. For example, the 6174delT Jewish founder 
mutation confers a high breast cancer risk. Other hypomorphic variants may cause FA in the 
compound heterozygous state but are not associated with breast cancer. 37 In the next decade, 
newly discovered FANC genes were sequenced in cohorts of familial breast cancer cases. By 
this candidate gene approach, an association between the FANC genes, FANCN (PALB2), 
and FANCO (RAD51C) and breast cancer was discovered.38  Bi-allelic mutations in the 
BRCA1 gene are not detected in FA patients, probably because at least one wild-type allele is 
necessary in embryonic development. However, one FA-like patient with early onset ovarian 
carcinoma, microcephaly and short stature, but no hematological problems or other typical 
congenital abnormalities, has been described with bi-allelic BRCA1 mutations. The patient 
displayed extreme sensitivity to the interstrand cross-linking agent carboplatin, not seen in 
patients with mono-allelic BRCA1 mutations.39  
The major breast cancer genes BRCA1 and BRCA2 both cooperate in the repair of double 
stranded breaks during DNA-replication and have similar disease features. Remarkably, 
however, BRCA1-associated breast cancer is more often estrogen (ER) negative or basal 
subtype, whereas BRCA2-associated tumors have a normal distribution among the different 
subtypes. With respect to morphology, medullary carcinomas are more frequently seen in 
tumors from BRCA1-mutation carriers. 
Breast tumors of the basal subtype display extensive genomic abnormalities and harbour 
the majority of BRCA1-mutated tumors.40  It is suggested that all basal tumors might have 
the same etiology as BRCA1 mutant tumors and share underlying defects in the FA/BRCA 
pathway.41  Several studies showed that a proportion of the basal like breast tumors had a 
lower expression of BRCA1 partly explained by hypermethylation of the BRCA1 promoter 
region, but underlying mutations or associations with other genes of the FA/BRCA pathway 
have not been determined in these studies.42 43 44  
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Figure 2. A simplified model of the FA/BRCA pathway. A Replication fork stalling when a DNA cross-link occurs. B Recruitment 
of the FA core complex. C) Monoubiquitination of the FANCI/FANCD2 heterodimer. D Unhooking of the cross-link and 5’-end 
resection of the breaks and facilitation of homologous recombination by the Ctip/MRN complex. E Translesion synthesis at the first 
strand and activation of homologous repair at the second strand. F RAD51 mediated D-loop formation and repair of the double 
stranded break by homologous recombination. G Two repaired strands of DNA. Proteins are coloured to indicate that these are 
encoded by a gene in which mutations have been associated to Fanconi anemia (blue) or both breast cancer and Fanconi anemia 
(red). 
The ATM/CHEK2 pathway in DNA damage signaling and breast cancer
The accurate replication of DNA is essential for survival of cells and preserving the integrity 
of the genome. There is a constant danger of adverse genetic changes by environmental stress 
and genotoxic agents such as ultraviolet light or ionizing radiation, drugs, and reactive cellular 
metabolites.45  Mutations  are  necessary  for  adaptation  and  evolution,  but  high  mutation 
rates  increase cancer susceptibility. DNA-repair pathways and cell cycle checkpoints are 
essential for the detection and repair of adverse DNA damage. Cell cycle checkpoint pathways 
are defined as cell signaling pathways involved in delay of the cell cycle in order to finish an 
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earlier initiated process such as mitosis or DNA replication. Cell cycle checkpoint pathways 
also have an integrated role in activation of DNA repair, cellular senescence and cell death.45  
Diverse and partly overlapping or redundant checkpoints operate in various cell-cycle phases 
and the ATM/CHEK2 pathway is one of them. Double stranded breaks in the DNA can 
activate the nuclear ATM protein. Autophosphorylation of ATM causes dissociation of 
dimeric ATM into monomeric ATM activating CHEK2 (checkpoint kinase-2). CHEK2 
mediated degradation of CDC25A (Cell division cycle 25 homolog A) is suggested to be 
essential for the intra-S-phase delay in response to double stranded breaks. It is thought that 
CHEK1, another signaling protein, regulates the physiological turnover of CDC25A during 
normal S-phase.45  CDC25A is probably not the only substrate of the CHEK2 kinase; other 
substrates may include other proteins involved in cell cycle control, such as the CDC25C 
phosphatases, PLK3 kinase and the E2F1 transcription factor, as well as in DNA repair, such 
as BRCA1, and regulation of cell death, including the P53-MDM2 interplay and PML1. 
This might reflect that CHEK2 has a broad and multifunctional role.46 
The CHEK2 gene and breast cancer 
Meijers-Heijboer et al. studied a large family with breast cancer susceptibility and in one 
branch of the family the disease was linked to chromosome 22q where CHEK2 is located. 
Subsequently, the CHEK2*1100delC mutation was discovered in these cases. To evaluate the 
significance of CHEK2*1100delC mutation, the frequency was determined in familial breast 
cancer cases. The variant was found in 5.1% of the individuals with familial breast cancer 
and 1.1% of controls and the increased breast cancer risk for a female carrier was estimated 
to be two-fold.20  A wide variation in the population frequencies of CHEK2*1100delC has 
been observed. The highest population frequencies have been found in the Netherlands 
(1.1–1.6%) and in Finland (1.1–1.4%). Based on a retrospective study of Adank et al47 , the 
cumulative breast cancer risk in first degree relatives with a likelihood of at least 50% of being 
CHEK2*1100delC carrier is 48% (95% CI: 40–57%). The data suggest that prognostic 
testing and subsequent intensified breast cancer surveillance is useful for CHEK2*1100delC 
carriers with familial breast cancer and their first-degree relatives. However, prospective trials 
are needed to determine the optimal screening strategy.48  Also other CHEK2 variants have 
been associated with breast cancer risk. The lle157Thr (c.470T>C) variant is associated with 
sporadic and familial breast cancer but appears to confer a lower risk than the 1100delC allele. 
The Ile157Thr variant was most frequently found in Poland and Finland (allele frequencies 
4.8 and 5.5% in the general population). The CHEK2 IVS2 +1 G>A splice site mutation 
was found in the Polish, German and Byelorussian populations to be associated with breast 
cancer, but due to the rarity the absolute breast cancer risk for carriers is difficult to estimate.46  
 Interestingly, in a Dutch familial breast cancer cohort 8 families with homozygous 
CHEK2*1100delC mutation carriers were found and multiple primary tumors occurred in 
a total of 7/10 homozygous females. Homozygous women were estimated to have a two-
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fold increased breast-cancer risk compared to heterozygous carriers. The phenotype of 
homozygous CHEK2*1100delC  women differs from that of bi-allelic mutation carriers 
in the other known moderate breast cancer risk genes which cause specific syndromes 
like Fanconi Anemia and Ataxia Teleangiectasia with cancer in childhood and congenital 
abnormalities. Remarkably, HER2 staining was positive in six out of 12 tumors (50%) in 
comparison to 20–25% in breast cancer tumors in the population.49  
The high breast cancer risk in homozygous carriers suggests that loss of heterozygosity 
might play a role in the etiology of tumors from heterozygous carriers. In agreement with this 
hypothesis, tumors from heterozygous CHEK2*1100delC mutation carriers showed reduced 
CHEK2 immunostaining in 80-100% of the tumors.50 51  However, in data of Massink et 
al. only 4 out of 17 tumors from CHEK2*1100delC heterozygous carriers showed loss of 
heterozygosity at the genomic level suggesting that other molecular mechanisms contribute 
to the reduced expression of CHEK2 in such tumors.52  The combined data do suggest that 
depletion of CHEK2 plays a role in tumorigenesis but the exact mechanism remains largely 
unknown. 
Breast cancer patients with a CHEK2*1100delC mutation more often have a hormonal 
positive disease compared to sporadic breast cancer cases. In addition, patients appear to 
have an unfavorable prognosis regarding the occurrence of contralateral breast cancer, distant 
metastasis-free survival and disease-free survival.53 54  This risk for contralateral breast cancer 
cannot be related to adjuvant radiotherapy or chemotherapy.54  Kriege et al. combined the 
data of different Dutch breast cancer cohorts and compared CHEK-carriers versus non-
CHEK2 carriers.55  The incidence of metachronous contralateral breast cancer was higher in 
CHEK2*1100delC mutation carriers than in non-carriers, with a 10-year risk of 28.9% vs 
8.5%, respectively. If stratified for adjuvant chemotherapy, the increased contralateral breast 
cancer rate associated with the CHEK2*1100delC mutation was observed in both, patients 
treated with and without chemotherapy. Survival outcomes beyond 6 years after breast 
cancer diagnosis were significantly worse for CHEK2 mutation carriers compared with non-
carriers with a 10 year distant disease free survival of approximately 55% compared to 40% 
(Multivariate HR 2.65 (95% CI 1.79–3.93), also irrespective of adjuvant chemotherapy). 
Also other studies also observed a worse distant disease-free survival in CHEK2*1100delC 
mutation carriers.56  53 57 
In literature, it is hypothesized that the unfavorable prognosis is due to hampered response 
to chemotherapy induced DNA damage. However, evidence for this hypothesis is not found 
in retrospective studies (i.e., comparing the group treated with and the group treated without 
adjuvant chemotherapy). 
When DNA damage cannot be repaired, CHEK2 is thought to be involved in the 
induction of apoptosis. In vivo experiments with Chek2-/- mice bearing gliomas, showed 
that loss of Chk2 potentiates radiation resistance of the tumor.58  The 50% survival times 
for Chek2+/+ and Chek2−/− mice after a sublethal dose of radiation were 12 and >30 days 
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respectively (P < 0.0001).59  These data suggest that the loss of CHEK2 might play a role in 
resistance to DNA damage. 
The current systemic therapy of breast cancer
Multiple chemotherapy combinations for (neo-) adjuvant treatment are used; but most 
treatment regimens include anthracyclines. In patients with metastatic breast cancer 
systemic therapy consists either of endocrine therapy in ER and/or PR positive tumors or 
chemotherapy in those patients with endocrine resistant disease or who have severe tumor 
related symptoms or rapidly progressive visceral disease. The main goal of the treatment is to 
prolong survival and improve quality of life. 
The first choice of treatment in the metastatic setting is often an anthracycline-containing 
regime. If the patient was pretreated in the adjuvant setting, reintroduction of anthracyclines 
can be considered if the maximum tolerable dose has not been reached.60  Other frequently 
used agents are taxanes, 5-fluorouracil (5-FU)derivatives, vinorelbine, and eribuline.
Anthracyclines are the most effective cytotoxic agents in breast cancer.61  This is based 
on large clinical trials including unselected patients with breast cancer (irrespective of 
molecular subtype) and using outcome measures such as disease free survival (DFS), response 
rate (RR) and overall survival (OS). The two anthracyclines used in the treatment of breast 
cancer are doxorubicin and epirubicin. Epirubicin is a 4’-epimer of doxorubicin, with 
a different orientation of the hydroxyl group and the same efficacy but fewer side effects 
then doxorubicin. The major concerns when combining epirubicin with novel agents is the 
cardiotoxicity of anthracyclines. The mechanism of action of epirubicin is: 1) intercalation 
between the base-pairs of the DNA, resulting in inhibition of DNA and RNA synthesis, 2) 
generation of toxic oxygen or drug free radicals, and 3) inhibition of topoisomerase II activity 
(involved in relaxation and separation of DNA strands during replication).62 
Interstrand cross-links (ICLs) are another type of highly toxic DNA lesions that prevent 
transcription and replication. DNA cross-linking agents, like cisplatin, carboplatin and 
Mitomycin C are some of the earliest used chemotherapeutic agents in the world. Tumors 
with a defect in the FA/BRCA pathway are extremely sensitive to DNA cross-linking agents. 
Nowadays, DNA cross-linking agents are more frequently used in triple negative breast cancer 
treatment. Single use of DNA cross-linking agents in metastatic breast cancer and primary 
breast cancer is moderately effective. However, two trials prospectively examined the addition 
of platinum to neoadjuvant chemotherapy regimens in TNBC and demonstrated improved 
rates of pathological complete response with the addition of carboplatin.63 64 The addition of 
carboplatin to standard treatment for TNBC may increase the percentage of patients eligible 
for breast conserving therapy but there is still ongoing debate if there is enough evidence 
for long-term outcome benefit. Therefore, clinical studies with cisplatin and carboplatin in 
primary and metastatic triple negative breast cancer are ongoing and focus on defining the 
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best combination and schedule of chemotherapy and identifying biomarkers of cross-linker 
sensitivity in this subtype. 
A prospective study in BRCA1 mutation carriers with metastatic breast cancer showed 
that cisplatin monotherapy was highly effective. The overall response rate was 80% in 
the 20 enrolled patients, and 4 patients were still alive after four years.65  An important 
retrospective finding in the BRCA1 mutation carriers with stage I breast cancer is that they 
have a worse clinical outcome if they do not receive adjuvant chemotherapy.66  In addition, 
another study showed that BRCA1/2 carriers have a better clinical response rate to neo-
adjuvant chemotherapy than non-carriers.67  This is irrespective of prognostic factors like age, 
size of tumor, and ER receptor status. Recently, a prospective neoadjuvant trial showed that 
adding carboplatin to paclitaxel/doxorubicin in patients with triple negative breast cancer 
increased the pathological complete response rate by 14% in patients without increased risk, 
by 20% (OR 2.29) in patients with family history only, and by 25% (OR 2.75) for patients 
with a genomic BRCA1/2 mutation (ASCO 2014, abstract 1005). This all suggests that 
BRCA1/2 mutation carriers might need a different treatment strategy then sporadic breast 
cancer patients. 
Targeted therapy in breast cancer
As shown in the previous section, cytotoxic agents that cause DNA cross-linking seems to 
be promising in BRCA1-related breast cancer. However, cytotoxic agents like cisplatin and 
carboplatin give severe chemotherapeutic side effects like nausea, vomiting, bone marrow 
suppression, hearing loss and nephrotoxicity. Nowadays, biologically targeted agents are of 
great interest, since they might have higher efficacy and lower toxicity. However, despite 
the high selectivity of these novel targeted therapies, a range of previously unknown side 
effects are sometimes reported, such as acne-like rash or folliculitis, interstitial lung disease 
and cardiomyopathy.68  Currently two different biological targeted agents are used in clinical 
practice in breast cancer. ER and PR positive breast cancer is the first example of cancer 
treatable with targeted agents. Estrogen-directed therapies are the first choice of treatment 
for this type of hormone receptor positive breast cancer and improve survival among women 
with early and advanced breast cancer. The HER-mediated signaling pathway regulates a 
variety of cellular processes including proliferation and survival. Patients with HER2 positive 
breast cancer (human epidermal receptor 2- amplified or also known as ERBB2-amplified) 
can be treated with trastuzumab, a monoclonal antibody against HER2.  The addition of 
monoclonal antibody pertuzumab to trastuzumab in the first line for metastatic breast cancer 
optimized HER2 blockade and improved overall survival.69 70 71  Dual blocking of HER1 
and HER2 by tyrosine kinase inhibitor lapatinib and trastuzumab-emtansine (monoclonal 
antibody trastuzumab linked to the cytotoxic agent DM1) both show clinical activity in 
patients with progression on trastuzumab treatment.72  73 
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Another interesting concept for targeted therapy is the concept of synthetic lethality, based 
on the lethal effect of simultaneous inactivation of two non-essential pathways. Genomic 
instability in cancer is frequently the result of a defective DNA repair pathway and inhibition 
of a second DNA-repair pathway or essential cell cycle checkpoint can kill such tumor cells. 
Defects in the FA/BRCA and ATM/CHEK2 pathway can be used as targets in this approach. 
A good example of synthetic lethality is the use of PARP (poly ADP ribose polymerase) 
inhibitors in tumours harbouring BRCA1/2 mutations.74  PARP1 is required for base 
excision repair and inhibition of PARP will lead to accumulation of single stranded breaks, 
converted to double stranded breaks during replication. BRCA1 and BRCA2 deficient cells 
are not able to repair these double stranded breaks and consequently these tumor cells die 
due to a mitotic catastrophe. Defects in other genes involved in double stranded break repair 
may also sensitize cells to PARP inhibition. For example, ATM-defective human cancer cells 
showed sensitivity to PARP inhibitors.75 Studies in mice revealed synthetic lethality between 
ATM (Ataxia telangiectasia mutated), the key mediator of response to double stranded breaks 
(DSBs) and DNA-PK an essential kinase in non-homologous end joining (NHEJ, direct 
ligation of double stranded breaks).76  Other findings suggest that ATM-deficient cancer cells 
become addicted to DNA repair via the NHEJ pathway to survive DNA DSBs.77 
 There are several concerns with respect to synthetic lethality. At first, cells can become 
resistant due to activation of overlapping pathways or reversion of the phenotype. For 
example, resistance to PARP can be acquired by reversion of a mutation in BRCA2.78  An 
intragenic deletion restored the open reading frame and resulted in a new functional BRCA2 
isoform. Homologous recombination (HR) can also be restored by loss of 53BP1, promoting 
different processing of broken DNA-ends and leading to competent HR.79  Secondly, the use 
of specific DNA repair pathways might be different depending on cell type and organism. 
The balance between the activities of different DNA repair pathways can differ between cells 
from different tissues as well as from different tumors. Also, the p53 status might influence 
such an approach. In p53-deficient cells, suppression of ATM dramatically sensitizes tumors 
to DNA damaging chemotherapy, whereas, in the presence of functional p53, suppression of 
ATM or its downstream target CHEK2 actually protects tumors from being killed by DNA-
damaging agents.80  
Outline of this thesis
Hereditary breast cancer can be explained by high and moderate breast cancer susceptibility 
genes and/or a combination of low risk alleles. Altogether it is estimated that all known high, 
moderate and low risk alleles explain 35% of the hereditability of breast cancer. The second 
and third chapters of this thesis describe the search for novel breast cancer genes which might 
explain part of the ‘missing hereditability’. In chapter 2, the novel FA gene SLX4/FANCP 
was analyzed in 729 familial breast cancer cases and one pathogenic splice site mutation was 
identified. In the third chapter, a mutation in the non-coding region of BRCA2 in a FA 
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patient is described. Functional experiments in a mouse-embryonic stem-cell based assay 
showed that the mutation was clearly pathogenic. Although similar pathogenic variants in the 
noncoding region of BRCA1 and BRCA2 were not identified in a cohort of familial breast 
cancer cases, this finding is relevant for mutation analysis in Hereditary Breast and Ovarian 
Cancer Syndrome families.
Functional knowledge of the breast cancer genes leads to the discovery of other breast 
cancer genes, provides understanding of tumorigenesis, and can lead to the development 
of novel targeted therapies for (familial) breast cancer. Recently, patients were identified 
with bi-allelic mutations in the breast cancer gene CHEK2. Cell lines of these patients were 
established and corrected with wild-type CHEK2. In chapter 4 the search for a cellular 
phenotype of CHEK2*1100delC homozygous cells is described and revealed a remarkable 
resistance of CHEK2-deficient cells to alkylating agents. 
 The second part of the thesis involves breast cancer therapy. In chapter 5, forty-one 
breast cancer cell lines we tested in a chromosomal breakage assay for their sensitivity to the 
DNA cross-linking agent Mitomycin C. Sensitivity to this agent is a hallmark of cells with 
a defect in the FA/BRCA pathway including tumors defective for BRCA1/2. Subsequently, 
the genetic background of the cell lines with a FA/BRCA-like phenotype was explored, in 
order to find new genetic markers for targeted therapy with DNA cross-linking agents. It is 
shown that RECQL5 amplification might be a potential biomarker for hypersensitivity to 
DNA cross-linking agents in HER2 positive breast cancer. In chapter 6, a BRCA1-deficient 
cell line is used in a kinase based siRNA screen combined with epidoxorubicin to reveal 
sensitizers for anthracycline therapy in breast cancer. The last chapter concerns a study on 
the use of chemotherapy in clinical practice. A cohort of 91 patients with metastatic breast 
cancer (MBC) receiving palliative chemotherapy was analysed retrospectively. The use of 
chemotherapeutic agents for MBC and their subsequential benefit was described. Based on 
observation of the patient and its medical data, a ‘clinical judgement’ is made whether or 
not to proceed with a new chemotherapy. Our findings indicate that clinical judgement will 
remain one of the main criteria for treatment guiding in the developing era of personalized 
medicine.
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CHAPTER 2
ANALYSIS of THE NovEL fANCoNI 
ANEmIA gENE SLX4/fANCP IN 
fAmILIAL BREAST CANCER CASES
Published in Human Mutation, 2013. January;34(1):70-3
Janine L. Bakker, Saskia E. van mil, gerry Crossan, Nelly Sabbaghian, Kim de Leeneer, Bruce 
Poppe, muriel A. Adank, Hans J. gille, Henk m.W. verheul, Hanne E. meijers-Heijboer, Johan 
P. de Winter, Kathleen Claes, Marc Tischkowitz and Quinten Waisfisz
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ABSTRACT
SLX4/FANCP is a recently discovered novel disease gene for Fanconi anemia, a rare recessive 
disorder characterized by chromosomal instability and increased cancer susceptibility. Three of 
the 15 Fanconi anemia genes are breast cancer susceptibility genes in heterozygous mutation 
carriers; BRCA2, PALB2, and BRIP1. To investigate if defects in SLX4 also predispose to 
breast cancer the gene was sequenced in a cohort of 729 BRCA1/BRCA2-negative familial 
breast cancer cases. We identified a single splice site mutation (c.2013+2 T>A) which causes 
a frame shift by skipping of exon 8. We also identified 39 missense variants, four of which 
were selected for functional testing in a mitomycin C induced growth inhibition assay and 
appeared indistinguishable from wild type. Although, this is the first study that describes a 
truncating SLX4 mutation in breast cancer patients our data indicate that germline mutations 
in SLX4 do not significantly contribute to familial breast cancer. 
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Approximately 20-25% of the familial breast cancer cases can be explained by high penetrance 
breast cancer genes such as BRCA1 and BRCA2, which also predispose to ovarian cancer.1 
Patients carrying such a high risk allele have a 5 to >10 fold increased risk of getting breast 
cancer, compared to the normal lifetime risk of one in 8 to one in 13 in Western European 
countries.2 Monoallelic germline mutations in another group of genes, such as ATM, CHEK2 
and PALB2, give rise to a moderate breast cancer risk (2 to 3 fold increased risk). ATM and 
CHEK2 both act in the same DNA damage response pathway and have been linked to the 
regulation of p53 dependent apoptosis in the presence of double strand breaks.3 The proteins 
encoded by two other moderate risk genes PALB2 and BRIP1, as well as those encoded by 
the high risk genes BRCA1 and BRCA2 are involved in the FA-BRCA pathway, a DNA-
repair pathway required for resistance to DNA interstrand cross-linking agents. Genome 
wide association studies have identified an additional 20 common low risk variants for breast 
cancer. All currently known high, moderate, and low risk genes together explain 28-35% of 
the familial clustering of breast cancer, leaving the majority of the risk unexplained.4 5
While monoallelic germline mutations in some of the FA-BRCA pathway members 
predispose to breast cancer, biallelic mutations in FA-BRCA genes cause Fanconi anemia, a 
rare recessive disorder characterized by chromosomal instability, developmental abnormalities, 
bone marrow failure, and a high incidence of cancer.6 The 15 known Fanconi anemia proteins 
and several other interacting proteins cooperate collectively in the FA-BRCA pathway, which 
protects the genome against replication fork blocking lesions and genetic instability. This 
pathway can be separated in three groups of proteins: the FA core complex, the FANCI-
FANCD2 (ID) complex and the downstream proteins. The FA core complex consists of 
eight FA proteins and is essential for activation of the pathway by monoubiquitination of 
the ID complex. The monoubiquitinated ID complex is present in nuclear foci together 
with the downstream proteins.7 Interestingly, all currently known breast cancer susceptibility 
genes of the FA-BRCA pathway, BRCA2/FANCD1, PALB2/FANCN and BRIP1/FANCJ, 
act in the downstream part of the pathway. Recently, SLX4/FANCP (MIM# 613278), was 
identified as a novel Fanconi anemia gene.8 9 SLX4 acts as a scaffold for other repair nucleases 
(XPF-ERCC1, MUS81-EME1) and may play a role in resolving Holliday junctions.10 
11 Cells of SLX4-deficient FA patients are sensitive for DNA cross-linking agents, while 
the monoubiquitination of FANCD2 is unaffected.8 9 This suggests a function for SLX4 
downstream in the pathway and therefore SLX4 is a candidate breast cancer susceptibility 
gene. To date, three studies that examined the role of SLX4 in a combined total of 672 
hereditary breast cancer have been published and to date no clear pathogenic SLX4 mutations 
have been found.12 13 14
In this study we selected a cohort of 729 unrelated familial breast cancer cases, negative 
for mutations in BRCA1 and BRCA2, from the department of Clinical Genetics at VU 
University Medical Center Amsterdam (VUmc, The Netherlands, n=562), from McGill 
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University Health Centre (Canada, n=74) and from Ghent University Hospital (Belgium, 
n=93). The cohort included cases with familial breast cancer, bilateral breast cancer, male 
breast cancer and early onset disease and was selected by clinical geneticists based on current 
clinical guidelines. Genomic DNA was isolated from peripheral blood samples by standard 
methods and PCR primers were designed to cover all 18 coding exons and intron/exon 
boundaries of SLX4. 
Mutation screening of SLX4 revealed one case with an alteration in the second nucleotide of 
intron 8 disrupting the splice donor site (c.2013+2 T>A). Analysis of cDNA from lymphoblasts 
of this patient showed skipping of exon 8, which results in a frame shift and generates a 
premature stop codon in exon 9. This mutant transcript was expressed at reduced levels and 
treatment with cyclohexamide, an inhibitor of nonsense-mediated mRNA decay, increased 
the stability of the transcript (Figure 1A). The patient presented with a T2N0M0 breast tumor 
at the age of 52 years; two separate invasive ductal adenocarcinomas were identified in the 
resected material which were both negative for estrogen and progesterone receptor expression. 
Only one of the tumors was available for further analysis and DNA was extracted from 
sections of paraffin-embedded tumor tissue after microdissection. We designed a primer pair 
surrounding the splice site mutation (forward primer: 5’-TCTGACTGGGTTTGTGGTG-3’ 
and reverse primer: 5’-ACACATGGCAAGTGGGATG-3’) and sequenced the amplified 
fragment. No loss of heterozygosity was observed when analyzing the splice site mutation in 
tumor DNA. 
515504-L-bw-Bakker
Processed on: 1-12-2017 PDF page: 37
37
M               WTc.2
01
3+
2 
T>
A 
 
c.2
01
3+
2 
T>
A
x6 x7 x8 x9
x6 x7 x9
+CHX              no CHX            +CHX 
544 bp
455 bp
c.2013+2 T>A
B85
B52 multifocal
Gastric CA 85
Gastric CA 67
c.2013+2 T>A
LOH -
A
B
 
Figure 1. Analysis of the c.2013+2 T>A splice site mutation. A: Primers located in exon 6 and 9 (forward primer: 
5’-CTCCTCCACCTGAACGCA-3’ and reverse primer: 5’- TCCCCGCTGTCCGTCTGA -3’) were used to PCR amplify cDNA 
fragments from lymphoblasts. Cells were treated with 250 mg/l cyclohexamide for 4 hours where indicated (+CHX). B: Pedigree of 
the family with the splice site mutation c.2013+2 T>A. Individuals with breast cancer are shown with filled symbols and the age of 
diagnosis as well as the occurrence of other cancers are indicated (Gastric CA= Gastric carcinoma). Only two individuals were tested 
for the SLX4 mutation and both were found to be carriers. No loss of heterozygosity was observed, i.e. tumor retained both wild 
type and mutant alleles (LOH-).
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The pedigree of the family is shown in figure 1B. The mother of the case was diagnosed with 
breast cancer at the age of 85 years and died two years after diagnosis. Her father died at 
the age of 85 years due to a gastric carcinoma, but unfortunately, no material was available 
from either parent. The daughter of the case is also a carrier of the c.2013+2 T>A splice site 
mutation and has not developed any malignancies up to the age of 42 years. Using a Taqman 
assay, the splice site mutation was not detected in 651 ethnically matched control samples. 
DNA samples from irreversibly anonymised controls were used following the code for Proper 
Secondary Use of Human Tissue and were obtained from the DNA diagnostic laboratory of 
VUmc. 
Since we observed one truncating mutation, we decided to further analyze other SLX4 
variants present in our cohort based on their potential pathogenicity. We identified a total of 
102 different variants (Supp. table S1, all submitted to the LOVD database, www.lovd.nl/
SLX4) and in silico analysis was performed for all missense variants and all intronic variants. 
Two rare missense variants (p.Arg1550Trp and p.Arg1814Cys) were selected for functional 
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 Amino Acid Change  
 Patient 
Mouse 
Construct 
Functional 
Assay 
 MMC  
  p.Pro378Thr  p.Pro202Thr Resistant  
  p.Glu787Lys  p.Glu602Lys Resistant  
 p.Arg1550Trp p.Arg1324Trp Resistant  
  p.Arg1814Cys  p.Arg1545Cys Resistant  
     
Figure 2. Functional test of missense variants in complementation assay. The graph shows Mitomycin C (MMC) sensitivity of 
Slx4-deficient MEFs and MEFs transfected with wild type Slx4 or Slx4 missense variants. In addition, an overview of selected 
human missense variants, corresponding mouse missense variants and functional outcome of the complementation assay is displayed 
underneath.
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testing because they were the only rare missense variants predicted to be pathogenic by at least 
two out of three prediction programs (PolyPhen2 , SIFT and Align GVGD). In addition, 
we selected two other missense variants for functional testing: 1) variant p.Glu787Lys was 
selected because it is the only rare missense variant situated in a functional domain of SLX4, 
the BTB domain which is involved in XPF binding 11, 2) variant p.Pro378Thr was selected 
because this rare missense variant is encoded by exon 5 which is skipped due to splice site 
mutations in two out of the four currently known SLX4 families.8 9 These four human 
missense variants were all located in conserved amino acids and each was introduced into 
mouse Slx4 cDNA by using the QuikChange site-directed mutagenesis kit (Stratagene). The 
pLOXBSR expression plasmids with Slx4 cDNA were transfected into Slx4-deficient Mouse 
Embryonic Fibroblasts (MEFs) using Lipofectamine LTX (Invitrogen). Positive clones were 
selected using 10 μg/ml Blasticidin and screened for Slx4 expression by Western blotting. 
At least two clones were tested for each missense variant. Five hundred MEFs per well were 
plated in a 96 wells plate and after 24 hours different concentrations of MMC were added 
(in triplicate). After seven days the viability of the cells was measured with a Cell Titer Blue 
Assay (Promega). As shown in figure 2, the four missense variants were indistinguishable 
from wild type Slx4.
 In summary, the present study identified one deleterious SLX4/FANCP mutation in 
729 familial breast cancer patients. The splice site mutation c.2013+2 T>A results in a frame 
shift due to exon skipping and consequently in a premature stop codon and instability of the 
transcript. Although this mutation was identified in a breast cancer case and likely affects 
the gene function, no loss of heterozygosity was observed in the breast tumor of the patient 
carrying this mutation. Since no suitable antibodies for immunohistochemistry are available, 
we were unable to investigate whether SLX4 expression could have been lost by alternative 
mechanisms of gene inactivation. Four SLX4 missense variants were selected for further 
investigation based upon pathogenicity prediction software programs, functional knowledge 
of the SLX4 protein and the location of previously reported mutations in Fanconi anemia 
patients. All four variants complemented MMC sensitivity of Slx4-deficient MEFs and appear 
not to be deleterious in murine cells. Although we assume that the other rare missense variants 
are less likely to affect the protein function, we cannot exclude this possibility without further 
studies. Combining our results with the recently published data summarized in Supp. Table 
S212 13 14, only one truncating mutation has been identified in 1401 familial breast cancer 
cases. The absence of loss of heterozygosity in the tumor from our case does not support a 
causal role for SLX4 in tumorigenesis. However LOH is not a consistent feature in tumors 
related to other breast cancer-predisposing FA genes such as PALB2.4 15 In view of this, SLX4 
remains a candidate breast cancer susceptibility gene and warrants further sequencing efforts 
in larger familial breast cancer cohorts. However, even if the association with breast cancer 
is confirmed, the apparent rarity of SLX4 mutations means that this gene would account for 
only a very small proportion of all familial breast cancers.
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Table 1A. All variants with splice prediction
Varianta Exon Changeb SNP Prediction Programmesc Numberd
Splice site 
finder-like
NN-splice Human 
Splice 
finder
syn1 1 C/T c.90 C>T p.(=) rs118089506 - - - 7
syn2 1 T/C c.237 T>C p.(=) - - - 2
syn3 1 A/G c.465 A>G p.(=) rs138512851 - - - 1
syn4 2 C/T c.555 C>T p.(=) rs74640850  - - - 67
syn5 2 C/T c.678 C>T p.(=) rs28516461 - - - 12
syn6 2 G/A c.753 G>A p.(=) rs8061528 - - - 202
syn7 4 C/T c.999 C>T p.(=) rs7198338 - - - 1
syn8 4 A/G c.1152 A>G p.(=) rs112511042 - - - 65
syn9 7 G/A c.1641G>A p.(=) - - - 1
syn10 7 C/T c.1755 C>T p.(=) rs114016359 - - - 2
syn11 7 G/A c.1803 G>A p.(=) rs144892556 - - - 2
syn12 7 C/T c.1845 C>T p.(=) - - - 1
syn13 11A C/T c.2628 C>T p.(=) - - - 1
syn14 11A A/G c.2667 A>G p.(=) rs146790631 - - - 1
syn15 11B C/T c.2949 C>T p.(=) - - - 1
syn16 11B T/C c.3109 T>C p.(=) rs58735123 - - - 1
syn17 11B G/A c.3162 G>A p.(=) rs76488917 - - - 9
syn18 11C C/T c.3315 C>T p.(=)
 
rs183029626
- - - 1
syn19 11C G/A c.3783 G>A p.(=) rs77699867 - - - 1
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Table 1A. All variants with splice prediction
Varianta Exon Changeb SNP Prediction Programmesc Numberd
Splice site 
finder-like
NN-splice Human 
Splice 
finder
syn20 11D G/A c.3963 G>A p.(=) rs77699867 - - - 2
syn21 11D C/T c.4272 C>T p.(=) - - - 1
syn22 11E G/A c.4410 G>A p.(=) - - - 1
syn23 11E T/C c.4500 T>C p.(=) rs3810812 - - - 448
syn24 11E G/T c.4530 G>T p.(=)
 
rs139254595
- - - 1
syn25 11E G/A c.4581 G>A p.(=) rs78635099 - - - 1
syn26 13 C/T c.4797 C>T p.(=) - - - 1
syn27 13 C/T c.4887 C>T p.(=) - - - 1
as1 1 T/C c.112 C>T p.Leu38Phe rs141167501 - - - 1
as2 1 G/T c.421 G>T p.Gly141Trp rs137976282 - - - 2
as3 2 T/C c.590 T>C p.Val197Ala rs147826749 - - - 2
as4 2 C/T c.610 C>T p.Arg204Cys rs79842542 - - - 65
as5 2 G/A c.710 G>A p.Arg237Gln rs138615800 - - - 9
as6 3 A/G c.851 A>G p.His284Arg - - - 1
as7 4 C/A c.1132 C>A p.Pro378Thr - - - 1
as8 4 C/A c.1153 C>A p.Pro385Thr rs115694169 - - - 2
as9 4 A/G c.1156 A>G p.Met386Val rs113490934 - - - 65
as10 5 C/T c.1271 C>T p.Ala424Val - - - 1
as11 6 T/G c.1371 T>G p.Asn457Lys rs74319927 - - - 64
as12 6 A/G c.1372 A>G p.Lys458Glu rs149126845 - - - 1
as13 6 G/A c.1513 G>A p.Ala505Thr - - - 1
as14 6 G/A c.1517 G>A p.Ser506Asn - - - 1
as15 7 G/A c.1702 G>A p.Val568Met - - - 1
as16 7 T/C c.1736 T>C p.Leu579Pro - - - 1
as17 8 T/C c.2012 T>C p.Leu671Ser rs77985244
Primary splice 
site decreased 
(82,03>81,63)
- - 65
as18 11A G/A c.2359 G>A p.Glu787Lys rs140600202 - - - 3
as19 11A C/T c.2609 C>T p.Ala870Val rs149584080 - -
Ectopic 
splice site 
created 
with score 
71.90
4
as20 11A T/G c.2681 T>G p.Val894Gly
 
rs145137472
- - - 2
2
SL
X4
/f
A
N
C
P 
IN
 f
A
m
IL
IA
L 
BR
EA
ST
 C
A
N
C
ER
515504-L-bw-Bakker
Processed on: 1-12-2017 PDF page: 42
42
Table 1A. All variants with splice prediction
Varianta Exon Changeb SNP Prediction Programmesc Numberd
Splice site 
finder-like
NN-splice Human 
Splice 
finder
as21 11B C/T c.2786 C>T p.Pro929Leu rs117707719 - - - 1
as22 11B G/C c.2824 G>C p.Glu942Gln rs114014006 - - - 2
as23 11B
GC/
AT
c.2854_2855 
GC>AT
p.Ala952Met
rs59939128/
rs78637028
- - - 55
as24 11B C/T c.2924 C>T p.Pro975Leu rs114472821 - - - 1
as25 11B C/A c.3019 C>A p.Gln1007Lys rs138798067 - - - 1
as26 11 C/T c.3178C>T p.Arg1060Trp - - - 2
as27 11C C/T c.3365 C>T p.Pro1122Leu rs714181 - - - 76
as28 11C C/A c.3368 C>A p.Ser1123Tyr rs144647122 - - - 1
as29 11C C/T c.3662 C>T p.Ala1221Val rs3827530 - - - 68
as30 11D C/T c.3812 C>T p.Ser1271Phe rs3810813 - - - 54
as31 11D C/T c.3857 C>T p.Ala1286Val rs149011965 - - - 6
as32 12 T>G c.3860 T>G p.Val 1287Gly - - - 1
as33 11D A/G c.4024 A>G p.Ser1342Gly rs140051968 - - - 3
as34 11D A/T c.4261 A>T p.Ile1421Phe
 
rs141567438
- - - 2
as35 11E C/G c.4427 C>G p.Thr1476Ser - - - 1
as36 12 C/T c.4648 C>T p.Arg1550Trp  rs77021998 - - - 3
as37 13 C/T c.5081C>T p.Ala1694Val - - - 1
as38 14 C/T c.5440 C>T p.Arg1814Cys - - - 1
as39 14 A/G c.5501 A>G p.Asn1834Ser rs111738042 - - - 7
iv1 intron 4 C/G c.1164 C>G rs59622164 - - - 65
iv2
intron 
10
G/C c.2328-9 G>C rs73505419 - - - 1
iv3
intron 
11
T/C c.4637-110 T>C rs74005837 - - - 1
iv4
intron 
12
G/T c.4739+24 G>T rs12933120 - - - 133
iv5 3’ UTR A/G c.*8 A>G rs3751839 - - - 57
iv6 3’ UTR C/T c.*113 C>T rs76661336 - - - 56
iv7 intron 1 C/T c.536-80 C>T rs137869443 - - - 1
iv8 intron 2 T/G c.761-32 T>G rs118098382 - - - 29
iv9 intron 3 C/T c.950+29 C>T - - - 1
iv10 intron 4 C/T c.1163+10 C>T rs80116508 - - - 66
iv11 intron 4 C/T c.1163+194 C>T - - - 1
iv12 intron 5 T/C c.1366+11 T>C rs76350200 - - - 67
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Table 1A. All variants with splice prediction
Varianta Exon Changeb SNP Prediction Programmesc Numberd
Splice site 
finder-like
NN-splice Human 
Splice 
finder
iv13 intron 5 G/T c.1367-44G>T rs185962726 - - - 2
iv14 intron 7 G/A c1924+5 G>A 
Primary splice 
site decreased 
(90>78) 
No ectopic site 
recognized
Primary 
splice site  
decreased 
(0.9>0.6) 
No 
ectopic 
site 
recognized
Primary 
splice site  
decreased 
(96.5>84.3) 
Ectopic site 
with score 
of 81.33 
1
iv15 intron 7 C/T c.1924+59 C>T - - - 1
iv16 intron 7 G/A c.1924+127 G>A - - - 1
iv17 intron 7 C/T c.1925-122 C>T - - - 1
iv18 intron 7 T/G c.1925-106 T>G - - - 5
iv19 intron 7 G/A c.1925-95 G>A rs180740748 - - - 14
iv20 intron 7 G/A c.1925-30 G>A rs149916101 - - - 2
iv21 intron 8 G/A c.2013+23 G>A
 
rs112226642
- - - 65
iv22 intron 8 C/G c.2013+130 C>G - - - 1
iv23 intron 8 G/C c.2013+137 G>C rs80186343 - - - 65
iv24 intron 8 G/A c.2014-28 G>A - - - 1
iv25 intron 9 C/T c.2160+50 C>T rs75762935 - - - 66
iv26 intron 9 G/A c.2161-136 G>A
 
rs139226142
- - - 1
iv27
intron 
10
del
c.2328-35del
CCCATCTCCACGC
- - - 2
iv28
intron 
11
C/T c.4637-267 C>T - - - 1
iv29
intron 
11
G/A c.4637-234 G>A - - - 1
iv30
intron 
11
C/T c.4637-227 C>T  rs75693937 - - - 65
iv31
intron 
11
A/G c.4637-210 A>G - - - 1
iv32
intron 
12
G/A c.4739+31G>A - - - 2
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Table 1A. All variants with splice prediction
Varianta Exon Changeb SNP Prediction Programmesc Numberd
Splice site 
finder-like
NN-splice Human 
Splice 
finder
iv33
intron 
12
G/A c.4739+79 G>A rs74762428 - - - 20
iv34
intron 
12
C/G c.4739+90C>G - - - 2
iv35 3’ UTR G/A c.*102 C>T - - - 1
mut1 intron 8 T/A c.2013+2 T>A
Primary splice 
site destroyed
Primary 
splice site 
destroyed
Primary 
splice site 
destroyed
1
a syn = synonymous variant, as=amino acid substitition, iv=intronic variant, mut=deleterious mutation  
bVariant nomenclature is based on the reference sequence NM_032444.2. Nucleotide numbering reflects cDNA numbering with 
+1 corresponding to the A of the ATG translation initiation codon in the reference sequence. 
c Data retrieved from Alamut version 1.0 july 2010 
d Number of breast cancer cases with variant (heterozygous or homozygous)
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Table 1B. Missense variants and prediction of pathogenicity
Varianta Exon Changeb SNP Prediction Programmesc Numberd
Polyphen SIFT Align 
GVGD
as1 1 T/C c.112 C>T p.Leu38Phe rs141167501 Benign
Affect protein 
function (low 
conf.)
C0 1
as2 1 G/T c.421 G>T p.Gly141Trp rs137976282
Possibly 
damaging
Tolerated C0 2
as3 2 T/C c.590 T>C p.Val197Ala rs147826749 Benign Tolerated C0 2
as4 2 C/T c.610 C>T p.Arg204Cys rs79842542
Probably 
damaging
Affect protein 
function (low 
conf.)
C0 65
as5 2 G/A c.710 G>A p.Arg237Gln rs138615800 Benign Tolerated C0 9
as6 3 A/G c.851 A>G p.His284Arg Benign Tolerated C0 1
as7 4 C/A c.1132 C>A p.Pro378Thr
Probably 
damaging
Tolerated C0 1
as8 4 C/A c.1153 C>A p.Pro385Thr rs115694169
Possibly 
damaging
Tolerated C0 2
as9 4 A/G c.1156 A>G p.Met386Val rs113490934 Benign Tolerated C0 65
as10 5 C/T c.1271C>T p.Ala424Val Benign
Affect protein 
function (low 
conf.)
C0 1
as11 6 T/G c.1371 T>G p.Asn457Lys rs74319927 Benign Tolerated C0 64
as12 6 A/G c.1372 G>A p.Lys458Glu rs149126845 Benign Tolerated C0 1
as13 6 G/A c.1513 G>A p.Ala505Thr Benign Tolerated C0 1
as14 6 G/A c.1517 G>A p.Ser506Asn Benign
Affect protein 
function (low 
conf.)
C0 1
as15 7 G/A c.1702G>A p.Val568Met Benign Tolerated C0 1
as16 7 T/C c.1736 T>C p.Leu579Pro Benign Tolerated C0 1
as17 8 T/C c.2012 T>C p.Leu671Ser rs77985244 Benign Tolerated C0 65
as18 11A G/A c.2359 G>A p.Glu787Lys rs140600202 Benign Tolerated C0 3
as19 11A C/T c.2609 C>T p.Ala870Val rs149584080 Benign Tolerated C0 4
as20 11A T/G c.2681 T>G p.Val894Gly  rs145137472
Possibly 
damaging
Tolerated C0 2
as21 11B C/T c.2786 C>T p.Pro929Leu rs117707719 Benign Tolerated C0 1
as22 11B G/C c.2824 G>C p.Glu942Gln rs114014006 Benign Tolerated C0 2
as23 11B GC/AT
c.2854_2855 
GC>AT
p.Ala952Met
rs59939128/
rs78637028
Possibly 
damaging
Affect protein 
function
C0 55
as24 11B C/T c.2924 C>T p.Pro975Leu rs114472821 Benign Tolerated C0 1
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Table 1B. Missense variants and prediction of pathogenicity
Varianta Exon Changeb SNP Prediction Programmesc Numberd
Polyphen SIFT Align 
GVGD
as25 11B C/A c.3019 C>A p.Gln1007Lys rs138798067 Benign Tolerated C0 1
as26 11 C/T c.3178C>T p.Arg1060Trp
Probably 
damaging
Tolerated C0 2
as27 11C C/T c.3365 C>T p.Pro1122Leu rs714181 Benign Tolerated C0 76
as28 11C C/A c.3368 C>A p.Ser1123Tyr rs144647122
Possibly 
damaging
Tolerated C0 1
as29 11C C/T c.3662 C>T p.Ala1221Val rs3827530 Benign Tolerated C0 68
as30 11D C/T c.3812 C>T p.Ser1271Phe rs3810813
Probably 
damaging
Affect protein 
function
C0 54
as31 11D C/T c.3857 C>T p.Ala1286Val rs149011965 Benign Tolerated C0 6
as32 12 T>G c.3860T>G p.Val 1287Gly
Possibly 
damaging
Tolerated C0 1
as33 11D A/G c.4024 A>G p.Ser1342Gly rs140051968
Possibly 
damaging
Tolerated C0 3
as34 11D A/T c.4261 A>T p.Ile1421Phe  rs141567438
Possibly 
damaging
Tolerated C0 2
as35 11E C/G c.4427 C>G p.Thr1476Ser Benign Tolerated C0 1
as36 12 C/T c.4648 C>T p.Arg1550Trp  rs77021998
Probably 
damaging
Affect protein 
function (low 
conf.)
C0 3
as37 13 C/T c.5081C>T p.Ala1694Val Benign Tolerated C0 1
as38 14 C/T c.5440 C>T p.Arg1814Cys
Probably 
damaging
Affect protein 
function
C0 1
as39 14 A/G c.5501 A>G p.Asn1834Ser rs111738042 Benign Tolerated C0 7
a syn = synonymous variant, as=amino acid substitition, iv=intronic variant, mut=deleterious mutation  
bVariant nomenclature is based on the reference sequence NM_032444.2. Nucleotide numbering reflects cDNA numbering with 
+1 corresponding to the A of the ATG translation initiation codon in the reference sequence. 
c Data retrieved from Alamut version 1.0 july 2010  
d Number of breast cancer cases with variant (heterozygous or homozygous)
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CHAPTER 3
A NovEL SPLICE SITE muTATIoN IN 
NoN-CoDINg REgIoN of BRCA2: 
ImPLICATIoNS foR fANCoNI 
ANEmIA AND fAmILIAL BREAST 
CANCER DIAgNoSTICS
Published in Human Mutation, 2014. April;35(4):442-6
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ABSTRACT
Fanconi Anemia (FA) is a rare recessive disorder with chromosomal instability, congenital 
abnormalities and a high cancer risk. The breast cancer susceptibility gene BRCA2 (FANCD1) 
is one of the 16 genes involved in this recessive disease. We have identified a novel mutation 
in the splice donor site close to non-coding exon 1 of BRCA2 in a Japanese FA family. This 
mutation may account for the FA phenotype in a patient originally reported to have biallelic 
mutations in BRCA2. Subsequent functional studies revealed that one of the mutations, 
K2729N, was a neutral change. As reported here, a more careful analysis resulted in the 
identification of a novel splice site mutation. Functional analysis using a mouse embryonic 
stem cell-based assay revealed that it causes aberrant splicing, reduced transcript levels and 
hypersensitivity to DNA damaging agents, suggesting that it is likely to be pathogenic. 
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Although similar pathogenic variants in the non-coding region of BRCA1 and 2 were not 
identified in a cohort of 752 familial breast cancer cases, we still think this finding is relevant 
for mutation analysis in HBOC families in a diagnostic setting. 
Linkage studies in the 90’s identified BRCA2 as a high risk breast cancer gene.1 Patients with 
a mutation in BRCA2 have lifetime risk of getting breast and ovarian cancer of 50-60% and 
a 5-20%, respectively.2 In addition to the association with ‘Hereditary Breast and Ovarian 
Cancer Syndrome’ (HBOC), BRCA2 is also associated with Fanconi anemia (FA) in biallelic 
mutation carriers.3 FA is a rare recessive disorder characterized by chromosomal instability, 
bone marrow failure, congenital abnormalities and a high cancer risk, in particular acute 
myeloid leukemia (AML) and head and neck squamous cell carcinomas at young age. Until 
now, 16 different genes have been shown to cause FA.4 
Compared to other FA subtypes, patients with biallelic BRCA2 or PALB2 (FA-D and 
FA-N) mutations have a more severe phenotype with high risk of solid childhood tumors 
particularly Wilms tumor and medulloblastoma.3 5 6 Cells of FA patients are in general 
characterized by hypersensitivity to cross-linking agents such as mitomycin C (MMC) and 
enhanced levels of spontaneous as well as MMC-induced chromosomal aberrations.7 An 
additional hallmark of the BRCA2 and PALB2-deficient cells is their inability to recruit 
Rad51 to double strand breaks, essential for homologous repair. 8 One of our reported FA-D1 
patients carried a nonsense mutation c.8732C>A (p.S2835X) in BRCA2 (#MIM 600185) 
on one allele and a missense mutation c.8415G>T (p.K2729N) on the other allele.9 The 
patient was diagnosed with AML at the age of 2 years. Recently, Biswas et al. used a mouse 
embryonic stem cell-based assay to characterize BRCA2 variants associated with FA. In this 
study, the missense variant K2729N was found to be neutral. Embryonic stem cells with 
this variant were indistinguishable from wild type BRCA2 and exhibited no effect on cell 
survival, sensitivity to DNA-damaging agents and were proficient in RAD51 focus formation 
and homologous recombination.10 No other possible pathogenic variants were identified in 
the initial screening of BRCA2 and resequencing of the coding exons did not reveal any 
new variants. To determine the cause of FA in the patient carrying the K2729N allele, we 
decided to analyze cDNA from the patient cells. However, as reported previously, a MMC-
sensitive lymphoblastoid cell line (LCL) was not available from the patient.9 The patient 
presented with acute leukemia and after a chemotherapy protocol, he received a bone marrow 
transplantation from his HLA-identical sister. In addition, the established AML cell lines from 
the patient appeared to be reverted. Reversion of the cellular FA phenotype to wild type often 
occurs. In these cases, a spontaneous correction of a mutant allele by mitotic recombination, 
gene conversion, or secondary mutations can restore the function of the affected FA gene.9 
11 However, early passages of the AML cells appeared sensitive in a chromosomal breakage 
test. These cells, with minimal passages, were used for sequence analysis of BRCA2 cDNA. 
We observed that both alleles were detected at equal levels, based on heterozygous SNPs 
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in the BRCA2 coding region. We expected the allele carrying the premature stop codon 
(p.S2835X) to be present at a reduced level due to nonsense mediated mRNA decay. Indeed, 
inhibition of nonsense mediated mRNA decay by cyclohexamide treatment of the cells 
stabilized the transcript with the premature stop codon while the transcript of the other 
allele remained relatively low (data not shown). These results suggested that the transcripts of 
both alleles were present at reduced levels. To identify a mutation that could cause this low 
expression which was unaffected by the inhibition of nonsense mediated mRNA decay we 
subsequently analyzed the region encoding the 5’UTR- and 3’UTR-region of BRCA2 DNA 
by sequencing. A splice site mutation, c.-40+1 G>A, disrupting the donor site of non-coding 
exon 1 was identified. Analysis of this variant in the family showed that one of the parents was 
heterozygous for this splice site mutation and that the healthy sister carried the premature 
stop mutation and not the splice site mutation (Supplementary Table 1). 
The effect of the splice site mutation on mRNA splicing was further analyzed. Primer 
pairs were designed for amplifying a fragment ranging from non-coding exon 1 to coding 
exon 2 and cDNA was analyzed from the parent carrying the splice site mutation, the FA 
patient and a wild type control. After PCR amplification, a smaller fragment was detected 
in the cDNA from the AML cells of the patient, which was absent in the control and sibling 
LCL sample (Supp. Fig. S1A). In cDNA from the parent this smaller transcript was expressed 
at almost undetectable levels as compared to the wild type transcript. The expression of this 
alternative transcript was again not influenced by the treatment with cyclohexamide (data 
not shown). The fragment was subsequently cloned into a vector (Zero Blunt® PCR Cloning 
Kit, Invitrogen) to generate clones with the alternative transcript. Sequence analysis of these 
clones showed that the splice site mutation c.-40+1 G>A leads to disruption of this donor 
site and the use of an alternative donor site in the middle of exon 1 (Fig. 1B). To test whether 
this was a naturally occurring alternative transcript we designed a primer set specific for 
this transcript (Forward primer: 5’-TGTCTTTTGCGGCGACT-3’ and Reverse primer: 
5’-ACGATATTCCTCCAATGCA-3’) of which the forward primer spans the alternative 
exon 1 to exon 2 transcript. PCR analysis confirmed that the alternative transcript was clearly 
present in cDNA of samples with the splice site mutation c.-40+1 G>A while control samples 
showed only very little or no product (Fig. 1C). The reduced levels of the aberrant transcript 
might be due to a lower stability of the transcript or due to lower efficiency of splicing itself. It 
is known that regulatory proteins interact with specific sequences (exonic splicing enhancers 
or silencers) in the pre-mRNAs and subsequently stimulate or repress exon recognition.12 
Possibly, the alternative pre-mRNA transcript is missing such an exonic splicing enhancer. 
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EXON 1 Aberrant transcript
c.-138                                 c.-39                        Start Codon           
EXON 2
Wild type transcriptEXON 1 EXON 2
Start Codon       
285 bp
186 bp
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GGGCTTGTGGCGCGAGCTTCTGAAACTAGGCGGCAGAGGCGGAGCCGCTGTGGCACTGCTGCGCCTCTGCT
GCGCCTCGGGTGTCTTTTGCGGCGGTGGGTCGCCGCCGGGAGAAGCGTGAGGGGACAGATTTGTGACCGGC
GCGGTTTTTGTCAGCTTACTCCGGCCAAAAAAGAACTGCACCTCTGGAGCGGGTTAGTGGTGGTGGTAGTG
GGTTGGGACGAGCGCGTCTTCCGCAGTCCCAGTCCAGCGTGGCGGGGGAGCGCCTCACGCCCCGGGTCGCT
GCCGCGGCTTCTTGCCCTTTTGTCTCTGCCAACCCCCACCCATGCCTGAGAGAAAGGTCCTTGCCCGAAGG
CAGATTTTCGCCAAGCAAATTCGAGCCCCGCCCCTTCCCTGGGTCTCCATTTCCCGCCTCCGGCCCGGCCT
TTGGGCTCCGCCTTCAGCTCAAGACTTAACTTCCCTCCCAGCTGTCCCAGATGACGCCATCTGAAATTTCT
TGGAAACACGATCACTTTAACGGAATATTGCTGTTTTGGGGAAGTGTTTTACAGCTGCTGGGCACGCTGTA
TTTGCCTTACTTAAGCCCCTGGTAATTGCTGTATTCCGAAGACATGCTGATGGGAATTACCAGGCGGCGTT
GGTCTCTAACTGGAGCCCTCTGTCCCCACTAGCCACGCGTCACTGGTTAGCGTGATTGAAACTAAATCGTA
TGAAAATCCTCTTCTCTAGTCGCACTAGCCACGTTTCGAGTGCTTAATGTGGCTAGTGGCACCGGTTTGGA
CAGCACAGCTGTAAAATGTTCCCATCCTCACAGTAAGCTGTTACCGTTCCAGGAGATGGGACTGAATTAGA
ATTCAAACAAATTTTCCAGCGCTTCTGAGTTTTACCTCAGTCACATAATAAGGAATGCATCCCTGTGTAAG
TGCATTTTGGTCTTCTGTTTTGCAGACTTATTTACCAAGCATTGGAGGAATATCGTAGGTAAAAATGCCTA
TTGGATCCAAAGAGAGGCCAACATTTTTTGAAATTTTTAAGACACGCTGCAACAAAGCAGGTATTGACAAA
TTTTATATAACTTTATAAATTACACCGAGAAAGTGTTTTCTAAAAAATGCTTGCTAAAAACCCAGTACGTC
ACAGTGTTGCTTAGAACCATAAACTGTTCCTTATGTGTGTATAAATCCAGTTAACAACATAATCATCGTTT
GCAGGTTAACCACATGATAAATATAGAACGTCTAGTGGATAAAGAGGAAACTGGCCCCTTGACTAGCAGTA
GGAACAATTACTAACAAATCAG 
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Figure 1. Analysis of human BRCA2 splice site mutation c.-40+1 G>A.  
A Primers to exon 1 and in exon 2 (Forward primer: 5’-CGAGCTTCTGAAACTAGGC-3’ and Reverse primer: 5’- 
CTTTGTTGCAGCGTGTCTTA-3’) were used to PCR amplify cDNA fragments (nested PCR with identical primers) from 
the patient AML cells, LCL of parent, sibling and wild type control. The PCR fragments of the patient AML cells were cloned 
into a blunt vector and subsequently sequenced. The wild type and alternative fragment is shown on electrophoresis and in 
a schematic picture. B Genomic sequence exon 1 and 2 of BRCA2 (indicated in grey). Sequencing of cDNA revealed that 
the splice site mutation led to the disruption of the original splice site in intron 1 and use of an alternative splice site within 
exon1, resulting in a 99 nt shorter transcript. The original and alternative splice donor sites and the start codon are indicated in 
black. The original mutated splice donor site is underlined. C Primers specific for this alternative transcript (Forward primer: 
5’-TGTCTTTTGCGGCGACT-3’ and Reverse primer: 5’- TTCACAGGCCAAAGACGGTA -3’) confirmed that the alternative 
transcript (1235 bp) was highly expressed in cDNA of the parent and patient with the splice site mutation c.-40+1 G>A and not or 
very low expressed in the sibling and control sample.
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To provide direct evidence that the splice site mutation c.-40+1 G>A affects the expression of 
BRCA2, we examined c.-40+1 G>A using a mouse embryonic stem (ES) cell-based in vitro 
functional assay 13. We generated the c.-40+1 G>A mutation in a BAC clone containing full-
length human BRCA2 and expressed it in PL2F7 cells that have a mutant and a conditional 
allele of mouse Brca2. We confirmed the presence of the 5’ and the 3’ end of the human 
BRCA2 transgene in the ES cells by PCR and also confirmed the expression of the transgene 
by RT-PCR using primers to exons 11 and 18 (data not shown). 
We next examined the effect of the c.-40+1 G>A mutation on splicing in two PL2F7 
clones containing the BRCA2 mutant BAC (A2D7 and H2B1) using primers to exon 1 and 
exon 9, followed by a nested PCR using primers to exon 1 and exon 2. The correctly spliced 
form of 465 bp, was observed in the ES cells carrying the wild type BRCA2 (WT) while in 
both A2D7 and H2B1 mutant clones two fragments, one 306 bp and another 1159 bp in 
size were observed (Supp. Fig S2A). Sequence analysis confirmed that the 306 bp band in the 
mutant samples was the alternatively spliced form with loss of 99 nucleotides due to the use 
of an alternative donor site in the middle of exon 1 (Supp. Fig. S2B and S2C), similar to the 
patient samples. The 1159 bp band, however, retained the entire intron 1. Interestingly this 
splice form was not detected in the human samples. 
To examine the effect of aberrant splicing on transcript stability, we quantified the levels 
of the BRCA2 transcripts in mutant clones by q-PCR. The transcript levels were normalized 
to the BAC copy number. As shown in Figure 1A, we observed a significant reduction in 
transcript levels (A2D7, p=0.013 and H2B1, p=0.035) in the two mutants compared to 
WT, consistent with the results obtained in the FA patient. At present we do not fully 
understand why we did not detect the transcript retaining intron 1 in the human samples. 
It is possible that splicing or degradation of mRNA differs between cell types or between 
human and mice. We next examined the consequences at the cellular level of the c.-40+1 
G>A mutation. . We first tested its ability to rescue the viability of ES cells following deletion 
of endogenous Brca2. We have previously shown that Brca2-null ES cells are not viable. The 
mutants exhibited a 13-16 fold reduction (A2D7; 0.63% and H2B1; 0.52%) in the number 
of viable Brca2-null cells compared to cells carrying the WT BRCA2 (8.5%), indicating that 
the c.-40+1 G>A mutation severely affects BRCA2 function. Next, we assessed the DNA 
repair proficiency of the mutants by testing their sensitivity to DNA damaging agents and 
gamma-irradiation (IR). Both mutant clones, A2D7 and H2B1, were hypersensitive to the 
DNA damaging agents cisplatin, methyl methanesulfonate (MMS), MMC and IR compared 
to WT, suggesting a compromised DNA repair function (Fig. 2B). 
In most sequencing facilities, the non-coding exons of BRCA1 (#MIM 604370) and 
BRCA2 (#MIM 600185) are not sequenced. Therefore, we tested the contribution of 
BRCA1/2 non-coding exon mutations to familial breast cancer. A cohort of 752 unrelated 
familial non-BRCA1/2 breast cancer cases were selected from the department of Clinical 
Genetics at VU University Medical Center Amsterdam. Cases were selected by clinical 
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geneticists based on current clinical guidelines. Genomic DNA was isolated from peripheral 
blood samples by standard methods. PCR primers were designed to cover exon and exon/
intron boundaries of the non-coding exon 1 from BRCA1 and BRCA2. This mutation 
screening did not reveal any mutations in the splice donor sites. Online Supplementary 
Table 1 shows the observed variants and their prediction in splice site programs. This is in 
agreement with a previously published study, where the BRCA1 promotor/5’UTR region 
was screened in 150 Polish familial breast and/or ovarian cancer cases and no disease causing 
mutations in or close to non-coding exon 1 were reported.14 
In summary, we report a Fanconi anemia family with a novel mutation in the splice 
donor site close to non-coding exon 1 of BRCA2. This mutation leads to reduced expression 
of a transcript that lacks part of the 5’-UTR in human cells. A mouse ES cell based in vitro 
functional assay confirmed that the c.-40+1 G>A mutation affects splicing, and the resulting 
splice forms are unstable as seen by reduced transcript levels. Moreover, these experiments 
showed that BRCA2 containing c.-40+1 G>A rescues cell survival at a very reduced frequency 
and results in hypersensitivity to DNA damaging agents and gamma irradiation. Screening 
for BRCA1/2 non-coding exon mutations in a Dutch cohort of familial breast cancer cases 
did not reveal similar pathogenic variants. Since the mutation was found in a Japanese FA 
patient it would have been interesting to screen a Japanese cohort of familial breast cancer 
cases for this splice site mutation to test for a possible founder effect. Unfortunately, we did 
not have access to such a cohort of patients.
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Figure 2. Analysis of the BRCA2 c.-40+1 G>A splice site mutation in the mouse ES cell model 
A BRCA2 transcripts are present at lower levels in mutant clones (A2D7 and H2B1) compared to WT (Negative control - PL2F7 
cells do not carry human BRCA2) B Assessment of survival following exposure to DNA damaging agents. A metabolic cell 
proliferation assays (XTT) of cells 48h after treatment with cisplatin, MMS, MMC and gamma irradiation (IR) showed that both 
c.-40+1 G>A mutant clones were hypersensitive compared to wt cells.
Although we did not observe breast cancer cases with exon 1 splice site mutations, an 
increased breast/ovarian cancer risk as a consequence of such mutations cannot be excluded. 
We therefore recommend analyzing the non-coding exon of BRCA 1 and 2 in the screening 
A
B
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of familial breast and ovarian cancer. This study also highlights the importance of functional 
assays, where the mouse embryonic stem cell-based assay showed that the original missense 
variant (K2729N) in the FA patient was not pathogenic and consequently a novel pathogenic 
mutation in splice donor site close to non-coding exon 1 of BRCA2 was identified.
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Supplementary Table 1. Cell lines of members of the family of the FA patient with novel BRCA2 splice site mutation. Overview 
of the cell lines derived from this family and their mutation status and phenotype in a MMC- growth inhibition assay. The stop 
mutation was previously reported in old nomenclature as c.8732 C>A.
Mutation status Phenotype in MMC Growth 
 inhibition assay  Exon 1 Exon 20
Patient AML Cells (Not reverted) c.-40+1 G>A c.8504 C>A (p.S2835X) Sensitive
LCL Parent c.-40+1 G>A  - Resistant
LCL Sibling - c.8504 C>A (p.S2835X) Resistant
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Supplementary Table 2. Non-coding exon 1 BRCA1 and 2 variants identified in 752 familial breast cancer patients
Gene Exon Changea dbSNP Number of cases Prediction Programmesb
Splice site finder-like NN-splice Human Splice finder
BRCA1 Intron1 c.-20+101 C>G rs799905 397
Creating novel cryptic  
splice site (81.1)
-
Creating novel cryptic  
splice site (84.4)
BRCA1 Intron1 c.-20+55 G>A 1 - - -
BRCA1 Intron1 c.-20+11 C>T 4 - - -
BRCA1 5’UTR c.-86 C>T 1 -
Creating 
novelcryptic  
splice site 
(1.1)
Strengthening cryptic  
splice site (75.4>76.3.1)
BRCA1 5’UTR c.-54 G>A 1 - - -
BRCA1 5’UTR c.-20+73 C>T 1 - - -
BRCA2 Intron1 c.-40+164 G>A rs206119 716
Strengthening cryptic  
splice site (77.4>87.1)
-
Disrupting cryptic 
 splice site 
BRCA2 5’UTR c.-52 A>G rs206118 251 - - -
BRCA2 5’UTR c.-1011 C>T 1 - - -
WT A2D7 H2B1M
A
Exon1 Exon2
1159bp
465bp
306bp
B
Exon 1 Intron 1 Intron 1 Exon 2
C
Supplementary Figure 1. Analysis of BRCA2 c.-40+1 G>A splice site mutation transcripts in the mouse ES cell model 
A Nested PCR using primer pairs to exons 1 and 9 followed by primers to exons 1 and 2 produced a 465 bp band in WT and 306 
bp and 1159 bp bands in mutants, A2D7 and H2B1. M indicates DNA size maker. The larger fragment sizes, compared to those 
observed in the human samples are due to the presence of 180 bp and 120 bp myc-tags in the WT and mutant BACs, respectively. 
B The 306 bp band in mutants was the aberrantly spliced variant, due to use of a alternative donor site in exon 1, resulting in loss 
of 99 nucleotide, similar to that seen in human samples. C The 1159 bp band is a splice form that retains intron 1, a form not 
observed in human samples. Asterisk indicates the c.-40+1 G>A mutation in intron 1.
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Supplementary Figure 2. Analysis of BRCA2 c.-40+1 G>A splice site mutation transcripts in the mouse ES cell model 
A Nested PCR using primer pairs to exon 1 and 9 followed by primers to exon 1 and 2 produced a 465bp band in WT and a 306 
bp and 1159 bp band in mutants, A2D7 and H2B1. M indicates DNA size maker. The higher fragment sizes, compared to those 
observed in the human samples is due to the presence of a 180 bp and 120 bp myc-tag in the WT and mutants BACs, respectively. 
B The 306 bp band in mutants was the aberrantly spliced variant, due to use of an alternative donor site in exon 1, resulting in 
loss of 99 nucleotide, similar to that seen in human samples. C The 1159 bp band is a splice form that retains intron1, a form not 
observed in human samples. Asterisk indicates the c.-40+1 G>A mutation in intron 1.
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CHAPTER 4
RESISTANCE To ALKYLATINg 
AgENTS IN HumAN CELL LINES WITH 
HomozYgouS CHEK2*1100DELC 
muTATIoN
Preliminary report
Janine L. Bakker, muriel A. Adank, martin A. Rooimans, Henk m. W. verheul, 
Hanne Meijers-Heijboer, Quinten Waisfisz and Rob M. F. Wolthuis
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ABSTRACT
The breast cancer susceptibility gene CHEK2 has been shown to be part of the DNA damage 
response (DDR) pathway by regulating the cell cycle, apoptosis, and DNA repair. In this 
report, a unique set of cell lines derived from women homozygous for the CHEK2*1100delC 
mutation is used to investigate the role of CHEK2 in non-tumorigenic human cell lines. 
Analysis of the cell cycle, aneuploidy, and sensitivity to DNA damaging agents revealed that 
human CHEK2-deficient cells were resistant to the alkylating agents methyl methanesulfonate 
and temozolomide and the CHEK2-inhibitor NSC10955. These data may suggest that cells 
with a homozygous CHEK2*1100delC mutation have a phenotype with loss of normal 
apoptosis. Loss of apoptosis can result in resistance  to adjuvant chemotherapy and might 
explain the worse prognosis in CHEK2-associated breast cancer. Further studies have to 
confirm this hypothesis. 
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Introduction
Breast cancer susceptibility gene CHEK2
The cell cycle checkpoint kinase CHEK2 is a moderate breast cancer susceptibility gene and 
it is estimated that the truncating CHEK2*1100delC mutations result in a two to three fold 
increased breast cancer risk.1 2 The heterozygous mutation, which is predicted to result in 
truncation of the protein at codon 281 abrogating its kinase activity, is primarily present in 
Northern Europe. Tumors of these carriers showed a loss of heterozygosity (LOH) or low 
CHEK2 protein expression (immunohistochemical staining of wild-type CHEK2) in 27.3% 
and 80% of the tumors respectively, suggested to lead to loss of function of CHEK2.3  In data 
of Massink et al4 , LOH was detected in 20% and low mRNA in 60% of the breast tumors of 
heterozygous CHEK2*1100delC carriers. We have also described 10 cancer patients from 8 
families who were homozygous for the CHEK2*1100delC mutation. These patients suffered 
from a high incidence of multiple primary tumors. The female patients had an estimated 
increased breast cancer risk of at least four fold.5
CHEK2 as a multifunctional player in the DNA damage response pathway
Numerous studies on the function of CHEK2 in different model systems have been reported 
and describe that, in response to DNA double stranded breaks, CHEK is phosphorylated by 
ATM. Subsequently, activated CHEK2 has been shown to phosphorylate various substrates 
including p53, CDC25C, CDC25A, BRCA1, PML, and E2F-1, thereby acting as a signal 
transducer in the DNA damage response (DDR).6 In particular the connection between the 
tumor suppressor genes TP53 and CHEK2 has been studied in more detail. In the presence 
of DNA damage, CHEK2 has been described to phosphorylate Ser20 of p53 resulting in 
stabilization of p53, cell cycle arrest and apoptosis.7  Activated CHEK2 also phosphorylates 
MDMX resulting in its degradation which indirectly also activates p53.8 CHEK2 regulates 
the cell cycle also via CDC25A and CDC25C Phosphorylation of CDC25A promotes its 
proteosomal degradation which results in a G1 and S phase delay, while phosphorylation 
of CDC25C results in its sequestration into the cytoplasm inducing a G2/M arrest. These 
functions of CHEK2 may be redundant as these proteins are also targets of the cell cycle 
checkpoint kinase CHEK1.6 
Chek2 knockout mouse models 
Two different Chek2 knockout mouse models have been generated and showed abnormal 
IR-induced p53 stabilization in thymocytes and displayed resistance to IR-induced apoptosis 
at low dose irradiation.9 10 However, studies in human colon carcinoma and breast carcinoma 
cell lines with disrupted CHEK2 reported no difference in IR-induced p53 stabilization or 
apoptosis questioning the role of CHEK2 in the p53 DNA damage response pathway.11 12 
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MEFs from mice harboring a homozygous Chek2*1100delC mutation showed elevated levels 
of γH2AX and an altered cell cycle profile.13  Unlike ATM-deficient cells, the irradiated MEFS’s 
did not display substantial abnormalities in G2 arrest. In three different mouse models, the 
Chek2-/- mice had a low incidence of spontaneous tumor formation within one or two years 
compared to Chek2 +/- and Chek2 -/- mice..9 7 14 13  In two models, mice were challenged 
(locally or systemically) with the carcinogen DMBA and the Chek2-/- mice showed enhanced 
tumor formation.7 13  When a dominant negative variant of CHEK2 was overexpressed in a 
well-known mouse model of mammary tumorigenesis (Mouse Mamary tumor virus model 
(MMTV)) an increased rate of tumor formation was observed.15  Inactivation of Chek2 
together with a conditional disruption of Brca1 or overexpression of the oncogene RON also 
accelerated mammary tumor development.16 17 These latter observations suggest that Chek2 
deficiency may exacerbate genomic instability.
Human colorectal cell line HCT116 (CHEK2-/-) as a model for CHEK2-deficiency
Jallepalli et al. showed that in a colon carcinoma cell line lacking CHEK2, G1 and G2 
arrest were normal following irradiation.11  However when progression of the cell cycle 
without irradiation was studied in more detail, cells with inactive CHEK2 appeared to have 
an improper progression through mitosis, due to a lack of BRCA1 phosphorylation on 
Ser986. In live-cell microscopy experiments, these cells appeared to have a delay in mitosis 
and abnormal mitotic spindle assembly, which promotes missegregation of chromosomes. 
Eventually after prolonged culturing leading to aneuploidy. The aneuploidy caused by 
knockdown of CHEK2 was also observed in human fibroblasts.18 
 In this study, human cell lines of individuals with a homozygous CHEK2*1100delC 
mutation were derived. Subsequently, the phenotype of the cell lines was investigated by 
analysis of the cell cycle, aneuploidy, and sensitivity to DNA damaging agents.
Material and methods
Patients and cell lines
Blood samples and skin biopsies were collected from the patients homozygous for the 
CHEK2*1100delC mutation to establish lymphoblastoid and fibroblast cell lines. Written 
informed consent was obtained from all homozygous females and their family members 
to use their DNA for further investigation (following institutional guidelines). Fibroblasts 
were immortalized by transfection with expression vectors encoding either SV40 large T or 
hTERT and selection with 1-10 μg of hygromycin per ml. CHEK2-deficient lymphoblast 
cell lines were corrected with a full length CHEK2 cDNA in a pMEP4 vector. 
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Cell culture and drug treatments
Lymphoblastoid cells were grown in RPMI1640 (GIBCO) supplemented with 10% fetal calf 
serum and 1% sodium pyruvate at 37°C, 95% humidity, and 5% CO2. Fibroblast cells were 
grown in F-10 (GIBCO) supplemented with 10% fetal calf serum at 37°C, 95% humidity, and 
2% CO2. For growth inhibition tests lymphoblastoid cells were treated with Camptothecin 
(Sigma, cat.C9911-250mg), Cisplatin (Teva, cat.51.642.705), Hydroxyurea (Sigma, cat.
H8627-5g), Mitomycin C (MMC, Sigma, cat.M0440-25mg), Methylmethanesulfonate 
(MMS, Sigma, cat.129925-25g), Olaparib (Selleck Chemicals, cat.S1060-25mg) and 
CHEK2-inhibitor NSC109555 (Sigma, cat.SML0781-5mg). 
Western Blotting
Rabbit anti-CHEK2 (Epitomics, #3428-1, N-terminus, amino acid 1-200) and Rabbit 
anti-Tubulin (1:1000, Santa Cruz) were used as primary antibodies. Horseradish peroxidase 
(HRP)-conjugated goat anti-rabbit (1:5000; GE Healthcare) was used as secondary antibody, 
and the signal was detected with chemiluminescence (ECL Plus Western blotting detection 
reagent; GE Healthcare). 
Cell cycle analysis and irradiation
CHEK2 wild type and homozygous CHEK2*1100delC primary fibroblasts were plated and 
grown to 60% confluency and irradiated with varying dosages. After 48 hours cells were 
trypsinized, washed in cold PBS, and treated with lysis buffer (NaCl 0,150 mM, Tris/HCl 
0,1 M, MgCl2 0,5 mM, CaCl2 1mM, BSA 0,35%, Igepal 0,1%) for 15 minutes at −4
◦C. 
Cells were then stained with PI/RNase staining buffer (BD Biosciences) for 10 minutes and 
analyzed on a FACS flow cytometer (BD FACSCalibur, BD Biosciences). Irradiation was 
carried out in an irradiator that uses 137Cs source to produce a dose-rate of 20 rads/sec.
Results
CHEK2-deficient human cell lines derived from homozygous 
CHEK2*1100delC patients
Initially, 8 families with 10 individuals homozygous for the CHEK2*1100delC mutation 
were identified (Figure 1). CHEK2-deficient cell lines were obtained from 6 individuals of 
these families. In total, we obtained 5 lymphoblastoid cell lines and three primary fibroblast 
cell lines homozygous for the CHEK2*1100delC mutation (Table 1). Several primary 
fibroblasts were immortalized with hTERT and SV40 and all lymfoblastoid cell lines were 
immortalized with Epstein-Barr virus (Table 1) One lymphoblastoid cell line heterozygous 
for the CHEK2*1100delC mutation was collected. 
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Figure 1. Cell lines derived from families with homozygous CHEK2*1100delC mutations. 
Pedigrees of breast cancer patients homozygous for the CHEK2*1100delC mutation. Genotyping results are mentioned above 
each individual (+/+ =homozygous, +/- =heterozygous, and -/- =wild-type). Individuals with breast cancer (B) are shown as filled 
circles, with the age at diagnosis. Other cancers are indicated beneath the relevant individuals. Carc=carcinoma of unknown 
type, Co=colon, Cx=cervical, Eso=esophageal, Leu=leukemia, Lu=lung, Mel=melanoma (Oc=ocular; is=in situ), Ov=ovarian, 
Pa=pancreatic, Re=renal, Sarc=chondrosarcoma, Sk=skin, Thym=thymoma, Ut=uterine, and d=age of death. All CHEK2*1100delC 
mutation carriers are negatively tested for BRCA1/2 and additional test results are indicated below the particular individual. This 
figure is kindly provided and published by Adank et al. 19  
Table 1. Description of patient derived cell lines with homozygous and heterozygous CHEK2*1100delC mutations. 
Number Family nr Chek2*1100delC Cancer history Available cell lines
VU1494 1 Homozygous B 55 and B 56 Lymphoblasts, Fibroblasts (primary, SV40, Htert)
VU1495 1 Homozygous B 63 and B 67 Lymphoblasts, Fibroblasts (primary, SV40)
VU1621 8 Homozygous B 26 Lymphoblasts, Fibroblasts (primary, SV40)
VU1674 5 Homozygous B 45 Lymphoblasts
VU1675 5 Homozygous B 47 and Co 43 Lymphoblasts
VU1676 2 Heterozygous B 44 Lymphoblasts
Human CHEK2 deficient lymphoblasts show resistance to alkylating agents
Cells with a defect in DNA repair or DDR are sensitive to certain DNA damaging agents. 
ATM deficient cells are sensitive to ionizing radiation while BRCA1 deficient cells are 
sensitive to DNA crosslinking agents, topoisomerase 1 inhibitors, and ionizing radiation. 
515504-L-bw-Bakker
Processed on: 1-12-2017 PDF page: 71
71
In addition, inhibition of the enzyme PARP, which is involved in DNA single strand break 
repair, is synthetic lethal for cells with a defect in BRCA1 and BRCA2.20  Lymphoblastoid cell 
lines with a homozygous CHEK2*1100delC mutation were analyzed for their sensitivity to 
crosslinking agents, a topoisomerase I inhibitor, alkylating agents, a CHEK2 kinase inhibitor 
and the PARP inhibitor Olaparib. Corrected CHEK2-deficient cells (Figure 2) and FANCM-
deficient lymphoblastoid cell lines were used as controls in these assays. CHEK2-deficient 
cell lines showed resistance to CHEK2 inhibition (Figure 4). Surprisingly, CHEK2-deficient 
lymphoblasts were also resistant to alkylating agents (Figure 3). This resistance is not related 
to replication stress because CHEK2-deficient cells were not resistant to cross-linking agents 
(Figure 5). The lymphoblastoid cell lines were also screened for sensitivity to other commonly 
used agents like doxorubin, taxol, irrinotecan, cisplatin, and gemcitabine (data not shown), 
but there were no differences detected between the CHEK2-deficient and corrected cell lines. 
Cell cycle analysis in patient-derived fibroblasts 
In order to study the effect of CHEK2 deficiency on the cell cycle, cell cycle analysis was 
performed on primary fibroblasts from patients homozygous for the CHEK2*1100delC 
mutation. As shown in Figure 6, the cell cycle profiles from CHEK2-deficient primary 
fibroblasts with and without exposure to 10 Gy of ionizing radiation was comparable to wild 
type fibroblasts. In contrast, ATM-/- deficient fibroblasts displayed a prolonged accumulation 
in G2/M phase due to radiosensitivity. 
Aneuploidy in immortalized human fibroblasts
Disruption of CHEK2 has been associated with aneuploidy and chromosomal instability in 
vitro.18  To study aneuploidy in immortalized homozygous CHEK2*1100delC fibroblasts, 
the number of chromosomes per metaphase were recorded after prolonged culturing (Figure 
7). Aneuploidy was observed in 64% and 68% of the CHEK2-deficient and wild type cells 
respectively. 
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VU1494-L +CHEK2      VU1494-L         VU1621-L             HSC93                VU867-L
(CHEK2*1100delC) (CHEK2*1100delC)           (WT)                       (FANCM)
Tubulin
CHEK2
Figure 2. Western blot analysis of CHEK2 in Human CHEK2-deficient, Wild-type en corrected lymphoblast cell lines. For each 
assay, two CHEK2-deficient cell lines with homozygous CHEK2*1100delC mutation (VU1494 and VU1621) and a corrected 
CHEK2-deficient cell line (VU1494 +CHEK2) were used. Wild type (HSC93) and FANCM –deficient (VU867) cells were used 
as controls.
Figure 3. Human CHEK2-deficient lymphoblasts show resistance to alkylating agents.  
For each assay, two CHEK2-deficient cell lines with homozygous CHEK2*1100delC mutation (VU1494 and VU1621) and a 
corrected CHEK2-deficient cell line (VU1494 +CHEK2) were used. Wild type (HSC93) and FANCM –deficient (VU867) cells 
were used as controls. A Growth inhibition assay with the alkylating agent Methyl methanesulfonate (MMS). The data represent 
mean ± S.E.M. (standard error of the mean) of three independent experiments. B Growth inhibition assay with the alkylating 
agent Temozolomide (TMZ) (single experiment) 
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Figure 4. Human CHEK2-deficient lymphoblasts show resistance to CHEK2 inhibition and no sensitivity to PARP inhibition. 
A Growth inhibition assay with selective CHEK2-inhibitor (NSC 109555) B Growth inhibition assay with PARP-inhibitor 
Olaparib. 
Figure 5. Human CHEK2-deficient lymphoblasts do not show major sensitivity or resistance to cross-linking agents, Hydroxyurea, 
or topoisomerase I inhibitor. 
A Growth inhibition assay with the cross linking agent Mitomycin C (MMC). B Growth inhibition assay with replication 
inhibitor Hydroxyurea (HU.) C  Growth inhibition assay with the cross linking agent Cisplatin. D Growth inhibition assay with 
the topoisomerase I inhibitor Camptothecin.
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WT WT + IR
1100delC 1100delC + IR
ATM-/- ATM-/- + IR
B
FEN-F (WT) VU1494-F (CHEK2 -/-) ATM-F (ATM-/-)
G1 S G2/M G1 S G2/M G1 S G2/M
- IR
Percent cell population 87 2 9 89 1 8 74 4 19
+IR (48hr)
Percent cell population 86 3 10 90 1 7 66 2 25
Figure 6.  A Flow cytometry of wild type ATM-/- and homozygous CHEK2*1100delC primary fibroblasts following radiation of 
10 Gy and in absence of radiation. B Cell cycle distribution wild type, ATM-/- and homozygous CHEK2*1100delC fibroblasts.
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B
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Figure 7. Individual chromosome numbers from metaphase spreads of cultured human fibroblasts with and without homozygous 
CHEK2*1100delC mutation after 30 passages (n=51).
Discussion
In this report, human lymphoblastoid and fibroblast cell lines derived from individuals with 
a homozygous CHEK2*1100delC mutation were used to investigate the role of CHEK2 in 
human cells. The high incidence of multiple primary tumors in women homozygous for 
this mutation suggests that CHEK2 plays an important role in preventing tumorigenesis.5 
Growth inhibition tests with DNA damaging agents revealed that human cells with a 
homozygous CHEK2*1100delC mutation were resistant to alkylating agents. MMS 
(methyl methanesulfonate) and temozolomide methylate DNA at N7-deoxyguanosine, 
N3-deoxyadenosine and O6-methylguanine. O6-methylguanine lesions are the most 
mutagenic and cytotoxic and can be reversed by the DNA repair enzyme O6-methylguanine 
methyltransferase (MGMT).21 22  Not only tumors with high levels of MGMT, but also 
defects in the mismatch repair system and apoptotic pathways can be involved in resistance 
to alkylating agents. Defects in the mismatch repair pathway cause resistance to the alkylating 
agent temozolomide, presumably because the cells become tolerant to the mispairing of 
O6-methylguanine with thymine.23  Alkylating agents have shown the strongest effect in 
glioma and hematological cancers. It is suggested that defects in the ATM/CHEK2/p53 
cascade accelerates tumor formation and is involved in radiation resistance in a glioma mouse 
model.24  It is not known to what extend the expression of CHEK2 is involved in response of 
human or mouse glioma to alkylating agents. In the past the role of CHEK2 in the p53 DNA 
damage axis has been questioned, since in mouse models deletion of Chek2 did not appear 
to have a major impact on p53 function or the cell cycle.9 14  In addition, Chek2-deficient 
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mouse models did not display spontaneous cancer predisposition like Brca1/2 or p53 deficient 
mouse models. However, immature thymocytes of Chek2 -/- mice are resistant to irradiation 
induced apoptosis, suggesting that CHEK2 is involved in apoptosis in certain cell types.9 
Further functional studies with CHEK2-deficient lymphoblasts need to show if the resistance 
to alkylating agents is related to apoptotic pathways or ineffective cell cycle arrest. Changes in 
DNA methylation are also associated with the development of drug resistance.25  This might 
explain why a worse distant disease-free and worse breast cancer-specific survival is observed 
for CHEK2-associated compared to non-CHEK2-associated breast cancer in the group of 
patients with adjuvant chemotherapy.26  However, no differential efficacy of chemotherapy 
given for metastatic breast cancer was observed in CHEK2*1100delC mutation carriers versus 
non-CHEK2*1100delC mutation carriers.27  It would be interesting to do a subanalysis in the 
CHEK2*1100delC-carriers with loss of heterozygosity. In conclusion, we were able to detect 
a clear phenotype of resistance to methylating agents in CHEK2-deficient human cells which 
might explain resistance to adjuvant therapy in CHEK2-associated breast cancer. Further 
studies are necessary to understand the mechanism of this resistance and its involvement in 
breast cancer development.  
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CHAPTER 5
ANALYSIS of THE fANCoNI ANEmIA 
REPAIR PATHWAY IN BREAST CANCER 
IDENTIfIES RECQL5 AmPLIfICATIoN 
AS A mEDIAToR of DNA 
CRoSSLINKER SENSITIvITY
Submitted
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ABSTRACT
Repair of DNA interstrand crosslinks requires the Fanconi anemia/BRCA (FA/BRCA) 
pathway. Biallelic germline mutations in FA/BRCA genes confer hypersensitivity to DNA 
crosslinking agents such as mitomycin C. Heterozygous mutations in some FA/BRCA genes 
predispose to breast cancer. Here, we screened for alterations in the FA/BRCA DNA repair 
pathway that might be relevant for breast cancer. We scored the induction of chromosomal 
breaks in a set of 40 breast cancer cell lines upon treatment with mitomycin C. Next, we analyzed 
exomes and copy number alterations of the mitomycin C-sensitive cell lines in relation to the 
FA/BRCA pathway. We functionally explored the effect of a remarkable amplification of the 
DNA helicase RECQL5. Interestingly, we found that mitomycin C-induced chromosomal 
breaks were strongly increased in five non-BRCA-mutated luminal breast cancer cell lines. 
These cell lines still showed RAD51 focus formation and FANCD2 monoubiquitination, 
indicating that the FA core complex signaling and homologous recombination were not 
abrogated. We created an overview of potentially deleterious variants, homozygous loss of 
function variants as well as amplifications, that might be associated to the FA/BRCA repair 
pathway. Unexpectedly, one sensitive cell line had a focal amplification of RECQL5 on the 
HER2 amplicon on chromosome 17. While RECQL5 normally supports DNA repair and 
proliferation, we show that reducing the amplicon-derived RECQL5 expression attenuates 
mitomycin C-sensitivity. Importantly, fibroblasts become sensitive to mitomycin C upon 
RECQL5 overexpression. This indicates that RECQL5 amplification, when giving rise to 
sufficient protein expression, has a dominant negative effect that is toxic when combined with 
DNA crosslinks. In conclusion, the mitomycin C-induced chromosomal breakage assay can 
be used to identify genomic alterations which contribute to a FA/BRCA-like phenotypical 
response in luminal and HER2 positive breast cancer. We identified potentially relevant 
missense mutations in Fanconi anemia DNA repair pathway genes. We show that RECQL5 
amplification might be a potential biomarker for hypersensitivity to DNA crosslinking agents 
in HER2 positive breast cancer.
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Introduction
One of the key hallmarks of cancer is genomic instability.1 A critical pathway involved in 
protection of the genome and prevention of tumorigenesis is the Fanconi Anemia (FA)/BRCA 
repair pathway. The pathway is thought to be essential for the repair of DNA interstrand 
cross-links (ICLs), as well as downstream DNA double strand breaks.2 FA is characterized 
by developmental abnormalities, bone marrow failure, and a high risk of developing cancer. 
Until now, nineteen FA genes have been identified that may cooperate in DNA repair.3 At least 
eight FA proteins form a multisubunit E3 ubiquitin ligase complex, which monoubiquitinates 
FANCD2 and FANCI. This central FANCD2/I complex then localizes to DNA lesions and 
coordinates unhooking of the cross-links, by acting as a landing platform for endonucleases. 
Unhooking eventually leads to a double strand break, which is resolved by the downstream 
FA proteins through homologous recombination (HR).4 Germline mutations in several of 
the downstream members of this pathway, like BRCA1/2, PALB2 and RAD51C, predispose 
to breast and/or ovarian cancer. Due to loss of the wild-type allele, tumors of patients with 
BRCA1/2 mutations become hypersensitive to DNA cross-linking agents such as cisplatin 
and mitomycin C (MMC).5 There is substantial evidence that a portion of sporadic breast 
cancers have defects in the FA/BRCA pathway too6  7, especially regarding the basal subtype of 
breast cancer, which shows substantial chromosomal instability 8. Much less is known about 
the status of the FA pathway in luminal A, luminal B and ERBB2 (HER2-positive) subtypes. 
Markers like promotor methylation, changes in the expression of FA/BRCA genes, or RAD51 
focus formation, are often used to screen for FA/BRCA defects.9  8 However, the gold standard 
revealing a functional FA/BRCA defect in cells, is the induction of chromosomal breaks in 
response to crosslinking agents.10 In this study we used this assay to evaluate 40 breast cancer 
cell lines for FA/BRCA repair pathway defects. We investigated genomic alterations that may 
underlie the induction of chromosomal breakage after exposure to MMC. 
Methods
Cell culture, growth inhibition assay and chromosomal breakage analysis
Breast cancer cells were cultured in DMEM with 10% FBS or RPMI with 1% Natriumpyruvate 
and 10% FBS. Growth inhibition assays were performed using mitomycin C (Takeda 
Netherlands), Camptothecin (Sigma) and PARP inhibitor (KU58948, Axon Medchem). In 
a 96 wells plate 1500-3500 cells were seeded and 24 hours later different concentrations 
of the agent were added (in triplicate). After 5-10 days, when cells were ~ 70% confluent, 
viability of the cells was measured by Cell Titer Blue Assay (Promega). Ten microliter of Cell 
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Titer Blue was added in every well for 3-6 hours and afterwards absorbance was measured 
at 570 nm. At least two independent experiments were performed for each drug condition. 
For the chromosomal breakage analysis, cells were seeded in 80 cm2 tissue culture flasks and 
cultured at 37°C in the presence or absence of 100 nM MMC. After 48 hours, metaphase 
spreads were Giemsa-stained and analyzed for microscopically visible chromosomal breaks as 
described by Oostra et al.10 From each coded culture, at least 50 metaphases were examined 
for chromosomal damage. The presence of chromatid breaks and interchanges was expressed 
as break events per cell. After scoring, the slides were decoded and the results were analyzed. 
In every experiment positive and negative control conditions were implemented.
Lentiviral preparations
The open reading frame of human RECQL5 was cloned into a doxycycline-
regulated lentiviral vector (pLVX-TRE3G). The following primers were 
used to amplify RECQL5 cDNA, with addition of EcoR1 restriction sites: 
3’-GATAgaattcgccaccATGAGCAGCCACCATACCACCTTT CC-5’ and 
5’-GATAgaattcTCATCTCTGGGGGCCACACAGG-3’. Viruses were generated in 
HEK293T cells and titers were determined using the Lenti-X Tet-On 3G Inducible 
Expression System (Clontech) according to the manufacturer’s instructions. We used 0,75 
ug/ml doxycycline (Dox) to induce expression of RECQL5iIn fibroblasts and 50 nM MMC 
to induce chromosomal breakage. 
Immunoblot, immunofluorescence, and scoring of Rad51 foci
For immunoblotting, cells were lysed on ice with ice-cold lysis buffer consisting of 10 mM 
Tris-HCl, (pH 7.5), 150 mM NaCl, 0.5 mM EDTA, 0.5% NP40 and protease inhibitors. 
The primary antibodies used were: anti-FANCD2 (Santa Cruz, sc-20022, 1:500), anti-alpha-
tubulin (D-10) (Santa Cruz, sc-5274, 1:5000), anti-Vinculin (H-10) (Santa Cruz, sc-25336, 
1:1000), anti-RECQL5 (Santa Cruz, sc-16157, 1:250). For immunofluorescence, cells 
were seeded onto coverslips and incubated for 24 hours at 37°C and 5% CO2. Irradiation 
was performed using a 137Cs source (0.7 Gy/min) achieving a total of 10Gy and cells were 
subsequently cultured for 2 hours. RAD51 immunofluorescent staining was performed 
as described by Napal et al.11. The following antibodies were used: anti-FANCD2 (Novus 
NB100-182, 1:200), anti-TP53BP1 (Novus, 100305, 1:1000), anti-RAD51 (kind gift of 
R. Kanaar, Erasmus University, Rotterdam, 1:2,500), anti-Geminin (Genetex, GTX116125, 
1:400). The ratio of RAD51 foci positive cells among geminin positive cells was calculated. 
At least 50 geminin positive cells were counted for each sample. To generate error bars the 
standard error was estimated assuming a binomial distribution.
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Chromosomal FISH analysis
FISH was performed as previously described12. Here, we used an ERBB2 specific probe 
(RP11-9L15) and a RECQL5 specific probe (RP11-196E5) purchased from BlueGnome, 
according to the manufacturer’s instructions, following our established laboratory protocol. 
siRNA mediated knockdown
The breast cancer cell lines UACC893 and UACC812, and the SV-40 immortalized 
human fibroblast cell line LN9SV, were transfected with 0.1 ul Lipofectamine RNAimax 
(Invitrogen) and 25 mM siRNA. The following siRNA’s were used: RECQL5 siRNA (Santa 
Cruz, sc-38221), USP32 (Dharmacon smartpool M-006080-03-005), PSMB3 (Qiagen, 
Hs_PSMB3_6), FANCD2 (Dharmacon smartpool M-016376-02-0010), siControl Non-
targeting siRNA #2 (Dharmacon) as a negative control, and PLK1 (Dharmacon smartpool 
M-003290-01-0005) as a positive control. MMC was added 24 hours after transfection. Cell 
viability was measured as described above. For the chromosomal breakage analysis, cells were 
transfected in a T75 flask with 25nM or 50nM MMC. After 48 hours material was collected 
for Western blotting and chromosomal breakage analysis as described before. 
Statistical analysis
Data with regard to the amount of breaks were analyzed in SPSS (IBM software). For 
comparison of different subtypes or subgroups, an independent sample T-test was performed. 
For comparison of breaks in the cell lines UACC893 after knockdown with siRECQL5, a 
chi-square test was performed using different classes of breaks per cell. The software used for 
analysis of expression and genomic data is mentioned in the following section. Pearson chi-
square test was used to reveal significant difference (p<0.01) between the samples related to 
the distribution of classes of MMC-induced and spontaneous chromosomal breaks.
Gene expression microarray and SNP microarray copy number analyses
Total RNA and DNA were isolated from breast cancer cell lines and mRNA expression and 
copy number data were collected as described by Riaz et al13. The data files were imported 
in Partek Genomics Suite 6.6 and Log2 transformed before analysis. ANOVA analysis was 
then used to determine differentially expressed probe-sets. Unpaired copy number analysis 
was performed in Partek, comparing signal Log2 ratios to a custom created reference baseline 
of 90 HapMap CEPH samples with European ancestry (CEU). The genomic segmentation 
algorithm was used to detect gained and deleted segments and estimate copy number level 
with stringent parameters (P<0.0001, in bins of >20 markers, signal/noise ≥0.45). SNP, gene, 
and cytogenetic band locations are based on the hg19 Genome build. For analysis of the 
RECQL5 amplification in primary breast tumors the following data sets were used: Tumor 
samples of Jonsson et al.14, Wang et al.15 and Massink et al.16. 
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Exome sequencing
Genomic DNA of the cell lines was isolated using QIAamp DNA Mini Kit (Qiagen). Libraries 
were prepared as described by Ameziane et al.17 Nimblegen SeqCAP EZ Human Exome 
Library v3.0 kit (Roche) was used for exome enrichment. Sequencing on an Illuma HiSeq 
2000 and data processing was performed as previously described17. Annotated variants were 
further filtered by mappability>0.9, alternative allele frequency in exome sequencing project 
(ESP) <5% (present in at least 90 % of the sequence reads), and by discarding synonymous 
variants. The automated gene prioritization tool ToppGene18 in combination with Combined 
Annotation Dependent Depletion (CADD score >15, CADD version 1.3) was used to 
select genes associated to the FA/BRCA repair pathway with possible pathogenic variants. 
ToppGene ranked candidate genes based on functional similarity to the known FA/BRCA 
genes and the CADD score selected possible pathogenic variants identified in by sequencing 
of the exome. We also screened for homozygous clear loss of function variants (not reported 
in 1000 genomes or exome sequencing project). All presented variants were visually checked 
using IGV (Integrative Genomic Viewer). We evaluated the effect of identified rare missense 
variants using three in silico algorithms, PolyPhen4, SIFT and Align GVGD (Alamut Visual 
2.7.1 April 2015).
Results
MMC-induced chromosomal breakage in sporadic breast tumor cell lines
MMC-induced chromosomal breakage analysis was performed on a panel of 40 breast 
cancer cell lines. Metaphase spreads of all four BRCA1-deficient basal breast cancer cell 
lines19 showed an elevated number of MMC-induced chromosomal breaks (Figure 1 and 
Supplementary Table 1), and a significantly elevated frequency of spontaneous chromosomal 
breaks compared to other breast cancer cell lines (Supplementary Table 1). In addition, five 
breast cancer cell lines revealed a similar sensitivity to MMC as the BRCA1-deficient cell 
lines. To our surprise, these cell lines were all of the luminal subtype and not of the basal 
subtype and did not show an elevated number of spontaneous breaks compared to other 
luminal cell lines (Figure 1 and Supplementary Table 1).
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Figure 1. MMC-induced chromosomal breakage analysis in 40 breast cancer cell lines.  
Waterfall plot of the MMC breakage analysis results of the 26 most sensitive breast cancer cell lines. B indicates BRCA1-deficient 
cell lines and F indicates FA/BRCA-like cell lines. Cells were treated with 100nM MMC for 48 hour before fixation. An example 
of a metaphase spread with chromosomal breaks (encircled in red) is depicted on the right. 
Sensitivity to DNA-damaging agents and radiation-induced RAD51 foci in FA/BRCA-like 
sporadic breast cancer cell lines
We next investigated the status of the FA/BRCA pathway by analyzing FANCD2 
monoubiquitination in response to MMC treatment (Supplementary Figure 1). In all five 
luminal FA/BRCA-like cell lines, the mono-ubiquitinated isoform of FANCD2 was detected 
after MMC or hydroxyurea treatment, indicating that the upstream FA pathway was intact. 
The five FA/BRCA-like breast cancer cell lines, two BRCA1-deficient breast cancer cell lines, 
and two non-sensitive cell lines were additionally tested for their sensitivity to MMC, the 
topoisomerase I inhibitor camptothecin, and the PARP inhibitor KU58948, using growth 
inhibition assays in 96 well plates with Cell Titer Blue as a read out. All BRCA1-deficient 
and FA/BRCA-like cell lines were hypersensitive to MMC as well as to camptothecin, which 
indirectly leads to double stranded breaks too (Supplementary Figure 2). An important 
hallmark of the homologous recombination repair pathway of double stranded breaks is 
the formation of RAD51 foci upon treatment with irradiation. We analyzed RAD51 foci 
formation after irradiation and simultaneously stained for geminin expression, which is a 
marker for the G2-M phase of the cell cycle20, to correct for differences in proliferation 
between the cell lines. Subsequently, the number of RAD51-positive cells among geminin 
positive cells was calculated. All FA/BRCA-like cell lines were able to induce RAD51 foci 
after ionizing radiation, whereas each of the BRCA1-deficient cell lines lacked induction of 
RAD51 foci (Figure 2). Cells deficient in double stranded break repair and lacking RAD51 
foci induction, e.g. cells with a defect in BRCA1/2, PALB2, or RAD51C, are sensitive to 
PARP inhibitors21. We found that only three out of the four BRCA1-deficient cell lines, 
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and two of the five FA/BRCA-like cell lines (MDA-MB-330, SUM185PE), were sensitive 
to PARP inhibition, while the other cell lines were resistant (Supplementary Figure 3). 
Resistance in BRCA1-deficient mammary tumors could be due to somatic loss of TP53BP1, 
which partially restores homologous recombination.22 23 However, in HCC1937, the 
BRCA1-deficient PARPi- resistant cell line, the level of 53BP1 foci was comparable to that 
in the PARP sensitive BRCA1-deficient cell lines (Supplementary Figure 4B). The SUM185 
cell line carries a homozygous missense variant in 53BP1 (c.4084C>T; p.Arg1319His, see 
below), that apparently does not confer PARP inhibitor bypass, in line with its predicted 
benign effect on protein function (Table 1 and see below). In conclusion, despite the cross-
linker hypersensitivity, based on ionizing radiation induced RAD51 foci, homologous 
recombination in the identified FA/BRCA like cell lines appeared to be intact. 
                 FA/BRCA-like                                                        WT                       BRCA1-decient               
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Figure 2. Radiation-induced RAD51 focus formation  
A Quantification of RAD51 foci in 5 FA/BRCA-like, 1 positive control (breast cancer cell line MDA-MB-231) and 4 negative 
control (BRCA1-deficient) cell lines. Average data are shown with standard error of the mean of three independent experiments. B 
RAD51 and Geminin immunofluorescence staining in FA/BRCA-like cell lines; Nuclei are shown in blue with DAPI, RAD51 foci 
in red and geminin in green.
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Variants in DNA repair genes in cell lines with a FA/BRCA-like phenotype 
We subsequently performed whole exome sequencing to screen for putative mutations in 
DNA repair genes that might explain the observed FA/BRCA-like phenotype in the five 
MMC-sensitive cell lines. At first, based on a Knudson’s two-hit model of gene mutation, 
we screened for possible pathogenic homozygous variants. A ToppGene Prioritization tool 
was used to rank the genes according to their functional similarity to the FA/BRCA genes 
(Supplementary Table 2).
 Secondly, we screened all homozygous truncating variants (deletions, frameshift, 
nonsense, and splice site variants, see Supplementary Table 4. The results show several 
potentially relevant variants that, alone or in combination, may contribute to MMC 
sensitivity. For example, the MM330 cell line harbors a homozygous BRCA1 missense 
variant (c.1076T>C; p.(Gln356Arg)) that is relatively common and was reported not to 
be involved in hereditary breast cancer.24 25 However, there is one study showing that this 
SNP acts as a low risk allele with an odds ratio of 1.5.26 Nevertheless, MM330 in addition 
carries potentially damaging homozygous missense variants of ATM and SMAD4. Inhibition 
of ATM is particularly poorly tolerated in FA cells27, and, in mice, Smad4 deletion leads 
to reduced function of the FA proteins.28 So, potentially in combination with these ATM 
and SMAD4 alterations, the common BRCA1 variant found in this cell line could be 
less benign, and contribute to the increased MMC sensitivity. However, pinpointing the 
functional implications of each of, or particularly the combination of, the identified missense 
variants, is a daunting task that requires both rescue experiments in cancer cell lines and 
precise gene editing approaches in non-transformed model cell lines. Table 1 summarize the 
potentially deleterious homozygous variants that we identified in genes that are significantly 
associated with the FA/BRCA pathway, and that might contribute to the observed MMC 
response. The table reveals that several of such variants, such as a FAN1 missense variant 
(c.440T>G; p.(Met50Arg)), classified as potentially damaging by the Polyphen-2 prediction 
algorithm, appear relatively frequently in the general population. As an additional example, 
SUM185 cells combine a fairly rare, homozygous missense variant in RBBP8/CTIP with a 
common but possibly damaging MUS81 allele. RBBP8/CTIP inactivation causes increased 
cross-linker sensitivity29 30 while MUS81 inactivation in itself has no effect, but is reported 
to enhance crosslinker sensitivity of FA cells.31 MUS81 plays a role in the processing of 
aberrant replication forks and loss of MUS81 in human cells leads to a small increase of 
sensitivity to cross-linking agents suggesting that there may be functional redundancy 
between the MUS81 and other repair proteins in the response to DNA damage32. This 
further raises the interesting possibility that combinations of weak alleles may reduce the 
competence of the downstream FA/BRCA repair pathway, even though single variants are 
well tolerated. Furthermore, a fairly common but possible pathogenic variant was detected 
in the nucleotide excision repair protein ERCC6. ERCC6, part of the transcription coupled 
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E
RECQL5
Vinculin
SUM52        SUM44        SUM185       UACC893      SUM1315
RECQL5
Vinculin
A
B
MMC - +        - +
Dox - - +       +
LN9SV tetRECQL5
P < 0,01
P < 0,01
C
Figure 3. Focal amplification of helicase RECQL5 in a FA/BRCA-like cell line. A SNP array data of chromosome 17 shows a 
high level focal amplification of RECQL5. B Western blot analysis shows a high expression of RECQL5 protein in UACC893 
compared to other breast cancer cell lines. C Cell viability assay of UACC893 (RECQL5 amplification) and UACC812 (no 
RECQL5 amplification) after treatment with MMC. Knockdown of RECQL5 in UACC893 cells results in a decreased sensitivity 
to MMC. In the control cell line UACC812, RECQL5 knockdown increases sensitivity to MMC. D MMC-induced chromosomal 
breakage assay of SV40-immortalized human fibroblast cell lines LN9SV with inducible lentiviral vector with RECQL5. Fifty 
metaphases were counted per condition. An amount of 0,75 microgram/ml doxycycline (Dox) was used to induce expression of 
RECQL5 and 50 nM MMC to induce chromosomal breakage. Pearson chi-square test shows a significant difference (p<0,01) 
between the samples related to the distribution of classes of MMC-induced and spontaneous chromosomal breaks. E Metaphase 
FISH analysis in UACC893 using the RECQL5 probe (green) and an ERBB2 probe (red). The illustration shows chromosomes 
with coloring of single copies of the genes on chromosome 17. Other chromosomes show a ERBB2/RECQL5 co-amplification 
with abundant coloring (yellow) of ERBB2 and RECQL5. F Western blot analysis of induced expression of RECQL5 in SV40-
immortalized human fibroblast (LN9SV tertRECQL5).
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nucleotide excision repair-dependent pathway contributes to the removal of cisplatin and 
MMC ICLs33 and ERCC6 mutations were functionally associated with platinum sensitivity 
in epithelial ovarian cancer34. Supplementary Table 4 shows homozygous truncating and 
splice site variants, but this revealed no additional hints towards mechanisms of acquired 
MMC sensitivity. In conclusion, no unequivocally deleterious, low frequency alleles in the 
FA pathway were identified in these five MMC sensitive cell lines. However, in several cell 
lines variants were found in genes that have been implicated in DNA repair and the DNA 
damage response. 
Focal amplification of helicase RECQL5 in ERBB2 positive breast cancer 
To further explore the DNA repair pathways in the FA/BRCA-like breast cancer cell lines, 
we screened for significant up- or down-regulated genes involved in DNA repair or DNA 
damage signaling. We compared the gene expression of 101 DNA repair genes35 (listed in 
Supplementary Table 3). Interestingly, this analysis revealed abundant expression of the 
helicase RECQL5 in cell line UACC893. Copy number analysis showed a small segmental 
high level DNA amplification (188 kb, mean copy number 37.7) including the ERBB2 
and RECQL5 genes, resulting in extremely high RECQL5 protein expression levels (Figure 
3A and B). Breakpoint analysis by exome sequencing showed that this amplification was 
positioned on chromosome 17 (data not shown). Paradoxically, at physiological expression 
levels, RECQL5 has been suggested to positively regulate HR by preventing inappropriate 
HR events36 and protects FA-defective cells against MMC-induced damage.37 Furthermore, 
very recently, high expression of RECQL5 was reported to correlate with aggressive luminal 
and HER2 subtypes, and to promote proliferation of the untransformed MCF10 breast 
epithelial cell line when expressed at moderate levels.38 Therefore, we hypothesized that 
rigorous amplification of RECQL5 expression may act in a dominant negative manner, and 
could interfere with DNA repair and thereby contributing to the phenotype of UACC893 
cells. To test this, we first used siRNAs in an attempt to silence RECQL5 in UACC893 
cells, as well as in a control breast cancer cell line with normal RECQL5 levels, UACC812. 
Interestingly, RECQL5 knockdown partially reversed the sensitivity of cell line UACC893 
to MMC, but, in marked contrast, sensitized the control breast cancer cell line UACC812 to 
MMC (Figure 3C). These results indicate that reducing the overexpression of RECQL5 in 
UACC812 rescues repair of DNA cross-links. We also analyzed MMC-induced chromosomal 
breakage after RECQL5 knockdown in UACC893 and found significantly less chromosomal 
breaks (Supplementary Figure 5). However, by RNAi, it was not possible to fully dampen 
expression from the RECQL5 amplicon. To further investigate the implications of RECQL5 
overexpression, we then expressed a strongly inducible RECQL5 expression plasmid in a 
wild-type SV-40 immortalized human fibroblast cell line by lentiviral transduction (LN9SV 
tertRECQL5). Interestingly, in cell clones that displayed severe induction of protein 
overexpression, RECQL5 was by itself sufficient to cause a significant elevation of MMC-
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induced chromosomal breakage (Figure 3D) in SV40 immortalized human fibroblasts. 
Next, genomic breast cancer data sets were analyzed. A similar focal amplification of 
RECQL5 was observed in three ERBB2 amplification positive breast tumors in a total of 
three data sets with a combined number of 107 primary ERBB2 positive tumors.39  15  16 The 
RECQL5 amplification was not observed in the 940 tumors without ERBB2 amplification. 
ERBB2 and RECQL5 are both located on chromosome 17 (17q12 and 17q25). This suggests 
that a subset of the ERBB2 amplified tumors may be hypersensitive to cross-linking agents. 
Using fluorescence in situ hybridization (FISH) of cell line UACC893 with two differentially 
labeled chromosome 17-specific probes for RECQL5 and ERBB2, we confirmed that 
RECQL5 was indeed co-amplified with ERBB2 (Figure 3E). 
Discussion
 
MMC-induced chromosomal breakage was analyzed in a set of 40 breast cancer cell lines, 
which revealed five cell lines that display a FA/BRCA-like phenotype in the absence of 
deleterious BRCA1 or BRCA2 mutations. It is important to note that these five cell lines 
were all of the luminal or ERBB2 subtype, while most BRCA1 associated breast tumors are of 
the triple negative subtype40. In contrast to the BRCA1-deficient cell lines, all FA/BRCA-like 
cell lines form RAD51-foci upon ionizing radiation, indicating that RAD51 foci formation 
alone is an insufficient marker for the response to DNA-crosslinking agents. Only some of 
the cell lines with the FA/BRCA-like phenotype were sensitive to PARP-inhibition, in line 
with results obtained from 30 genetically altered avian DT40 cell lines with deletions in 
specific DNA repair genes.21 These DT40 cell line data show that not only HR proteins but 
also several components of the FA pathway (without a physical interaction with RAD51) are 
involved in the repair of PARP-DNA complexes. Possibly, the sensitivity to PARP inhibition 
is not only explained by a defect in HR but also by replication stress, related to trapped 
PARP complexes on the chromatin.21 One BRCA1-deficient cell line HCC1937 appeared 
to be resistant to PARP inhibition. The PARP-resistance in this cell line was not explained 
by loss of TP53BP1 function (Supplementary Figure 4B) described to restore homologous 
recombination.41
We then explored the underlying mechanism of the FA/BRCA-like phenotype in these 
five luminal breast cancer cell lines. We identified a focal, dominant negative RECQL5 
amplification to cause the enhanced MMC-induced chromosomal breakage in UACC893. 
RECQL5 is a helicase that is involved in DNA replication and interacts with RAD51 thereby 
inhibiting RAD51-mediated D-loop formation.42 Paradoxically, Recql5-deficient mice 
are highly cancer prone and Recql5-deficient ES cells show elevated levels of RAD51 and 
γH2AX foci.42 In response to replication stress, Recql5-deficient cells develop an increased 
level of chromosomal aberrations.42 Here, we find a related phenotype in cells that overexpress 
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RECQL5. We hypothesize therefore that overexpression of the helicase RECQL5 disrupts 
normal RAD51-mediated replication fork reversal. This replication fork reversal is necessary 
to bypass DNA damage during replication in human cells and is involved in a global response 
to genotoxic treatments.43 We emphasize that focal RECQL5 amplifications were also 
observed in ERBB2 positive primary breast cancer samples. The HER2/ERBB2 amplicon 
may incorporate sequences from multiple locations of the long arm of chromosome 17, 
and so HER2 may not be the only oncogene on this amplicon.44 For example, other studies 
described a 17q12–q21 amplicon harboring HER2/TOP2A co-amplification, associated 
with better relapse-free survival in patients treated with anthracycline-based chemotherapy.45 
Importantly, in a recent breast cancer cohort study, higher expression levels of RECQL5 were 
correlated to aggressive phenotypes, HER2 expression and poor survival outcomes .38 These 
observations are in line with our finding that RECQL5 and HER2 may be co-amplified 
and that RECQL5 overexpression interferes with DNA damage repair and result in tumors 
with a more chromosomal instable and more aggressive phenotype. Future studies should 
reveal if the response to chemotherapy and overall survival of the subgroup of patients with 
RECQL5/ERBB2 amplified tumors is different. 
Our study did not resolve the underlying mechanisms that conferred MMC sensitivity in 
the other four cell lines with a FA/BRCA-like phenotype. The phenotype might be due to 
acquired or inherited mutations in DNA repair genes that are unknown or were not included 
in our analysis, or a specific combination of mutations in known DNA repair genes. We did 
not explore epigenetic changes in these cell lines and so altered methylation of DNA repair 
genes may explain the FA/BRCA phenotype. However, aberrant methylation of the promoter 
regions of BRCA1/2 is highly unlikely since RAD51 foci formation was intact in these cell 
lines. Potentially, the MMC-induced breaks are a reflection of ongoing, forced activation of 
cell cycle progression, instead of direct DNA repair defects, a phenomenon that is associated 
with DNA replication stress-induced double strand breaks. DNA replication stress may also 
lead to sister chromatid cohesion defects, that are known to increase MMC-sensitivity in 
certain cases.46 This in line with the oncogene-induced DNA damage model that predicts 
that activation of oncogenes like MYC or Cyclin E induce genomic instability in cells that 
fail to arrest in G1 phase or are defective in acquiring senescence.47 Several of the investigated 
breast cancer cell lines displayed amplification of CCND1 gene, which is also associated with 
increased DNA replication stress (results not shown). Alternatively, aberrant activation of 
cell cycle regulated kinases like CDK1 and WEE1 can modulate cellular responses to DNA 
damage in TP53-defective cancer cells during interphase.48 
In conclusion, we screened the functionality of the FA/BRCA pathway in breast cancer 
and identified a subset of luminal non-BRCA1/2 mutated cell lines that are hypersensitive 
in an MMC-induced chromosomal breakage assay. RAD51 and FANCD2 appear not to 
be useful as markers for this hypersensitive phenotype. Whole exome sequencing did not 
reveal clear loss of function mutations in DNA repair genes. In one cell line however, the 
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phenotype appeared to be the result of a focal RECQL5 amplification, a possible new marker 
for hypersensitivity to DNA-damaging agents in a subset of patients with HER2 positive 
breast cancer. In conclusion, RECQL5 is a promising marker for chemotherapy sensitivity 
and prognosis that warrant further investigation.
SUM52                   SUM185
- 24hr                +72hr                         - +24hr               +72hr  MMC 100nM
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ND
MDA-MB-330         UACC893
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- 24hr                +72hr           MMC 100nM
0 +6hr                    +24hr                   0                       +6hr                 +24hr 1uM HU
SUM52                    SUM185
Supplementary Figure 1. FANCD2 monoubiquitination in BRCA1-like cell lines  
A FANCD2 Western Blot analysis of BRCA-like cell lines after treatment with 100 nM MMC shows a long and short form of 
FANCD2 after treatment in all cell lines, except cell lines SUM185. B Subsequent analysis of FANCD2 after 1uM Hydroxyurea 
(HU) in cell lines SUM52 and SUM185 shows little monoubiquitination of FANCD2 in SUM185 after prolonged treatment 
with HU. 
A
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Supplementary Figure 2. Sensitivity in Cell Titer Blue assay to DNA damaging agents.  
Plot of IC50 values for the BRCA1-like, BRCA1-deficient and control cell lines obtained for different DNA damaging agents A 
Mitomycin C (MMC) B Camptothecin 
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Supplementary Figure 3. PARP inhibitor sensitivity of BRCA1-deficient and BRCA-like cell lines
Growth inhibition assay after treatment with MMC in 96 wells format and Cell Titer Blue 
read out. Cell lines depicted with dashed lines are resistant to PARP inhibitor and cell lines 
with solid lines are sensitive to PARP inhibitor. BRCA1-deficient cell lines are depicted 
in red and BRCA1-like cell lines in blue. The figure shows that one BRCA1 deficient cell 
line (MDA-MB-436) is hypersensitive to PARP inhibition, while the others (SUM149, 
SUM1315) have intermediate sensitivity to PARP inhibitor. The BRCA1 cell line HCC1937 
is clearly resistant to PARP inhibitor. Two of the BRCA1-like cell lines (MDA-MB-330 and 
SUM185) show an intermediate sensitivity to PARP inhibitor.
A
515504-L-bw-Bakker
Processed on: 1-12-2017 PDF page: 99
99
Supplementary Figure 4. TP53BP1 in BRCA1-deficient and BRCA1-like cell lines. 
A mRNA expression in PARP sensitive (n=5, MDA-MB-436, SUM149, SUM1315, SUM185) and PARP resistant (n=4, 
HCC1937, SUM44, SUM52, UACC893) for TP53bp1 (probe 203050_at). B TP53BP1 focus formation upon 1hr treatment 
with 1 μM camptothecin in BRCA1-deficient cell lines
p < 0,001
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Supplementary Figure 5. MMC-induced chromosomal breakage assay in cell line UACC893 with and without knockdown of 
RECQL5 with siRNAs.
MMC-induced chromosomal breakage assay of cell line UACC893 (with amplification 
of helicase RECQL5) after RECQL5 knockdown (25nM MMC). Pearson chi-square test 
shows a significant difference between the two samples related to the distribution of breaks in 
different classes. Western blot shows an incomplete knockdown of the high protein expression 
of RECQL5 compared to breast cancer cell line SUM185PE (No RECQL5 amplification).
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Supplementary table 1. Chromosomal breakage assay in set of 40 breast cancer cell lines 
Cell lines Subtype BRCA1 
mutation
Treated 
100nM 
MMC
0 breaks 1 break 2 breaks 3-9 
breaks
≥ 10 
breaks
>3breaks  Estimation 
Average 
breaks p/cell 
MDA-MB-436 Basal Yes Yes 0 0 0 4 96 4  9.8 
No 76 16 8 0 0 0  0.3 
SUM-185 Luminal No Yes 0 0 0 4 96 100  9.8 
No 90 6 2 2 0 2  0.2 
HCC1937 Basal Yes Yes 0 0 0 6 94 100  9.7 
No 56 26 12 6 0 6  0.8 
SUM44PE Luminal No Yes 2 4 0 20 74 94  8.4 
No 90 10 0 0 0 0  0.1 
MDA-MB-330 Luminal No Yes 0 4 0 32 64 96  8.0 
No 100 0 0 0 0 0  - 
SUM52PE Luminal No Yes 12 2 0 30 56 86  7.1 
No 82 10 2 6 0 6  0.4 
UACC893 Luminal No Yes 4 10 4 26 56 82  7.1 
No 80 12 8 0 0 0  0.3 
SUM149PT Basal Yes Yes 8 10 10 23 49 72  6.4 
No 86 8 2 4 0 4  0.3 
SUM 1315MO2 Basal Yes Yes 10 16 4 40 30 70  5.2 
No 84 4 6 6 0 6  0.5 
MDA-MB-361 Luminal No Yes 8 2 10 54 26 80  5.5 
No 94 4 2 0 0 0  0.1 
MDA-MB-453 Luminal No Yes 30 10 16 26 18 44  3.5 
No 86 8 2 4 0 4  0.3 
DU4475 Luminal No Yes 20 16 14 34 16 50  3.7 
No 80 18 0 2 0 2  0.3 
MDA-MB-157 basal No Yes 34 24 8 20 14 34  2.8 
No 78 16 6 0 0 0  0.3 
SK-BR-3 Luminal No Yes 44 16 6 26 8 34  2.4 
No 96 4 0 0 0 0  0.0 
SUM159PT Basal No Yes 42 16 12 22 8 30  2.3 
No 86 12 2 0 0 0  0.2 
CAMA-1 Luminal No Yes 10 24 22 38 6 44  3.2 
No 96 4 0 0 0 0  0.0 
MCF-7 Luminal No Yes 24 18 14 38 6 44  3.0 
No 82 16 2 0 0 0  0.2 
515504-L-bw-Bakker
Processed on: 1-12-2017 PDF page: 101
101
Supplementary table 1. Chromosomal breakage assay in set of 40 breast cancer cell lines 
Cell lines Subtype BRCA1 
mutation
Treated 
100nM 
MMC
0 breaks 1 break 2 breaks 3-9 
breaks
≥ 10 
breaks
>3breaks  Estimation 
Average 
breaks p/cell 
OCUB-M Luminal No Yes 20 28 10 36 6 42  2.9 
No 68 20 12 0 0 0  0.4 
SUM229PE Basal No Yes 32 28 22 12 6 18  1.9 
No 82 16 0 2 0 2  0.3 
BT483 Luminal No Yes 34 22 18 22 4 26  2.1 
No 74 14 4 8 0 8  0.6 
MDA-MB-231 Basal No Yes 42 24 20 12 2 14  1.4 
No 98 2 0 0 0 0  0.0 
BT20 Basal No Yes 38 18 30 12 2 14  1.6 
No 82 12 2 4 0 4  0.4 
MDA-MB-468 Basal No Yes 60 18 12 8 2 10  1.0 
No 92 8 0 0 0 0  0.1 
SK-BR-5 Luminal No Yes 66 22 2 8 2 10  0.9 
No 88 12 0 0 0 0  0.1 
MDA-MB-
134VI Luminal No Yes 66 22 6 4 2 6  0.7 
No 94 6 0 0 0 0  0.1 
BT474 Luminal No Yes 58 16 16 10 0 10  1.0 
No 90 10 0 0 0 0  0.1 
BT549 Basal No Yes 80 8 6 6 0 6  0.5 
No 94 4 0 0 2 2  0.2 
EVSA-T Luminal No Yes 80 10 6 4 0 4  0.4 
No 98 2 0 0 0 0  0.0 
ZR75-30 Luminal No Yes 84 10 2 4 0 4  0.3 
No 100 0 0 0 0 0  - 
MPE600 Luminal No Yes 56 26 14 4 0 4  0.7 
No 90 8 2 0 0 0  0.1 
MDA-MB-
175VI Luminal No Yes 86 8 4 2 0 2  0.3 
No 92 8 0 0 0 0  0.1 
OCUB-F Luminal No Yes 78 16 4 2 0 2  0.3 
No 90 8 2 0 0 0  0.1 
Hs578T Basal No Yes 56 32 10 2 0 2  0.6 
No 96 4 0 0 0 0  0.0 
ZR75-1 Luminal No Yes 90 6 2 2 0 2  0.2 
No 98 2 0 0 0 0  0.0 
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Supplementary table 1. Chromosomal breakage assay in set of 40 breast cancer cell lines 
Cell lines Subtype BRCA1 
mutation
Treated 
100nM 
MMC
0 breaks 1 break 2 breaks 3-9 
breaks
≥ 10 
breaks
>3breaks  Estimation 
Average 
breaks p/cell 
MDA-MB-435S Basal No Yes 78 16 6 0 0 0  0.3 
No 98 2 0 0 0 0  0.0 
MDA-MB-415 Luminal No Yes 90 10 0 0 0 0  0.1 
No 80 18 0 2 0 2  0.3 
T47D Luminal No Yes 90 10 0 0 0 0  0.1 
No 94 6 0 0 0 0  0.1 
UACC-812 Luminal No Yes 94 6 0 0 0 0  0.1 
No 94 4 2 0 0 0  0.1 
SUM190PT Luminal No Yes 74 24 2 0 0 0  0.3 
No 94 6 0 0 0 0  0.1 
SKBR7 Basal No Yes 81 16 3 0 0 0  0.2 
No 90 10 0 0 0 0  0.1 
Supplementary Table 2. Fanconi anemia genes used in ToppGene Prioritization tool
Fanconi Name Used gene symbols
FANCT UBE2T
FANCL PHF9
FANCD2
FANCE
FANCG XRCC9
FANCC
FANCF
FANCD1 BRCA2
FANCI
FANCP SLX4
FANCQ ERCC4
FANCN PALB2
FANCA FANCA
FANCO RAD51C
FANCJ BRIP1
FANCB FAAP95
FANCM
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Supplementary Table 3. Genes implicated in DNA repair 
Genes
ATM HELQ RECQL
ATR HLTF RECQL4
BAP1 LIG4 RECQL5
BARD1 MCPH1 REV1
BCAS2 MEN1 REV3
BCCIP MLH1 RNF168
BLM MRE11A RNF4
BRCA1 MSH2 RNF8
BRCA2 MSH3 RPA4
BRCC36 MUS81 RTEL1
BRIP1 NBA1 SETMAR
C19orf40 NBS1 SHFM1
CCDC98 NHEJ1 SHPRH
CDC5L PALB2 SLX1
DCC PCNA SLX1B
DCLRE1B PLRG1 SLX4
DCLRE1C POLN SMARCA5
DMC1 PRKDC SNM1A
EME1 PRPF19 TP53BP1
EME2 RAD18 UBE2A
EMSY RAD18 UBE2B
ERCC1 RAD50 UBE2N
FANCA RAD51AP1 UBE2V2
FANCB RAD51C UHRF1
FANCC RAD51D USP11
FANCD2 RAD51L1 WRN
FANCE RAD52 XPF
FANCF RAD52 XRCC2
FANCG RAD54B XRCC3
FANCI RAD54L XRCC4
FANCL RAD5L3 XRCC5
FANCM RAP80 XRCC6
FLNA RBBP8 ZNF318
GEN1 RDM1 
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CHAPTER 6
HumAN KINomE RNAI SCREEN 
IN ComBINATIoN WITH 
ANTHRACYCLINE IN A TRIPLE 
NEgATIvE BREAST CANCER CELL LINE
Preliminary report
Janine L. Bakker, Davy Rockx, Hanne Meijers-Heijboer, Renée X. de Menezes, Quinten Waisfisz, 
Henk m. W. verheul, victor W. van Beusechem
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ABSTRACT
Introduction: Triple negative breast cancer (TNBC) is the most aggressive histological 
subtype of breast cancer. Treatment with combination chemotherapy including anthracycline 
is standard of care. Here, we present an RNAi screen on a BRCA1-deficient triple negative 
breast cancer cell line to identify molecular targets to improve the antitumor activity of 
anthracycline in TNBC. 
Methods: A cell viability screen was done with a human kinome siRNA library on HCC1937 
cells with and without epidoxorubicin at IC50 concentration. Possible candidates were 
validated in dose response curves.
Results and Conclusion: The RNAi screen did not identify any potential target in the human 
kinome to increase the antitumor activity of epidoxorubicin in triple negative breast cancer. 
Nevertheless, many strong lethal kinase targets were identified which need further analysis. 
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Introduction
Breast cancer is the most common malignant tumor in women.1 In the last decades the 
outcome of primary breast cancer has improved dramatically. Adjuvant treatment with 
anthracycline based chemotherapy in patients with poor prognosis based on pathological 
and clinical characteristics had a major contribution in improvement of the prognosis. The 
use of adjuvant targeted treatment with anti-hormonal and anti-HER2 agents in patients 
with hormonal positive and HER2 amplified breast cancer, respectively, has been another 
improvement in the therapy of breast cancer.2  With the current adjuvant regimes using 
cytotoxic chemotherapy and hormonal treatment still 10 to 20 percent of the breast cancer 
patients relapse within 10 years.3  About 10 percent of breast cancer patients have triple 
negative breast cancer, i.e. without expression of estrogen, progesterone, and HER2. Triple 
negative breast cancer (TNBC) has a dismal  prognosis and no targeted treatment is available 
for this breast cancer subtype.4 5 6  In the neoadjuvant setting, addition of bevacizumab 
(anti-VEGF-A monoclonal antibody)  to chemotherapeutic regimes has shown increased 
pathological response rates in TNBC (27.9% versus 39.3% (P=0.003)) however, long term 
follow up results are missing.7 We hypothesized that identification of novel treatment targets 
could lead to improvement of current chemotherapeutic treatment strategies for patients 
with TNBC.
There is an association between TNBC and BRCA1-mutations and BRCA1 promotor 
methylation.8 9  Dysfunction of this DNA-repair pathway has been suggested to be a general 
molecular characteristic of TNBC, the most aggressive and genomically instable histological 
subtype of breast cancer. Targeted treatment strategies for BRCA-deficient breast cancer are 
under investigation; particularly the concept of synthetic lethality is of great interest. A well-
known example of synthetic lethality is the PARP1-inhibitor; blockade of the repair of single 
strand breaks by PARP inhibition is lethal in combination with a defect in double stranded 
break repair (for example by mutations in BRCA1).10 
The primary goal of our study is to identify critical survival kinases in TNBC treated 
with epidoxorubicin (an anthracycline). In addition, we investigate if inhibition of kinases 
could be lethal in BRCA1-deficient breast cancer cells. We focus on the human kinome 
because protein kinases play important roles in regulating (tumor) cellular functions, such as 
regulation of cell proliferation, metabolism, survival/apoptosis and motility, as well as DNA 
damage repair and drug resistance. Kinases are commonly activated in cancers and many 
kinase-inhibitors are used to treat cancer. 
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Material and methods
Cell culture and compounds
HCC1937 BRCA1-deficient triple negative breast cancer cells (kindly provided by J. 
Martens, Erasmus UMC, Rotterdam, ATCC CRL-2336) were cultured in RPMI with 1% 
Sodium pyruvate and 10% FBS. We confirmed the original BRCA1 c.5382insC mutation by 
Sanger sequencing. Epidoxorubicin (E9406, Sigma-Aldrich, The Netherlands) was diluted in 
RPMI to the desired concentration prior to use. 
siRNA library screening
The transfection of HCC1937 cells was optimized with different transfection reagents 
and culture conditions. Best results were obtained with 15 nM siRNA and 0.075% 
Lipofectamine RNAiMAX transfection reagent (Life Technologies) yielding a pre-automated 
transfection efficiency of approximately 75% and a Z’-factor (comparing siNT to siPLK1) 
around 0.8. The siRNA kinome screen was performed at the RNA Interference Functional 
Oncogenomics Laboratory (RIFOL) core facility of the VUmc Cancer Center Amsterdam, 
using an automated platform and the Human Protein Kinases ON-TARGETplus siRNA 
library from Thermo Fisher Scientific Dharmacon (Lafayette, CO). This library comprises 
siRNA pools targeting 788 kinase and kinase-associated genes and was arrayed for screening 
in 96-well plate format. siRNA against PLK1 was used as a positive control for cell death 
and siCONTROL#2 treated wells served as negative controls. For confirmation studies, 
individual siGENOME siRNAs (TFS Dharmacon) were used. The screens were performed 
three times, each time including one set of plates with epidoxorubicin and one without. 
HCC1937 cells were plated at a density of 1250 cells/well in 80 μl RPMI medium in 96-well 
plates (Greiner) and transfected with siRNAs the next day. To this end, siRNA diluted in 10 
μl siRNA buffer and Lipofectamine RNAiMAX transfection reagent diluted in 10 μl Opti-
MEM medium (Life Technologies) were premixed and added to the cells after 30 minutes. 
Two days after transfection, 20 μl epidoxorubicin was added to a final concentration of 12.5 
nM. In the untreated setting medium without epidoxorubicin was added. Cells were fixed 
with formaldehyde (Thermo Scientific CAT# 28908 diluted to 4%), washed with PBS and 
stained with DAPI (1:3000, D9564 Sigma-Aldrich 1 mg/ml) five days after the start of 
epidoxorubicin treatment. The TTP Labtech Acumen eX3 microplate cytometer was used to 
estimate the number of cells per well. Acumen Explorer software (TTP Labtech) was used for 
data acquisition and analysis.
Plate data was read and configured in R (The R Project for Statistical Computing) using 
the cellHTS2 software package.25  We used the negative control-medians per plate to center 
plate-specific effects as described by Posthuma de Boer et al.26  We compared the 3 treated 
and 3 untreated normalised values per gene using moderated T statistics, which are ideal 
when the number of samples per group is smaller than five. This approach improves the 
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variance estimated by considering all measured genes. The moderated t-statistics yields a 
p-value per gene, which is then corrected for multiple testing using the false discovery rate 
(FDR).27   For identification of genes essential for survival, robust Z scores were determined 
using normalized cell counts.   
Validation experiments
The cell line HCC1937 was transfected and treated as described in the previous section. For the 
deconvolution experiment, cell viability was determined using the CellTiter-Blue (CTB) Cell 
Viability Assay (Promega) after treatment with different concentrations of epidoxorubicin (0, 
10, 15, and 20 nM). For the dose response curves the following concentrations epidoxorubicin 
were used: 0, 1, 2, 4, 8, 16, 32, 62.5, 125, 250, and 500 nM. For the read-out of the dose 
response curve experiment, cells were fixed and stained with DAPI as described above. The 
following siRNAs were used: CALM1 siRNA (Dharmacon, set of 4, MU-017646-01-0002), 
CAMK1G siRNA (Dharmacon, set of 4, MU-004941-01-0002), BTK siRNA (Dharmacon, 
set of 4, MU-003107-01-0002), BRD2 siRNA (Dharmacon, set of 4, MU-004935-02-
0002),  siGENOME Non-Targeting siRNA Pool #2 (Dharmacon, D-001206-14-05), 
siUBB positive control (Dharmacon Smartpool, M-013382-01-0005) and siPLK1 positive 
control (Dharmacon, Smartpool, M-003290-01). To determine gene knockdown efficiency, 
real-time quantitative RT-PCR (qRT-PCR) was performed using the LightCycler® 480 
DNA SYBR Green I Master and the LightCycler® 480 system (Roche Applied Science, IN, 
USA) according to the manufacturer’s protocol. Total mRNA was isolated using High Pure 
RNA Isolation Kit (Roche, IN, USA) and cDNA synthesis was performed using iScript™ 
cDNA synthesis Kit (Bio-Rad, CA, USA) following the manufacturers protocol. Relative 
gene expression was determined using the ∆∆Cq method described by Haimes and colleagues 
(http://www.thermoscientificbio.com). 
Results
siRNA screen combined with epidoxorubicin in HCC1937 TNBC cells
A cell viability screen was performed on HCC1937, a BRCA1-mutant triple negative breast 
cancer cell line, using an siRNA library targeting the human kinome. Cells were subjected 
to epidoxorubicin (EPI) at an approximate IC50 concentration (12.5 nM) two days after 
siRNA transfection and cell viability was assessed by counting DAPI-stained nuclei 5 days 
later, using the Acumen eX3 microplate cytometer (Figure 1A). Screens were performed 
in triplicate (three individual screening sessions) each time including pairs of plates with 
and without EPI. Supplementary Table 1 shows normalized data and computed treatment 
effects of all genes. The transfection conditions used resulted in a reduction of 70-80% cell 
viability in siPLK1 transfected cytotoxicity controls as compared to cells transfected with 
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Figure 1. siRNA cell viability screen of the human kinome in triple negative breast cancer cell line HCC1937. A Screening protocol. 
B Volcano plot representation of the screen results showing the magnitude (x axis T-statistic) and significance (y axis, FDR) of the 
combined effect of gene silencing and EPI-treatment. C Candidate genes exhibiting a epidoxorubicin-sensitizing effect.
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Gene symbol Gene ID Gene name T statistic P value FDR
BRD2 6046 Bromodomain containing 2 2.812 0.005 0.042
CALM1 801 Calmodulin 1 2.672 0.008 0.057
BTK 695 Bruton agammaglobulinemia tyrosine kinase 2.521 0.012 0.079
CAMK1G 57172 Calcium/calmodulin-dependent protein kinase 2.434 0.016 0.088
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siCONTROL#2, a non-targeting siRNA. The combined effects of EPI plus siRNA treatment 
was analyzed using an empirical-Bayes linear model.11  siRNAs were selected that were more 
effective in reducing cell viability when combined with epidoxorubicin than in the absence of 
epidoxorubicin. Figure 1B shows a Volcano plot with the interaction T-statistics representing 
the combined effect of gene silencing and EPI-treatment on the x-axis and the significance 
(false discovery rate) on the y-axis. Four siRNAs met our selection criteria, i.e. they had a 
positive T-statistic for interaction effect with a false discovery rate (FDR) < 0.1 and a p-value 
< 0.05 (Figure 1C). Two of the identified target genes (CAMK1G and CALM1) are part of the 
Calcium/Calmodulin-Dependent Pathway, a pathway thought to be involved in multidrug 
resistance by activation of P-glycoprotein-mediated drug efflux and interfering with cell-cycle 
progression.12 13  The bruton kinase BTK is involved in B-cell development14  and BRD2 is a 
member of the bromodomain extra terminal (BET) family of proteins involved in regulation 
of transcription and alternative RNA splicing.15 
Validation experiments reveal no increased cytotoxicity of silencing candidate kinases in 
combination with epidoxorubicin treatment
The increased cytotoxicity of EPI by silencing of CALM1, CAMK1G, BTK, or BRD2 
observed in the RNAi screen could not be confirmed in independent experiments. The 
discovery screen was performed with pools of four siRNAs targeting distinct sequences on 
the target mRNA. Figure 2A shows reanalysis with the four individual siRNAs. For CALM1, 
BTK and BRD2 only a single siRNA modestly sensitized the breast cancer cells to low-dose 
EPI treatment, while a few other siRNAs were cytotoxic per se. The identification of these 
candidate targets was therefore contributed to off-target-effects. In contrast, three out of four 
distinct siRNAs targeting CAMK1G sensitized HCC1937 cells to 10nM EPI. Figure 2B 
shows EPI dose response curves for HCC1937 cells transfected with non-targeting control 
and CAMK1G siRNA pools. As can be seen, in these experiments EPI exhibited an IC50 of 
approximately 40 nM which is different compared to the initial screen where a concentration 
of 12,5 nM resulted in 50% cell death. Silencing CAMK1G did not influence the IC50 
in two independent experiments. To investigate if the lack of sensitization could be caused 
by insufficient gene silencing, gene-specific knockdown was measured by quantitative real-
time PCR. Unfortunately, knockdown of CAMK1G could not be confirmed, because the 
endogenous expression of CAMK1G was already very low (data not shown). Because of the 
small sensitizing effect found in the initial screen (cell viability in combination with EPI 
reduced from 50% with siNT to 43% with siCAMK1G) and the inability to convincingly 
reproduce this effect, no follow-up experiments were performed with this candidate. 
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A
B
Figure 2. Independent confirmation of candidate target genes. A Deconvolution of 4 distinct siRNAs targeting candidate genes with 
0, 10, 15, and 20 nM epidoxorubicin in a CellTiter-Blue viability assay. B EPI dose-response analysis of HCT1937 cells transfected 
with siCAMK1G or siNT.
Genes possibly involved in survival of HCC1937 BRCA1-deficient triple negative 
breast cancer cells
To investigate if certain kinases could be essential for survival of HCC1937 cells, the screen 
data in the absence of EPI were analyzed separately. Raw viability values were normalised 
per plate and between replicates, and Z-scores were calculated. The hit selection threshold 
was set at a cell viability robust Z score <-2.0. At this threshold, none of the negative control 
siRNAs included on the plates were selected, whereas all positive control siRNAs targeting 
siPLK1 were scored as lethal. Table 1 lists all genes that reached the selection threshold in at 
least 2 of the 3 screens. This uncovered 17 kinases possibly important for the survival of this 
BRCA1-deficient breast cancer cell line. The list includes well-known lethal hits like PLK1, 
AURKB, CHEK1 and WEE1, known to be crucially involved in mitosis, as well as several 
less usual suspects. This is illustrated by STRING protein interaction network analysis (Figure 
3) revealing that four candidates do not appear to interact in any way with other candidate 
targets and could thus represent unique cellular functions. NUP62 plays a role in centrosome 
integrity and knockdown of NUP62 in HeLa cells induced mitotic arrest and mitotic cell 
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death.16  The small heat shock protein HSPB8 is implicated in autophagy of misfolded proteins 
and is mutated in patients with distal hereditary motor neuropathy.17  Overexpression of 
HSPB8 is a key factor in resistance of multiple myeloma cells to the proteasome inhibitor 
velcade.18  TWF2 is a regulator of actin dynamics.19  PCK2 a mitochondrial enzyme involved 
in gluconeogenesis and is related to glucose-independent tumor cell growth. Upregulation 
of PCK2 is related to resistance to 5-fluorouracil (5-FU), but the underlying mechanism is 
not known. As far as is currently known, none of these genes have a direct interaction with 
BRCA1. Before making further conclusions, these findings need independent confirmation 
and validation in multiple cancer cell lines 
Table 1. Candidate lethal target genes in breast cancer cell line HCC1937. All genes are listed with a robust Z score <-2 in at least 
2/3 screens (ranked based on average Z scores in 3 screens). 
Gene Entrez ID Gene Symbol Gene Name 
Z score
1 2 3
7465 WEE1 WEE1 G2 checkpoint kinase -3,35 -4,97 -4,42
1111 CHEK1 checkpoint kinase 1 -3,02 -3,31 -3,40
984 CDC2L1 cyclin-dependent kinase 11B -2,71 -3,24 -3,42
728642 CDC2L2 cyclin-dependent kinase 11A -3,47 -2,85 -2,96
5347 PLK1 polo-like kinase 1 -2,61 -2,69 -3,74
9212 AURKB aurora kinase B -3,32 -3,11 -2,47
983 CDC2 cyclin-dependent kinase 1 -2,83 -3,12 -2,59
2475
FRAP1
mechanistic target of rapamycin 
(MTOR) -2,85 -2,54 -2,88
5296
PIK3R2
phosphoinositide-3-kinase, regulatory 
subunit 2 -2,73 -2,31 -3,08
5515
PPP2CA
protein phosphatase 2, catalytic subunit, 
alpha -2,31 -3,03 -1,69
8317 CDC7 cell division cycle 7 -2,21 -2,73 -1,54
701
BUB1B
BUB1 mitotic checkpoint serine/
threonine kinase B -2,55 -2,17 -1,37
23636 NUP62 nucleoporin 62kDa -2,56 -0,90 -2,48
26353
HSPB8
heat shock protein family B (small) 
member 8 -2,22 -1,42 -2,02
5106 PCK2 phosphoenolpyruvate carboxykinase 2 -2,24 -1,20 -2,16
11344 PTK9L twinfilin actin-binding protein 2 -2,17 -0,15 -2,58
9201 DCAMKL1 doublecortin like kinase 1 -2,38 -0,20 -2,25
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Figure 3. STRING protein interaction network analysis. Known interactions between the 17 candidate lethal targets are shown 
in action view. Dark blue, direct protein binding; green, activation; red, inhibition; pink, post-translational modification; purple, 
catalysis; yellow, expression; black, (undefined) reaction.
Discussion and conclusion
Our screen represents an approach to identify druggable targets to enhance anthracycline 
toxicity in BRCA1-deficient TNBC. We did not detect promising targets to increase the 
cytotoxic activity of anthracycline in the TNBC cell line model used. In contrast, the silencing 
of several kinases yielded a stronger decrease in cell viability in the absence of EPI than 
in the presence of EPI (significant negative T-statistic; see Figure 1B). This could, in most 
cases, be explained by the fact that EPI reduced cell viability approximately 50% and kinase 
silencing alone was often much more cytotoxic. Consequently, although the two combined 
caused the strongest total reduction in cell viability, their interaction effect was negative. 
We hypothesize that in general cytotoxic agents might not be synergistic in combination 
with kinase inhibition. This could be caused by diminished cellular proliferation or lower 
expression of cell cycle related kinases due to cytotoxic chemotherapy. It is even speculated 
that inhibition of some tyrosine kinases like CDK4/6 inhibitors leads to cell cycle arrest and 
protection of TNBC cells from anthracycline-mediated cytotoxicity, resulting in preservation 
of cell viability.  The combination of tyrosine kinase inhibitor everolimus (mTor inhibitor) 
with hormonal treatment does also improve survival in metastatic breast cancer but has not 
yet been successful in combination with anthracycline in neo-adjuvant treatment and ‘real 
killing’ of breast cancer cells.20  In lung cancer, the addition of small-molecule inhibitors 
of EGFR to chemotherapy in the initial treatment of non–small-cell lung cancer did not 
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yield any additional benefit, where monotherapy led to partial response in 11-19% of the 
patients.21  The extreme sensitivity of some cancers like chronic myeloid leukemia with the 
BCR-ABL fusion gene and HER2-positive breast cancer to tyrosine kinase inhibition may 
reflect their absolute dependence on the targeted tyrosine kinases signaling pathways for 
survival. This explains why targeting the tyrosine kinase HER2 with monoclonal antibodies 
is more effective when added to chemotherapy for HER-2-overexpressing breast cancer than 
monotherapy with these monoclonal antibodies. It can also be the case that the aggressive 
chromosomal instable subtype TNBC is dependent on several signaling pathways which 
should be targeted at once. 
Nevertheless, the screen revealed several putative lethal targets involved in mitosis 
illustrated by the string network analysis. We speculate that targeting mitosis as monotherapy 
might be an attractive strategy in FA/BRCA pathway deficient tumors. BRCA1 regulates 
key effectors of the G2/M checkpoint22  and synergistic defects in BRCA1 and other 
compensating regulators of mitosis might be lethal for the cell. For example, in other studies 
it was shown that disruption of the FA/BRCA pathway led to hyper-activation of CHEK1 
and that FA pathway deficient cells were hypersensitive to CHEK1 inhibitors.23  The lethality 
screen hit PI3KR2 might be a novel potential target for triple negative breast cancer with 
an activated PI3K pathway. PI3K pathway-activating mutations are known drivers of breast 
cancer and PI3KR2, the regulator subunit of PI3K, might be a potential target for therapy.24 
After validation of the putative lethal targets, the effect of targeting PI3KR2 and possibly 
other lethal targets should be tested in a panel of triple negative and luminal breast cancer cell 
lines with and without BRCA1 mutations. It has to be explored if the putatively lethal effect 
can be attributed to the histological subtype, a synthetic lethality interaction with BRCA1, 
or other pathways in the tumor cells. 
In conclusion, our screen did not detect promising sensitizers for anthracycline therapy. 
Nevertheless, many strong lethal kinase targets were identified. Their silencing was often 
highly cytotoxic, also in combination with epidoxorubicin. Therefore, inhibiting these kinases 
could have an additive cytotoxic effect with epidoxorubicin in TNBC. Further research into 
the cytotoxic and cytostatic effects of these combinations in TNBC cells is warranted.
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Supplementary Table 1: Normalised screen data and treatment effect per gene
The genes with positive t-statistics mediate epidoxorubicin cytotoxicity; the gene products with negative t-statistics inhibit epidoxorubicin cytotoxicity
Accession Number Gene Symbol t-statistic p-value FDR Untreated Treated
Screen 
1
Screen 
2
Screen 
3 
Screen 
1
Screen 
2
Screen 
3 
NM_014911 AAK1 0,956 0,340 0,559 1799 4708 4251 -488 -2383 -3252
XM_927215 AATK 0,490 0,625 0,803 2027 5379 4109 -1327 -1483 -1366
NM_005157 ABL1 0,335 0,738 0,868 1836 4181 3169 -2152 -2382 -1576
NM_005158 ABL2 1,696 0,091 0,256 4544 4560 4075 -1504 -1874 -2123
NM_001105 ACVR1 1,265 0,207 0,430 1987 3642 3480 -3339 -2640 -2530
NM_020328 ACVR1B -0,504 0,615 0,797 2829 3258 2651 -1736 -896 -1833
NM_145259 ACVR1C 1,049 0,295 0,509 3058 6094 4805 -865 -141 -2142
NM_001616 ACVR2 -0,853 0,395 0,622 973 4108 1522 -1667 -1197 -2840
NM_001106 ACVR2B 0,644 0,520 0,728 1255 4717 4001 -2297 -1443 -2370
NM_000020 ACVRL1 1,178 0,240 0,459 1302 4097 2769 -3127 -2532 -3590
NM_020421 ADCK1 -0,078 0,938 0,969 1190 3585 2918 -2415 -2196 -1960
NM_052853 ADCK2 0,150 0,881 0,942 1931 3111 3032 -2806 -1795 -2157
NM_024876 ADCK4 -0,592 0,555 0,756 1224 2573 1303 -3509 -2024 -2346
NM_174922 ADCK5 1,174 0,242 0,460 2845 4357 4155 -2810 -1879 -1348
NM_006721 ADK 0,443 0,658 0,825 3230 2967 3595 -1626 -1793 -2351
NM_031284 ADP-GK 1,124 0,262 0,481 4510 4029 3779 -1426 -978 -2543
NM_033304 ADRA1A 0,144 0,885 0,942 1002 1856 2002 -3477 -2821 -3660
NM_000679 ADRA1B 0,485 0,628 0,804 5264 3950 2692 -981 -1099 -1688
NM_000024 ADRB2 -0,593 0,554 0,756 1477 1775 1885 -2349 -1808 -3683
NM_001619 ADRBK1 1,400 0,163 0,373 2920 3487 2754 -3325 -2491 -2968
NM_005160 ADRBK2 1,609 0,109 0,283 5053 5227 4464 -761 -1292 -1670
NM_000476 AK1 0,657 0,512 0,724 3739 3646 4085 -1546 -575 -2509
NM_001625 AK2 0,834 0,405 0,630 3959 3753 6042 -1467 -570 -758
NM_013410 AK3 0,451 0,653 0,824 3633 5068 5160 -135 -478 -1110
NM_016282 AK3L1 0,394 0,694 0,844 3584 2648 5111 -1940 -928 -1234
NM_174858 AK5 0,346 0,730 0,867 736 1507 787 -4503 -3368 -4420
NM_152327 AK7 1,214 0,226 0,446 3840 3672 4760 -1673 -2166 -1374
NM_001014431 AKT1 1,183 0,238 0,457 791 3075 4702 -3053 -2096 -3739
NM_001626 AKT2 0,473 0,637 0,813 -476 2889 3041 -3910 -2496 -3798
NM_181690 AKT3 1,425 0,155 0,360 4539 3406 5579 -641 -1648 -2217
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Supplementary Table 1: Normalised screen data and treatment effect per gene
The genes with positive t-statistics mediate epidoxorubicin cytotoxicity; the gene products with negative t-statistics inhibit epidoxorubicin cytotoxicity
Accession Number Gene Symbol t-statistic p-value FDR Untreated Treated
Screen 
1
Screen 
2
Screen 
3 
Screen 
1
Screen 
2
Screen 
3 
NM_004304 ALK -0,422 0,674 0,835 1719 3174 3563 -3233 206 -1910
NM_018571 ALS2CR2 -0,534 0,594 0,783 2094 2486 3354 -1546 -1832 -1815
NM_139158 ALS2CR7 -0,543 0,588 0,782 -677 2274 730 -5324 -2440 -2993
NM_020547 AMHR2 0,430 0,668 0,832 790 2377 2710 -3054 -2353 -4252
NM_178510 ANKK1 0,651 0,516 0,726 1447 4429 1334 -2078 -2556 -4263
NM_020639 ANKRD3 0,986 0,325 0,545 3970 4671 3473 -856 -1111 -2846
NM_005876 APEG1 0,275 0,784 0,893 2373 3956 4726 -1936 -1076 -1080
NM_001654 ARAF1 1,005 0,316 0,534 3366 3576 5179 -1492 -1482 -1874
NM_014840 ARK5 -0,535 0,593 0,783 3837 2740 4865 549 -1804 -417
NM_138292 ATM -0,264 0,792 0,896 3468 4088 3526 -28 -516 -2172
NM_001184 ATR -0,667 0,506 0,723 131 3051 1036 -4885 -1825 -1836
NM_198437 AURKA -2,609 0,010 0,065 -951 342 -2598 -3403 -2453 -5212
NM_004217 AURKB -3,713 0,000 0,007 -3670 -970 -2323 -5132 -3278 -3673
NM_001015879 AURKC -0,244 0,807 0,899 2586 1726 3378 -2188 -2149 -1822
NM_000706 AVPR1A -0,446 0,656 0,825 1068 2894 2308 -2600 -2474 -2000
NM_000707 AVPR1B -0,060 0,953 0,975 1740 4442 120 -3613 -2278 -2114
NM_001699 AXL 1,807 0,072 0,221 4645 2363 3635 -3163 -2026 -3153
NM_001700 AZU1 0,119 0,906 0,949 403 4318 2105 -2035 -2044 -3855
NM_004742 BAIAP1 -0,357 0,721 0,864 2404 3348 2332 -2133 -962 -2388
NM_005881 BCKDK 0,992 0,322 0,541 3889 3608 3030 -1538 -2686 -2181
NM_021574 BCR 0,592 0,554 0,756 3463 3008 5350 -2542 -388 -1197
NM_001715 BLK 0,064 0,949 0,975 3176 2017 2878 -1922 -2221 -2403
NM_017593 BMP2K 0,258 0,796 0,896 3906 2769 3344 -2394 -707 -1984
NM_004329 BMPR1A 1,659 0,098 0,266 4914 3527 4950 -3712 -1869 307
NM_001203 BMPR1B 0,001 0,999 0,999 1591 2242 4502 -2885 -1511 -1729
NM_001204 BMPR2 1,183 0,238 0,457 2900 459 3869 -3256 -2960 -3997
NM_001721 BMX 1,029 0,304 0,521 2292 4173 3726 -2535 -1623 -2684
NM_004333 BRAF -0,551 0,582 0,782 2075 2669 203 -2912 -2595 -2623
NM_005104 BRD2 2,812 0,005 0,042 3235 4393 5543 -2285 -1779 -4309
NM_007371 BRD3 1,311 0,191 0,407 4495 3779 6298 -1956 -226 -999
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Supplementary Table 1: Normalised screen data and treatment effect per gene
The genes with positive t-statistics mediate epidoxorubicin cytotoxicity; the gene products with negative t-statistics inhibit epidoxorubicin cytotoxicity
Accession Number Gene Symbol t-statistic p-value FDR Untreated Treated
Screen 
1
Screen 
2
Screen 
3 
Screen 
1
Screen 
2
Screen 
3 
NM_014299 BRD4 -1,630 0,104 0,276 -39 727 811 -3951 -2107 -2830
NM_001726 BRDT 1,720 0,087 0,249 5509 4725 6045 -1460 -940 -76
NM_000061 BTK 2,521 0,012 0,079 4771 4665 5325 -1403 -2695 -1886
NM_004336 BUB1 -2,841 0,005 0,040 -1667 776 -1302 -3915 -2716 -2891
NM_001211 BUB1B -3,670 0,000 0,008 -3963 -1649 -2218 -6372 -2839 -3772
NM_174944 C14ORF20 -1,263 0,208 0,430 2112 696 2947 -1434 -2613 -1491
NM_145025 C6ORF199 -0,373 0,709 0,856 2445 2919 -65 -2985 -2146 -3090
NM_022755 C9ORF12 -0,645 0,520 0,728 3801 1621 1979 -1000 -2389 -2052
NM_153710 C9ORF96 0,573 0,567 0,769 742 2272 2007 -4184 -2667 -4020
NM_152572 C9ORF98 1,498 0,135 0,332 2522 3802 2469 -4025 -3222 -2167
NM_006888 CALM1 2,672 0,008 0,057 4373 4818 4376 -3049 -3020 -1494
NM_001743 CALM2 1,039 0,300 0,517 2859 2980 3986 -2541 -1673 -3013
NM_005184 CALM3 0,795 0,428 0,649 332 2326 2347 -5060 -3237 -3154
NM_003656 CAMK1 0,959 0,338 0,558 29 3712 2355 -5081 -2543 -3176
NM_020397 CAMK1D 1,689 0,093 0,257 3009 4861 1668 -3364 -2801 -3003
NM_020439 CAMK1G 2,434 0,016 0,088 4273 3765 4294 -3372 -2500 -2319
NM_171825 CAMK2A 1,937 0,054 0,188 3353 3773 4217 -3441 -1732 -2779
NM_172084 CAMK2B -0,041 0,967 0,982 699 3262 -1235 -4549 -3163 -3917
NM_001221 CAMK2D 2,003 0,046 0,171 2878 3652 2811 -3772 -2670 -3670
NM_001222 CAMK2G 0,440 0,660 0,827 3992 3849 4581 -918 -224 -1993
NM_001744 CAMK4 -0,255 0,799 0,898 4673 3694 3802 -463 846 -2033
NM_172207 CAMKK1 -1,640 0,102 0,274 1119 1751 168 -2249 -2537 -2544
NM_172215 CAMKK2 -0,216 0,829 0,912 4322 2212 5174 -1254 407 -1359
NM_013276 CARKL -1,708 0,089 0,252 2371 3839 4262 -23 162 140
NM_003688 CASK -0,422 0,673 0,835 3659 3445 5451 -927 944 -861
NM_002982 CCL2 -0,369 0,713 0,857 3416 2922 4969 -1473 968 -1717
NM_002984 CCL4 -0,872 0,384 0,612 945 2523 2749 -4161 16 -1882
NM_012119 CCRK -1,479 0,140 0,338 1319 1153 1314 -2360 -1493 -3129
NM_052987 CDADC1 0,801 0,424 0,649 5389 3279 3887 -1884 -928 -1097
NM_015076 CDC2 -4,505 1,04E-5 0,001 -2919 -1282 -1996 -3787 -2368 -3242
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Supplementary Table 1: Normalised screen data and treatment effect per gene
The genes with positive t-statistics mediate epidoxorubicin cytotoxicity; the gene products with negative t-statistics inhibit epidoxorubicin cytotoxicity
Accession Number Gene Symbol t-statistic p-value FDR Untreated Treated
Screen 
1
Screen 
2
Screen 
3 
Screen 
1
Screen 
2
Screen 
3 
NM_030911 CDC2L1 -3,131 0,002 0,026 -1950 -948 -2194 -4446 -2827 -4450
NM_033379 CDC2L2 -3,473 0,001 0,013 -2706 -370 -1133 -4354 -2275 -3312
NM_033487 CDC2L5 -1,327 0,186 0,400 1876 2508 4139 -967 77 -1716
NM_033534 CDC42BPA -2,514 0,013 0,079 107 261 2794 -2157 -577 -2228
NM_031267 CDC42BPB -1,726 0,086 0,247 3241 1933 1768 -1833 -215 -1150
NM_014826 CDC7 -3,239 0,001 0,022 -2482 -1320 -166 -5068 -2238 -2951
NM_006035 CDK10 -0,125 0,900 0,947 2791 3403 4909 -116 -1318 -1607
NM_003503 CDK11 0,538 0,591 0,783 3311 2786 6189 434 -1365 -2611
NM_052827 CDK2 -2,700 0,007 0,054 -1990 205 -574 -3649 -2790 -3623
NM_001258 CDK3 -0,338 0,736 0,868 2005 2965 5570 -1589 69 -1545
NM_000075 CDK4 -0,551 0,582 0,782 5677 3827 5333 1575 -19 200
NM_004935 CDK5 -1,369 0,172 0,383 2799 2265 1780 -934 -1040 -2224
NM_003885 CDK5R1 -4,174 4,18E-5 0,004 -949 -204 -456 -2703 -725 -2207
NM_003936 CDK5R2 -1,111 0,268 0,483 1335 2108 2460 -1432 -1782 -2570
NM_001259 CDK6 -2,854 0,005 0,039 3532 2007 978 -924 -163 304
NM_001799 CDK7 -1,219 0,224 0,446 2943 2394 2650 -724 -981 -1729
NM_001260 CDK8 0,121 0,903 0,949 2173 2343 4794 -2815 -1374 -1265
NM_001261 CDK9 -3,465 0,001 0,013 -1701 -465 1537 -2476 -1511 -2377
NM_004196 CDKL1 -1,971 0,050 0,179 1721 1526 5107 -711 -238 -168
NM_003948 CDKL2 0,215 0,830 0,912 4376 2350 4860 -1541 -715 -1155
NM_016508 CDKL3 -1,436 0,152 0,357 2407 1322 2766 -1646 -581 -2146
NM_001009565 CDKL4 -0,664 0,507 0,723 2520 2789 3788 -1846 806 -2646
NM_001037343 CDKL5 -0,963 0,336 0,556 3171 1066 3307 -1598 -1131 -1772
NM_000389 CDKN1A -0,532 0,595 0,784 2458 2044 3661 -2229 -1210 -1528
NM_004064 CDKN1B -0,216 0,829 0,912 3221 3100 2820 -1920 -1048 -1811
NM_000076 CDKN1C 0,696 0,487 0,708 708 3494 2120 -4528 -2752 -2609
NM_004936 CDKN2B -0,448 0,655 0,825 2765 1919 4043 -1978 -593 -2038
NM_078626 CDKN2C 0,220 0,826 0,912 2902 3242 3678 -2050 -1785 -1349
NM_079421 CDKN2D -0,914 0,362 0,584 2318 3094 1870 -1199 -1590 -2109
NM_005192 CDKN3 -0,243 0,808 0,899 4723 4147 5145 -590 354 396
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Supplementary Table 1: Normalised screen data and treatment effect per gene
The genes with positive t-statistics mediate epidoxorubicin cytotoxicity; the gene products with negative t-statistics inhibit epidoxorubicin cytotoxicity
Accession Number Gene Symbol t-statistic p-value FDR Untreated Treated
Screen 
1
Screen 
2
Screen 
3 
Screen 
1
Screen 
2
Screen 
3 
NM_182661 CERK -0,319 0,750 0,874 3469 2794 3507 -1122 -1432 -1340
NM_001274 CHEK1 -4,076 6,22E-5 0,004 -3295 -1243 -2830 -5393 -2497 -3663
NM_145862 CHEK2 -0,613 0,540 0,743 4715 2298 1906 -2395 -621 -978
NM_212469 CHKA -2,317 0,021 0,103 -1096 602 1104 -2535 -2598 -2920
NM_005198 CHKB -1,840 0,067 0,213 1540 2376 1486 -2289 -763 -1411
NM_000738 CHRM1 -1,557 0,121 0,304 -79 976 1436 -3694 -1643 -2889
NM_001278 CHUK -0,516 0,607 0,794 4810 3558 2982 741 -656 -1898
NM_032630 CINP -1,677 0,095 0,261 232 2225 1339 -3525 -1495 -1428
NM_007174 CIT -1,058 0,291 0,509 2128 546 2925 -2531 -1727 -1951
NM_001823 CKB -1,411 0,160 0,367 2229 3128 1655 -2040 -1485 -393
NM_001824 CKM 0,242 0,809 0,899 2300 2900 2979 -4064 -1082 -1741
NM_020990 CKMT1B -1,242 0,216 0,440 166 1371 1178 -3501 -2483 -2661
NM_001825 CKMT2 -0,054 0,957 0,977 2097 2503 3375 -1986 -2111 -2253
NM_001826 CKS1B -1,729 0,085 0,247 -1811 -24 626 -4659 -3029 -3640
NM_001827 CKS2 -0,660 0,510 0,724 2066 3026 2975 -2067 109 -2776
NM_001024646 CLK1 -0,721 0,471 0,697 3333 1886 4338 -2556 -428 -99
NM_001291 CLK2 0,717 0,474 0,699 3429 2524 2842 -2137 -2089 -3226
NM_001292 CLK3 -1,051 0,294 0,509 895 1885 133 -3388 -2668 -2865
NM_020666 CLK4 -0,821 0,412 0,639 3477 2699 5827 15 -739 335
NM_006314 CNKSR1 -0,708 0,479 0,703 2117 2163 2072 -2496 -1911 -1936
NM_025233 COASY 1,855 0,065 0,209 3959 3474 5675 -3062 -1667 -1278
NM_031361 COL4A3BP 0,226 0,822 0,910 3609 2024 4144 -3353 -1262 -635
NM_012071 COMMD3 -1,546 0,123 0,308 1575 618 1479 -2386 -2156 -2394
NM_003909 CPNE3 0,402 0,688 0,843 3772 2999 4655 -2003 -976 -1058
NM_016441 CRIM1 -1,185 0,237 0,457 1062 1406 3297 -2323 -1373 -2029
NM_016507 CRK7 -0,458 0,648 0,820 -999 1950 1127 -4646 -2751 -3831
NM_005207 CRKL -1,782 0,076 0,227 -1340 494 -1419 -5446 -2929 -3867
NM_005211 CSF1R 0,547 0,585 0,782 1398 3142 3598 -3759 -2252 -1683
NM_004383 CSK 0,852 0,395 0,622 4743 4431 4078 -831 -1309 -1188
NM_001892 CSNK1A1 1,586 0,114 0,293 4054 2898 4591 -2420 -1786 -2670
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Supplementary Table 1: Normalised screen data and treatment effect per gene
The genes with positive t-statistics mediate epidoxorubicin cytotoxicity; the gene products with negative t-statistics inhibit epidoxorubicin cytotoxicity
Accession Number Gene Symbol t-statistic p-value FDR Untreated Treated
Screen 
1
Screen 
2
Screen 
3 
Screen 
1
Screen 
2
Screen 
3 
NM_145203 CSNK1A1L 1,228 0,220 0,444 2525 3810 2936 -3262 -2298 -2692
NM_001893 CSNK1D 0,796 0,427 0,649 3596 3479 2440 -2485 -2783 -1661
NM_001894 CSNK1E -0,979 0,328 0,548 -34 3560 1925 -3158 -1953 -1421
NM_022048 CSNK1G1 1,799 0,073 0,221 3506 3386 4997 -2728 -2590 -1747
NM_001319 CSNK1G2 -0,133 0,895 0,945 443 1720 1816 -3628 -2712 -3808
NM_001031812 CSNK1G3 -0,027 0,979 0,990 2347 2455 2396 -1686 -2427 -3081
NM_177560 CSNK2A1 -0,042 0,967 0,982 2046 4865 3667 -2551 -453 -771
NM_001896 CSNK2A2 0,263 0,793 0,896 2436 5255 4527 -488 -839 -1574
NM_001320 CSNK2B 0,567 0,571 0,773 1661 4106 4733 -3363 -615 -1418
NM_004938 DAPK1 -1,341 0,181 0,394 2603 3083 1892 -1639 -1493 -401
NM_014326 DAPK2 -0,943 0,347 0,566 3173 3756 3929 -1574 309 20
NM_001348 DAPK3 0,887 0,376 0,604 3002 5007 5625 -1313 -822 -914
NM_004734 DCAMKL1 -2,380 0,018 0,093 -1050 3213 -720 -3050 -587 -3272
NM_000788 DCK 0,801 0,424 0,649 3313 2905 4106 -2734 -1925 -1474
NM_013994 DDR1 -1,255 0,211 0,433 1036 2123 1186 -3030 -2025 -1927
NM_006182 DDR2 -2,062 0,040 0,158 2066 743 2443 -1591 -1359 -1109
NM_201554 DGKA -1,337 0,182 0,395 1915 1609 2202 -1888 -1951 -1565
NM_145695 DGKB -2,058 0,041 0,158 2349 1590 1541 -798 -1473 -1578
NM_003648 DGKD -0,589 0,556 0,757 1593 3445 3384 -946 -2074 -1542
NM_003647 DGKE -2,200 0,029 0,128 3862 2270 1323 477 -1148 -808
NM_001346 DGKG -0,623 0,534 0,738 3320 1854 4548 -651 -1980 -540
NM_152910 DGKH -0,847 0,398 0,622 1453 2671 1093 -3073 -1958 -2095
NM_004717 DGKI 0,001 0,999 0,999 3930 2651 2955 -2211 -1174 -1541
NM_001347 DGKQ -0,287 0,774 0,888 1090 1860 1939 -4310 -2173 -2367
NM_201533 DGKZ -0,687 0,493 0,711 1562 4047 4604 -1089 -1393 -33
NM_001929 DGUOK -0,451 0,652 0,824 96 2723 2972 -3595 -1867 -2067
NM_015518 DKFZP434C131 -2,093 0,037 0,153 2321 1598 1879 -643 -1925 -873
NM_015419 DKFZP564I1922 -1,483 0,139 0,338 1868 2914 2987 -828 -1641 -520
NM_015533 DKFZP586B1621 -1,691 0,092 0,257 2043 3240 2268 -1600 -285 -801
XM_291277 DKFZP761P0423 -2,583 0,010 0,068 2021 2764 2945 -508 -727 961
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Supplementary Table 1: Normalised screen data and treatment effect per gene
The genes with positive t-statistics mediate epidoxorubicin cytotoxicity; the gene products with negative t-statistics inhibit epidoxorubicin cytotoxicity
Accession Number Gene Symbol t-statistic p-value FDR Untreated Treated
Screen 
1
Screen 
2
Screen 
3 
Screen 
1
Screen 
2
Screen 
3 
NM_004087 DLG1 -0,969 0,333 0,555 3325 3906 1471 -1158 -1870 -295
NM_001364 DLG2 -1,480 0,140 0,338 3838 3133 666 -914 -1478 -704
NM_021120 DLG3 -2,633 0,009 0,062 2441 508 2037 -818 -819 -1256
NM_001365 DLG4 -1,280 0,202 0,424 3073 2380 2002 -1169 -1536 -1110
NM_004409 DMPK -2,641 0,009 0,061 2366 4278 3820 -162 1322 1462
NM_006260 DNAJC3 -0,022 0,982 0,991 4687 2408 2631 -1583 -1497 -1597
NM_001381 DOK1 -1,226 0,221 0,444 677 3049 1379 -3536 -1274 -1455
NM_012145 DTYMK -2,471 0,014 0,082 -680 1473 1043 -2298 -1793 -2349
NM_004417 DUSP1 -1,790 0,075 0,224 1278 967 -216 -2802 -2541 -2622
NM_144729 DUSP10 -1,213 0,226 0,446 1014 1462 1910 -1633 -2660 -2754
NM_004418 DUSP2 -1,103 0,271 0,487 -447 1609 1909 -3652 -2340 -2629
NM_022076 DUSP21 -2,405 0,017 0,090 1307 690 622 -2209 -1610 -2032
NM_001394 DUSP4 -2,498 0,013 0,079 360 2233 -1298 -2497 -2080 -2293
NM_004419 DUSP5 -1,391 0,165 0,375 1829 1554 2606 -1598 -1331 -2073
NM_022652 DUSP6 -1,175 0,241 0,460 337 1540 1847 -3663 -1465 -2662
NM_001947 DUSP7 -3,172 0,002 0,024 -1131 1508 185 -2116 -1609 -2220
NM_004420 DUSP8 -0,242 0,809 0,899 2852 4005 2843 -1741 -897 -1516
NM_199462 DUSTYPK -1,117 0,265 0,482 2744 244 3379 -574 -2518 -2178
NM_130438 DYRK1A -1,216 0,225 0,446 1688 3322 3253 -1408 -1380 -366
NM_006483 DYRK1B -0,035 0,972 0,984 564 2808 2865 -4065 -2016 -2051
NM_003583 DYRK2 -0,671 0,503 0,722 1694 3171 2884 -2163 -1185 -1687
NM_003582 DYRK3 -1,796 0,074 0,222 1845 1240 1780 -2270 -1730 -1117
NM_003845 DYRK4 -0,372 0,710 0,856 3568 4707 3775 -328 -790 -363
NM_001956 EDN2 -2,461 0,015 0,082 -1438 2036 360 -3320 -2246 -1722
NM_013302 EEF2K -2,290 0,023 0,109 -487 1274 -211 -3987 -1773 -2376
NM_004952 EFNA3 -0,058 0,954 0,975 887 1765 3615 -3272 -2089 -2684
NM_182689 EFNA4 -1,464 0,145 0,343 1564 1821 1008 -2645 -1180 -2586
NM_001406 EFNB3 0,424 0,672 0,835 4140 4242 4426 -1637 -1105 33
NM_201283 EGFR -0,192 0,848 0,920 3907 4286 4522 -949 -845 530
NM_004836 EIF2AK3 0,131 0,896 0,945 2566 3006 2589 -3150 -1291 -2184
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Supplementary Table 1: Normalised screen data and treatment effect per gene
The genes with positive t-statistics mediate epidoxorubicin cytotoxicity; the gene products with negative t-statistics inhibit epidoxorubicin cytotoxicity
Accession Number Gene Symbol t-statistic p-value FDR Untreated Treated
Screen 
1
Screen 
2
Screen 
3 
Screen 
1
Screen 
2
Screen 
3 
NM_001013703 EIF2AK4 1,554 0,122 0,305 3107 3310 4062 -2720 -2500 -2629
NM_018638 EKI1 -0,121 0,904 0,949 2078 1500 1638 -2593 -2866 -3483
NM_005232 EPHA1 -1,623 0,106 0,278 792 2355 316 -2424 -1830 -2681
NM_001004338 EPHA10 0,506 0,613 0,796 1708 4323 4122 -2413 -1666 -1497
NM_004431 EPHA2 0,913 0,362 0,584 197 3490 3723 -4127 -2715 -2522
NM_182644 EPHA3 -0,273 0,785 0,893 1912 4232 3313 -2255 -1618 -442
NM_004438 EPHA4 1,698 0,091 0,256 4963 2159 5980 -2619 -2109 -933
NM_182472 EPHA5 0,244 0,807 0,899 2663 3304 4023 -1868 -2125 -1085
XM_496653 EPHA6 -0,490 0,625 0,803 3666 3044 4492 -896 -581 -558
NM_004440 EPHA7 -1,361 0,175 0,385 2380 1727 2793 -320 -2380 -1454
NM_001006943 EPHA8 -0,625 0,532 0,737 688 1900 2481 -3293 -1929 -2603
NM_004441 EPHB1 -0,401 0,689 0,843 2312 1936 889 -2646 -2228 -3446
NM_017449 EPHB2 -1,670 0,096 0,262 517 844 3 -3447 -2707 -2780
NM_004443 EPHB3 -1,897 0,059 0,201 -379 1146 -1164 -3787 -2691 -3627
NM_004444 EPHB4 0,736 0,463 0,686 774 2571 3148 -4211 -2086 -3519
NM_004445 EPHB6 -0,199 0,843 0,920 248 2708 1960 -2459 -2829 -3756
NM_004448 ERBB2 0,705 0,482 0,705 1362 3278 5502 -2628 -1921 -1553
NM_001005915 ERBB3 0,693 0,489 0,708 1351 4156 3236 -2771 -2271 -2412
NM_005235 ERBB4 -0,628 0,530 0,737 3112 1531 140 -2814 -3033 -2250
NM_139021 ERK8 -2,152 0,032 0,138 895 1458 1401 -2031 -2265 -1042
NM_001433 ERN1 -0,712 0,477 0,702 2093 2173 2550 -2643 -1982 -1241
NM_033266 ERN2 -1,660 0,098 0,266 -1194 773 -123 -3820 -3178 -3858
NM_002685 EXOSC10 -0,727 0,468 0,693 468 2462 176 -3113 -3366 -3053
NM_033015 FASTK -0,095 0,924 0,959 788 2658 685 -3177 -3560 -3352
NM_005246 FER 0,702 0,483 0,706 2266 3853 1982 -3568 -2064 -2484
NM_002005 FES -1,612 0,108 0,282 184 2494 1868 -1212 -1695 -2958
NM_023110 FGFR1 -1,025 0,307 0,523 1390 3596 2368 -1876 -324 -2331
NM_022976 FGFR2 -1,204 0,230 0,447 2156 2683 309 -2402 -1246 -2640
NM_022965 FGFR3 -1,231 0,220 0,444 2701 2790 1766 -1973 -1864 -287
NM_022963 FGFR4 -1,802 0,073 0,221 1794 2285 2168 -2106 -242 -1362
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Supplementary Table 1: Normalised screen data and treatment effect per gene
The genes with positive t-statistics mediate epidoxorubicin cytotoxicity; the gene products with negative t-statistics inhibit epidoxorubicin cytotoxicity
Accession Number Gene Symbol t-statistic p-value FDR Untreated Treated
Screen 
1
Screen 
2
Screen 
3 
Screen 
1
Screen 
2
Screen 
3 
NM_005248 FGR -1,156 0,249 0,466 3846 2712 3055 -906 -506 -554
NM_017988 FLJ10074 0,366 0,715 0,857 4317 2295 3000 -911 -1550 -3305
NM_018208 FLJ10761 -1,616 0,107 0,281 -570 383 3853 -2414 -2868 -1394
NM_001031715 FLJ12476 -0,098 0,922 0,959 2107 2318 3292 -1629 -1962 -2905
XM_291344 FLJ12649 -0,762 0,447 0,667 3203 1637 1804 -319 -2136 -3438
NM_023018 FLJ13052 -1,961 0,051 0,181 1557 1254 -695 -1603 -2521 -3296
NM_024622 FLJ21901 -1,060 0,290 0,509 3998 2675 3543 -432 -165 -1001
NM_001018046 FLJ23074 -1,188 0,236 0,457 2324 928 2098 -2042 -2428 -1675
NM_032237 FLJ23356 -0,437 0,663 0,829 2507 2989 5233 -1203 -962 -468
NM_144610 FLJ25006 0,311 0,756 0,877 1804 1968 3273 -3084 -2058 -3049
NM_152534 FLJ32685 -2,406 0,017 0,090 1269 1462 763 -1975 -1812 -1183
NM_152649 FLJ34389 -1,165 0,245 0,466 241 2530 1964 -2617 -1578 -2610
NM_002019 FLT1 -0,465 0,643 0,816 2451 4928 4110 -421 -114 -1269
NM_004119 FLT3 -2,423 0,016 0,088 3578 3504 689 53 -1178 549
NM_002020 FLT4 -2,464 0,014 0,082 197 1370 620 -2508 -1390 -2225
NM_022158 FN3K -2,361 0,019 0,096 1006 2405 1995 -486 -1464 -1210
NM_024619 FN3KRP -0,544 0,587 0,782 3493 2654 3075 824 -1892 -2795
NM_004958 FRAP1 -2,910 0,004 0,036 -1029 220 -1460 -3916 -2315 -3217
NM_000144 FRDA -0,690 0,491 0,710 2420 2393 2233 -2192 -1011 -2489
NM_002031 FRK -0,597 0,551 0,755 2958 2056 2314 -1809 -1238 -2595
NM_145059 FUK -3,034 0,003 0,029 1051 1388 876 -970 -1180 -1442
NM_199335 FYB -1,367 0,173 0,383 3015 1590 5012 356 -735 -1013
NM_153048 FYN -0,434 0,665 0,830 3220 1397 4575 -1910 -1213 -1051
NM_005255 GAK -2,461 0,015 0,082 685 1567 1065 -1752 -1670 -1592
NM_000154 GALK1 -1,552 0,122 0,305 870 2055 925 -2445 -1263 -3019
NM_002044 GALK2 -2,588 0,010 0,068 2482 2138 2719 456 -538 -588
NM_002045 GAP43 -1,581 0,115 0,293 2709 1394 1723 -1445 -1375 -1871
NM_033507 GCK 0,287 0,774 0,888 3194 2909 3890 -1937 448 -3706
NM_001495 GFRA2 -1,260 0,209 0,431 1582 1798 2244 -1773 -1718 -2206
NM_000167 GK -2,734 0,007 0,050 962 1182 1601 -1166 -1261 -1480
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Supplementary Table 1: Normalised screen data and treatment effect per gene
The genes with positive t-statistics mediate epidoxorubicin cytotoxicity; the gene products with negative t-statistics inhibit epidoxorubicin cytotoxicity
Accession Number Gene Symbol t-statistic p-value FDR Untreated Treated
Screen 
1
Screen 
2
Screen 
3 
Screen 
1
Screen 
2
Screen 
3 
NM_033214 GK2 -1,729 0,085 0,247 -631 1145 1880 -2999 -1231 -3481
NM_005476 GNE -1,698 0,091 0,256 665 1140 2961 -2580 -1685 -1170
NM_005113 GOLGA5 -1,734 0,084 0,247 1617 988 4055 -2164 -74 -1180
NM_002929 GRK1 -1,675 0,095 0,261 -160 696 2285 -2999 -2301 -2141
NM_001004057 GRK4 -2,911 0,004 0,036 411 685 -1244 -3107 -1821 -2392
NM_005308 GRK5 -1,145 0,253 0,469 2783 1856 3845 -1597 -908 -606
NM_001004105 GRK6 0,546 0,586 0,782 2648 2084 3515 -1494 -2622 -3462
NM_139209 GRK7 -1,512 0,132 0,325 2023 2762 2227 -1448 -1250 -983
NM_031965 GSG2 -2,169 0,031 0,135 3125 -568 1406 -1233 -1217 -2561
NM_019884 GSK3A -2,083 0,038 0,153 -865 541 2137 -3053 -2197 -2161
NM_002093 GSK3B -1,206 0,229 0,447 1062 423 3087 -3015 -1058 -2775
NM_002096 GTF2F1 -0,526 0,599 0,787 1167 2633 2368 -3068 -1777 -2131
NM_005316 GTF2H1 -0,283 0,777 0,890 3615 1339 5341 -1059 -550 -1837
NM_004963 GUCY2C -0,765 0,445 0,666 4233 3463 2280 -555 -1395 -619
NM_000180 GUCY2D -0,258 0,796 0,896 1995 2512 3293 -2403 -1045 -2565
NM_001522 GUCY2F -1,589 0,113 0,292 3438 1914 1901 -2639 -1222 664
NM_000858 GUK1 -2,170 0,031 0,135 2722 2609 2779 -251 -1387 711
NM_052947 HAK -0,511 0,610 0,795 1626 2942 3146 -1631 -2032 -1806
NM_002110 HCK -1,582 0,115 0,293 2110 742 4087 -1197 -1096 -1244
NM_152696 HIPK1 -3,196 0,002 0,023 1273 303 1319 -1747 -717 -1128
NM_022740 HIPK2 -2,220 0,027 0,124 1882 154 2709 -2560 -1207 -357
NM_005734 HIPK3 0,502 0,616 0,797 1761 4478 3868 -2571 -668 -2377
NM_144685 HIPK4 -1,928 0,055 0,190 -304 113 2291 -2997 -2228 -2296
NM_000188 HK1 0,164 0,870 0,935 3691 1507 3558 -3086 -2235 -793
NM_000189 HK2 -1,102 0,272 0,487 731 162 2461 -3577 -2208 -2556
NM_002115 HK3 -0,410 0,682 0,840 3199 1851 3203 -1928 -1463 -1792
NM_031935 HMCN1 -1,392 0,165 0,375 5051 663 3382 -723 -1677 587
XM_175125 HMCN2 -2,004 0,046 0,171 879 1473 2916 -1780 -1998 -388
NM_014413 HRI -0,216 0,829 0,912 2083 3004 4411 -1591 -1993 -836
NM_017525 HSMDPKIN -0,347 0,729 0,867 2763 1322 3938 -2340 -1987 -1238
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Supplementary Table 1: Normalised screen data and treatment effect per gene
The genes with positive t-statistics mediate epidoxorubicin cytotoxicity; the gene products with negative t-statistics inhibit epidoxorubicin cytotoxicity
Accession Number Gene Symbol t-statistic p-value FDR Untreated Treated
Screen 
1
Screen 
2
Screen 
3 
Screen 
1
Screen 
2
Screen 
3 
NM_014365 HSPB8 -3,130 0,002 0,026 -1878 -480 -456 -3695 -2350 -3407
NM_014586 HUNK -0,134 0,894 0,945 1784 2553 4269 -1789 -1908 -1821
NM_014920 ICK -2,068 0,040 0,157 137 500 1139 -3853 -1840 -1810
NM_000875 IGF1R -0,877 0,381 0,609 2739 2097 1764 -1870 -2159 -1644
NM_000876 IGF2R -1,391 0,165 0,375 2805 2645 2879 -218 -501 -1937
NM_001006115 IHPK1 0,406 0,685 0,842 2419 161 4189 -2451 -2148 -4123
NM_001005911 IHPK2 -0,694 0,488 0,708 2061 1160 2253 -2863 -1945 -2446
NM_054111 IHPK3 -3,276 0,001 0,021 -2058 685 -901 -3408 -1418 -3645
NM_003640 IKBKAP 0,292 0,770 0,887 4426 2754 4428 -1983 -1690 88
NM_001556 IKBKB -1,830 0,068 0,217 1433 1342 725 -2251 -1625 -2523
NM_014002 IKBKE 0,196 0,845 0,920 295 1480 4945 -3321 -2208 -2708
NM_000586 IL2 0,276 0,783 0,893 2809 3092 4185 -1151 -1268 -2644
NM_001014794 ILK -2,211 0,028 0,126 -835 -1050 705 -4195 -2444 -3463
NM_030768 ILKAP -0,752 0,453 0,675 -796 1279 3382 -3697 -1951 -3036
NM_000208 INSR -0,673 0,501 0,721 768 233 2288 -2756 -2284 -4438
NM_014215 INSRR -1,119 0,264 0,482 1360 2272 -640 -3299 -2515 -2843
NM_152230 IPMK -1,120 0,264 0,482 503 1451 3867 -2605 -1209 -1996
NM_001025243 IRAK1 -1,487 0,138 0,338 1172 1254 192 -2750 -2149 -3231
NM_001570 IRAK2 -0,225 0,822 0,910 3817 4750 3677 -883 -1360 591
NM_007199 IRAK3 -0,625 0,532 0,737 1500 2802 2947 -2560 -1152 -1935
NM_016123 IRAK4 -2,335 0,020 0,099 -659 1458 2130 -2831 -2131 -680
NM_005544 IRS1 -0,117 0,907 0,949 2029 1817 1825 -3122 -2687 -2687
NM_005546 ITK -1,229 0,220 0,444 1962 1304 2303 -1366 -2309 -2151
NM_014216 ITPK1 0,865 0,388 0,615 877 2573 5356 -2664 -2505 -2679
NM_002220 ITPKA 0,325 0,745 0,871 2832 2649 5033 -969 -2163 -1629
NM_002221 ITPKB -0,811 0,418 0,644 2162 2183 -926 -1995 -2683 -4306
NM_025194 ITPKC 0,540 0,590 0,782 2406 3019 2069 -2061 -2116 -4140
NM_002227 JAK1 -0,142 0,887 0,942 2222 5808 4077 -330 -562 -1100
NM_004972 JAK2 -0,540 0,590 0,782 3287 2222 1666 -1206 -1990 -2738
NM_000215 JAK3 -0,209 0,835 0,916 4747 3282 1959 -1080 -1066 -1800
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Supplementary Table 1: Normalised screen data and treatment effect per gene
The genes with positive t-statistics mediate epidoxorubicin cytotoxicity; the gene products with negative t-statistics inhibit epidoxorubicin cytotoxicity
Accession Number Gene Symbol t-statistic p-value FDR Untreated Treated
Screen 
1
Screen 
2
Screen 
3 
Screen 
1
Screen 
2
Screen 
3 
NM_016281 JIK -0,871 0,385 0,612 4044 2741 1648 -1169 -1837 -838
NM_001024660 KALRN -2,012 0,045 0,169 3237 1990 2934 332 -1121 -484
NM_002253 KDR -0,086 0,932 0,964 4979 2600 2261 -1211 -874 -2318
NM_000221 KHK -1,818 0,070 0,220 1486 2728 -362 -2290 -1627 -2121
XM_291141 KIAA0303 -2,831 0,005 0,041 977 3105 3234 -712 -1267 2012
NM_016081 KIAA0992 -0,348 0,728 0,867 5418 1618 5036 -101 -1331 -72
NM_025164 KIAA0999 -2,336 0,020 0,099 1623 3673 -2174 -1026 -1407 -2864
NM_020791 KIAA1361 -0,791 0,430 0,650 4233 3927 2870 -211 -1244 2
XM_290923 KIAA1639 -0,263 0,793 0,896 3259 2723 2662 -991 -1745 -2423
XM_047355 KIAA1765 -0,540 0,590 0,782 2331 4189 2922 -1543 -369 -1754
NM_032435 KIAA1804 1,425 0,156 0,360 4190 3979 6112 -870 -865 -2013
NM_032430 KIAA1811 0,610 0,542 0,744 3516 4462 1435 -1624 -1724 -3236
XM_370878 KIAA2002 -2,505 0,013 0,079 51 914 1006 -1588 -1448 -3189
NM_000222 KIT 0,204 0,838 0,917 4115 2754 4172 -87 -1260 -2583
NM_014238 KSR -3,031 0,003 0,029 2166 114 -1929 -1627 -2005 -2797
NM_173598 KSR2 -2,757 0,006 0,048 1459 605 -111 -1228 -1304 -3068
NM_025144 LAK -1,479 0,140 0,338 1376 4299 3119 -1372 419 -986
NM_004690 LATS1 -2,899 0,004 0,036 3165 2084 -3410 -435 -1999 -2580
NM_014572 LATS2 -3,195 0,002 0,023 331 1408 -2069 -3046 -1562 -2112
NM_005356 LCK -2,919 0,004 0,036 284 905 -3396 -3345 -2061 -3814
NM_016735 LIMK1 0,260 0,795 0,896 4105 2624 4660 -1206 -1345 -1167
NM_001031801 LIMK2 -1,302 0,194 0,410 2730 3493 2435 -24 -1030 -1495
NM_014916 LMTK2 -0,810 0,419 0,644 3246 1744 -422 -2667 -1740 -3435
XM_055866 LMTK3 -0,483 0,629 0,805 2166 4326 4387 -664 -819 -886
XM_208545 LOC283155 -0,336 0,737 0,868 3335 4680 4614 -113 -783 -95
XM_496963 LOC286042 -1,024 0,307 0,523 2935 2670 1692 -1316 -2185 -1105
XM_370729 LOC387934 -2,909 0,004 0,036 2072 2116 -1575 -1828 -1643 -1001
XM_372002 LOC389599 -1,328 0,185 0,400 3257 2828 3482 -896 -1496 825
XM_497249 LOC390003 -3,219 0,001 0,022 1176 471 -1652 -3735 -2152 -407
XM_372663 LOC390777 -3,858 0,000 0,006 1515 209 -391 -1037 -1190 -1264
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Supplementary Table 1: Normalised screen data and treatment effect per gene
The genes with positive t-statistics mediate epidoxorubicin cytotoxicity; the gene products with negative t-statistics inhibit epidoxorubicin cytotoxicity
Accession Number Gene Symbol t-statistic p-value FDR Untreated Treated
Screen 
1
Screen 
2
Screen 
3 
Screen 
1
Screen 
2
Screen 
3 
XM_497791 LOC391295 -2,469 0,014 0,082 1674 2274 687 -2146 -1328 -166
XM_497921 LOC391533 -0,155 0,877 0,940 1554 3389 2321 -2580 -1853 -2373
XM_498003 LOC391783 -1,090 0,277 0,492 3313 1331 4203 -561 -1110 -1204
XM_498286 LOC392226 -0,445 0,657 0,825 1932 2616 2124 -2801 -1116 -2757
XM_498294 LOC392265 -2,128 0,034 0,144 2489 733 1205 -2339 -1263 -1107
NM_001013664 LOC392395 -2,044 0,042 0,161 1751 1908 804 -1418 -2100 -1381
XM_375150 LOC400301 -2,043 0,042 0,161 4309 2745 531 -899 -254 -562
XM_496596 LOC401007 -3,071 0,002 0,028 3432 1797 -1705 -667 -1408 -1003
XM_377941 LOC402269 -3,324 0,001 0,020 1613 512 468 -2780 -1210 498
XM_378043 LOC402353 -3,098 0,002 0,027 1714 1524 -1904 -3349 -758 -1119
XM_496112 LOC440332 -3,053 0,003 0,029 922 1602 -3644 -2665 -2322 -2745
XM_496234 LOC440451 -0,658 0,511 0,724 3432 2905 3548 -2386 -544 4
XM_496486 LOC440785 -2,771 0,006 0,046 346 946 -1139 -2899 -2095 -2382
XM_497052 LOC441435 -1,114 0,267 0,482 3585 3195 3966 -1433 -743 1257
XM_497521 LOC441777 -3,490 0,001 0,013 2082 2214 -2333 -2572 -767 -185
XM_497532 LOC441787 -2,053 0,041 0,158 3636 1227 1405 -1152 -1485 -402
XM_498204 LOC442313 -4,398 1,64E-5 0,002 -993 -449 -4300 -4725 -1979 -2265
XM_498300 LOC442402 -2,396 0,017 0,091 844 2672 311 -2303 -1543 -774
NM_138370 LOC91461 -4,886 1,87E-6 0,001 -2617 216 -4831 -4835 -2251 -2016
NM_024652 LRRK1 -2,955 0,003 0,034 87 1507 1579 -2721 -1248 115
NM_198578 LRRK2 -1,456 0,147 0,347 1756 1764 1411 -2478 -1325 -2097
NM_000627 LTBP1 -0,618 0,537 0,740 3428 2777 2989 -2008 -1879 168
NM_003573 LTBP4 -0,881 0,379 0,608 2921 867 4707 -2392 -1249 -85
NM_206961 LTK -1,326 0,186 0,400 3083 1119 2271 -2539 -2150 41
NM_001003786 LYK5 0,138 0,890 0,943 4251 2440 1657 -2998 -1695 -1765
NM_002350 LYN -2,689 0,008 0,055 1823 884 1414 -2696 -391 -509
NM_152900 MAGI-3 -0,694 0,489 0,708 1775 1365 3696 -3198 -177 -2493
NM_005906 MAK -0,514 0,608 0,794 2559 3954 3853 -1733 -1131 57
NM_002446 MAP2K1 0,547 0,585 0,782 4165 2181 3579 -3190 -1726 -991
NM_002419 MAP2K1IP1 -2,119 0,035 0,147 2317 2127 -1071 -1630 -1454 -2644
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Supplementary Table 1: Normalised screen data and treatment effect per gene
The genes with positive t-statistics mediate epidoxorubicin cytotoxicity; the gene products with negative t-statistics inhibit epidoxorubicin cytotoxicity
Accession Number Gene Symbol t-statistic p-value FDR Untreated Treated
Screen 
1
Screen 
2
Screen 
3 
Screen 
1
Screen 
2
Screen 
3 
NM_006301 MAP2K2 -0,467 0,641 0,816 4970 2855 3478 217 -1434 -769
NM_002755 MAP2K3 -2,098 0,037 0,152 885 2944 527 -1470 -1260 -2111
NM_021970 MAP2K4 -0,390 0,697 0,846 3425 2212 3269 -2871 -1045 -658
NM_030662 MAP2K5 0,279 0,780 0,892 4701 3629 5153 -535 -1240 101
NM_145109 MAP2K6 -1,085 0,279 0,495 4708 1405 1426 -1339 -1979 -860
NM_003010 MAP2K7 -1,971 0,050 0,179 2668 785 -2164 -3580 -1825 -2729
NM_145162 MAP3K1 -0,004 0,997 0,999 3328 2994 2475 -1976 -1293 -2382
NM_031988 MAP3K10 -3,411 0,001 0,015 1958 651 -2964 -1636 -2181 -2284
NM_145185 MAP3K11 -4,350 2,01E-5 0,002 -428 2552 -3053 -494 -1517 -2180
NM_138981 MAP3K12 -3,692 0,000 0,007 204 -1476 -5101 -3844 -3277 -4246
NM_138993 MAP3K13 -0,234 0,815 0,905 2770 3150 2053 -1310 -2394 -2198
NM_002969 MAP3K14 -1,675 0,095 0,261 -933 2360 446 -3475 -2744 -2147
XM_042066 MAP3K15 -0,204 0,838 0,917 3510 3289 3860 -1127 -1354 -810
NM_004721 MAP3K2 -1,471 0,143 0,341 -711 1738 2314 -1708 -2742 -2963
NM_003954 MAP3K3 -2,097 0,037 0,152 945 1124 -2374 -4272 -2292 -2878
NM_001001671 MAP3K4 -2,916 0,004 0,036 878 1842 -968 -1841 -1655 -1895
NM_006609 MAP3K5 0,665 0,507 0,723 4599 3247 3209 -1812 -838 -2416
NM_002401 MAP3K6 -0,471 0,638 0,813 2216 1214 150 -3196 -2686 -3817
NM_006724 MAP3K7 -0,143 0,887 0,942 3849 2840 764 -1435 -1911 -3299
NM_005923 MAP3K8 -0,320 0,749 0,874 2592 2353 1496 -2577 -1818 -2825
NM_004672 MAP3K9 -1,527 0,128 0,318 3946 2992 1449 -1339 -1511 623
NM_145333 MAP4K1 -1,652 0,100 0,269 503 2826 -467 -2272 -1686 -3468
NM_005204 MAP4K2 -1,216 0,225 0,446 2305 3604 2722 -882 -2571 689
NM_033141 MAP4K3 -1,543 0,124 0,309 2499 3317 2332 -663 -2067 285
NM_007181 MAP4K4 -3,773 0,000 0,006 130 2639 1169 -169 -976 83
NM_004579 MAP4K5 -3,029 0,003 0,029 2893 1275 2186 388 -1567 675
NM_003618 MAPK1 -1,483 0,139 0,338 2272 3606 2120 -886 -1228 -646
NM_004834 MAPK10 -2,978 0,003 0,033 899 1913 -677 -1848 -2142 -860
NM_006575 MAPK11 0,371 0,711 0,856 5406 2061 3991 -1509 -1637 -790
NM_138957 MAPK12 -2,729 0,007 0,051 3048 2238 -1419 -2193 -1398 -24
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Supplementary Table 1: Normalised screen data and treatment effect per gene
The genes with positive t-statistics mediate epidoxorubicin cytotoxicity; the gene products with negative t-statistics inhibit epidoxorubicin cytotoxicity
Accession Number Gene Symbol t-statistic p-value FDR Untreated Treated
Screen 
1
Screen 
2
Screen 
3 
Screen 
1
Screen 
2
Screen 
3 
NM_002754 MAPK13 0,421 0,674 0,835 3850 2721 4226 -57 -2829 -1833
NM_139013 MAPK14 -2,207 0,028 0,127 1828 2767 2788 -284 -2380 1155
NM_002746 MAPK3 -2,282 0,023 0,110 2875 1803 297 -761 -1608 -1393
NM_002747 MAPK4 -2,915 0,004 0,036 3830 1370 3239 277 -793 1849
NM_002748 MAPK6 -3,275 0,001 0,021 2772 1475 1430 328 -1638 747
NM_139032 MAPK7 -3,108 0,002 0,027 313 1134 -756 -1910 -2776 -1305
NM_139049 MAPK8 -4,591 7,09E-6 0,001 1916 496 -1451 821 -2631 15
NM_005456 MAPK8IP1 -2,670 0,008 0,057 1128 2035 -406 -2140 -2126 -735
NM_139124 MAPK8IP2 -3,613 0,000 0,009 -89 1143 302 -1820 -1746 -513
NM_033392 MAPK8IP3 -3,575 0,000 0,010 -78 2331 -2167 -1577 -2694 -999
NM_002752 MAPK9 -1,217 0,225 0,446 4519 2190 4146 53 -1264 666
NM_032960 MAPKAPK2 -3,996 8,55E-5 0,004 1038 1150 2960 -10 -1270 2073
NM_004635 MAPKAPK3 -3,497 0,001 0,013 2745 1233 -249 -954 -1717 777
NM_003668 MAPKAPK5 -3,008 0,003 0,031 4278 1277 2948 650 -1180 2212
NM_018650 MARK1 -4,044 7,07E-5 0,004 2761 584 -900 -273 -2080 614
NM_004954 MARK2 -3,790 0,000 0,006 1475 64 189 -1287 -2683 811
NM_002376 MARK3 -3,028 0,003 0,029 2007 1047 1919 -1086 -1439 619
NM_031417 MARK4 -3,959 9,88E-5 0,005 960 49 -1120 -1556 -1691 -1428
NM_015112 MAST2 -1,857 0,065 0,209 356 2562 4151 -2141 -1545 1037
XM_038150 MAST3 -2,395 0,017 0,091 1464 1998 894 -1875 -2228 0
NM_032844 MASTL -3,226 0,001 0,022 2393 1267 949 -690 -1682 610
NM_139354 MATK -2,258 0,025 0,114 3748 1584 1629 -948 -1404 529
NM_014791 MELK -3,798 0,000 0,006 1574 1611 1125 -97 -1583 1049
NM_006343 MERTK -3,574 0,000 0,010 -757 830 2205 -1712 -1568 106
NM_000245 MET -3,812 0,000 0,006 10 1337 -250 -1753 -836 -1253
NM_033115 MGC16169 -2,482 0,014 0,080 1531 69 -1002 -3211 -2234 -2191
NM_024069 MGC2749 -1,409 0,160 0,367 2227 2924 1839 -2029 -487 -1434
NM_153361 MGC42105 -1,108 0,269 0,484 2768 3558 3842 -844 -1381 707
NM_152619 MGC45428 0,175 0,861 0,929 4439 4686 2678 -1022 -1057 -1015
NM_032017 MGC4796 -0,061 0,951 0,975 2883 2234 386 -2243 -2307 -4251
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Supplementary Table 1: Normalised screen data and treatment effect per gene
The genes with positive t-statistics mediate epidoxorubicin cytotoxicity; the gene products with negative t-statistics inhibit epidoxorubicin cytotoxicity
Accession Number Gene Symbol t-statistic p-value FDR Untreated Treated
Screen 
1
Screen 
2
Screen 
3 
Screen 
1
Screen 
2
Screen 
3 
NM_024091 MGC5297 -0,795 0,427 0,649 5217 3752 3496 547 -1814 1278
NM_024046 MGC8407 -1,302 0,194 0,410 902 2358 3094 -2477 -398 -1957
NM_020778 MIDORI -1,947 0,053 0,184 -1815 2385 844 -3826 -1066 -3180
NM_015716 MINK -2,077 0,039 0,155 2800 3257 2542 -1444 -1376 2223
NM_198973 MKNK1 -2,426 0,016 0,088 3448 2262 2114 1251 -1700 -84
NM_017572 MKNK2 -2,151 0,032 0,138 2149 340 1625 -2424 -1358 -1181
NM_182493 MLCK -2,322 0,021 0,102 3012 1676 3273 -117 -1557 1010
NM_005372 MOS -1,726 0,086 0,247 1314 1848 2972 -2246 -1328 -428
NM_002436 MPP1 -2,035 0,043 0,163 3345 -1366 1782 -1054 -1887 -2565
NM_005374 MPP2 -3,895 0,000 0,006 -1928 -462 308 -2631 -1563 -2592
NM_001932 MPP3 -2,725 0,007 0,051 -313 1937 -399 -1314 -2752 -2325
NM_002447 MST1R -3,163 0,002 0,024 399 1427 851 -1623 -2019 -232
NM_018238 MULK -1,514 0,131 0,325 1755 1008 1564 -3282 -1235 -1829
NM_005592 MUSK -2,496 0,013 0,079 -285 1454 2692 -920 -2193 -1207
NM_002461 MVD -1,711 0,088 0,251 1473 1469 1413 -3062 -1921 -841
NM_000431 MVK -2,159 0,032 0,136 1782 1162 478 -1646 -2006 -2002
NM_053031 MYLK -3,753 0,000 0,006 -728 -295 -2963 -3402 -2440 -3180
NM_033118 MYLK2 0,419 0,675 0,835 2702 1598 1864 -3905 -2376 -3061
NM_017433 MYO3A -1,270 0,205 0,428 2502 2508 1966 -661 -1634 -2021
NM_138995 MYO3B -2,334 0,020 0,099 976 3694 -542 -1028 -1959 -1423
NM_017567 NAGK -1,276 0,203 0,425 2369 2513 1086 -1225 -2582 -1495
NM_153006 NAGS -2,194 0,029 0,129 2531 1274 279 -1095 -2129 -1657
NM_145910 NEK1 -2,268 0,024 0,113 -562 380 2466 -2237 -1967 -2272
NM_012224 NEK11 -3,111 0,002 0,027 1646 912 511 -254 -1654 -1710
NM_002497 NEK2 -1,957 0,051 0,182 3176 328 -169 -1494 -2282 -2410
NM_152720 NEK3 -0,965 0,336 0,556 2830 1505 4153 -1222 -644 -1684
NM_003157 NEK4 -1,051 0,294 0,509 342 2058 2738 -2079 -2404 -2205
NM_199289 NEK5 0,879 0,380 0,608 4041 2326 3517 -586 -2831 -3371
NM_014397 NEK6 -3,594 0,000 0,010 256 432 -1291 -1590 -2357 -2136
NM_133494 NEK7 -1,497 0,136 0,332 4651 819 1175 -1074 -2290 -646
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Supplementary Table 1: Normalised screen data and treatment effect per gene
The genes with positive t-statistics mediate epidoxorubicin cytotoxicity; the gene products with negative t-statistics inhibit epidoxorubicin cytotoxicity
Accession Number Gene Symbol t-statistic p-value FDR Untreated Treated
Screen 
1
Screen 
2
Screen 
3 
Screen 
1
Screen 
2
Screen 
3 
NM_178170 NEK8 -1,720 0,087 0,249 2379 1541 637 -2057 -2486 -1056
NM_033116 NEK9 -3,307 0,001 0,020 -1576 1669 -2192 -2558 -2345 -3276
NM_002499 NEO1 -2,709 0,007 0,053 2593 103 -2448 -908 -2645 -3693
NM_016231 NLK -2,873 0,004 0,038 646 238 -1951 -2730 -2209 -3372
NM_000269 NME1 -2,091 0,038 0,153 1532 393 -1161 -2513 -2868 -3072
NM_001018139 NME2 -3,279 0,001 0,021 278 38 -2509 -3019 -2401 -2990
NM_002513 NME3 -1,158 0,248 0,466 1290 750 660 -2178 -2657 -4029
NM_005009 NME4 -1,296 0,196 0,413 2403 3165 -648 -1405 -1894 -2955
NM_003551 NME5 -0,316 0,752 0,876 3792 3551 2276 -1176 -1026 -1849
NM_005793 NME6 -0,845 0,399 0,622 2473 1100 2104 -2704 -2629 -1336
NM_197972 NME7 0,023 0,982 0,991 3554 2594 3801 -1595 -2140 -831
NM_000906 NPR1 -0,380 0,705 0,854 3043 3730 2643 -695 -617 -2779
NM_003995 NPR2 -1,155 0,249 0,466 3348 3090 2165 -552 -1102 -1322
NM_013392 NRBP -0,650 0,516 0,726 3769 1985 3403 -1091 -907 -1679
NM_178564 NRBP2 -2,504 0,013 0,079 722 888 -1235 -2845 -2566 -2408
NM_198465 NRK -1,439 0,152 0,356 2842 506 -63 -2580 -2195 -2784
NM_001024629 NRP1 0,769 0,443 0,664 4804 4771 3097 -713 -1334 -1662
NM_201264 NRP2 -1,883 0,061 0,203 2449 1098 2587 -1360 -733 -1531
NM_001007792 NTRK1 0,138 0,890 0,943 3606 2520 3883 -1092 -1441 -2262
NM_001018064 NTRK2 -1,970 0,050 0,179 838 1744 1804 -1511 -2063 -1590
NM_002530 NTRK3 -0,565 0,572 0,773 3213 2384 5583 -167 -1283 -404
NM_012346 NUP62 -2,503 0,013 0,079 -395 1469 -205 -3112 -1963 -2252
NM_001001875 NYD-SP25 -3,253 0,001 0,021 1514 1267 -365 -1518 -2337 -16
NM_005109 OSR1 -0,939 0,349 0,569 3903 1731 3859 -500 -1003 -1111
NM_181093 PACE-1 0,094 0,925 0,959 2169 3100 492 -3095 -1786 -4053
NM_020804 PACSIN1 -1,735 0,084 0,247 53 2405 3280 -1530 -1983 -837
NM_002576 PAK1 -0,040 0,968 0,982 2789 4417 4862 -42 -1879 -369
NM_002577 PAK2 0,194 0,847 0,920 5241 3161 1673 -1092 -2090 -1690
NM_002578 PAK3 -1,275 0,204 0,425 2455 2141 1322 -1348 -2384 -1629
NM_001014834 PAK4 -1,378 0,170 0,382 4144 1944 2818 264 -1728 -631
515504-L-bw-Bakker
Processed on: 1-12-2017 PDF page: 139
139
Supplementary Table 1: Normalised screen data and treatment effect per gene
The genes with positive t-statistics mediate epidoxorubicin cytotoxicity; the gene products with negative t-statistics inhibit epidoxorubicin cytotoxicity
Accession Number Gene Symbol t-statistic p-value FDR Untreated Treated
Screen 
1
Screen 
2
Screen 
3 
Screen 
1
Screen 
2
Screen 
3 
NM_020168 PAK6 -2,537 0,012 0,076 2842 1967 -236 -983 -2237 -265
NM_177990 PAK7 -1,713 0,088 0,251 -119 2127 1823 -2328 -1669 -2341
NM_175854 PAN3 -1,007 0,315 0,533 3235 3504 3634 521 -969 -1124
NM_138316 PANK1 -0,334 0,739 0,868 2212 3580 4041 -1163 -1126 -1503
NM_153637 PANK2 -2,837 0,005 0,040 -1152 398 101 -3047 -1817 -3154
NM_024594 PANK3 -2,373 0,018 0,094 2075 747 166 -1647 -2229 -1664
NM_018216 PANK4 -1,313 0,190 0,407 920 2393 1292 -2719 -1813 -2043
NM_005443 PAPSS1 -0,397 0,692 0,844 3686 2273 3527 -1664 -1752 -564
NM_004670 PAPSS2 -0,371 0,711 0,856 2534 3526 4596 -1078 -854 -943
NM_015148 PASK 0,009 0,992 0,999 4162 3008 4448 -415 -658 -1791
NM_002591 PCK1 -0,630 0,529 0,736 1640 2000 2701 -2684 -1808 -2054
NM_001018073 PCK2 -2,961 0,003 0,034 -1060 769 -746 -3210 -2278 -2608
NM_006201 PCTK1 -0,741 0,459 0,683 2635 2964 4381 -1190 -1075 -361
NM_002595 PCTK2 -0,638 0,524 0,731 1363 2858 4025 -1715 -1332 -1567
NM_212502 PCTK3 -1,569 0,118 0,298 1142 -290 2380 -3537 -1642 -2100
NM_006206 PDGFRA -2,085 0,038 0,153 436 431 1627 -1968 -2203 -2593
NM_002609 PDGFRB -1,947 0,053 0,184 751 766 1469 -2608 -1786 -2228
NM_006207 PDGFRL -0,461 0,645 0,819 4358 2339 2072 -1756 -2011 -767
NM_152835 PDIK1L -1,159 0,248 0,466 3447 3402 4408 -202 -547 436
NM_002610 PDK1 -1,805 0,072 0,221 2068 814 2290 -1120 -2068 -1591
NM_002611 PDK2 -3,826 0,000 0,006 -2914 22 -730 -3345 -2246 -2871
NM_005391 PDK3 -0,352 0,725 0,865 3832 1658 5820 -1366 303 -1191
NM_002612 PDK4 -1,639 0,102 0,274 3106 1669 2336 -1105 -1122 -1033
NM_031268 PDPK1 -2,070 0,040 0,157 2089 1957 1891 -1395 -1169 -805
NM_003681 PDXK -1,375 0,170 0,382 1329 2755 1144 -2680 -1883 -1227
NM_002625 PFKFB1 -1,973 0,050 0,179 249 1032 5023 -1680 -1924 522
NM_001018053 PFKFB2 -1,371 0,172 0,383 1772 553 3287 -1979 -2098 -1330
NM_004566 PFKFB3 -0,367 0,714 0,857 2429 2730 3226 -2809 -746 -1601
NM_004567 PFKFB4 -1,319 0,188 0,404 586 2516 987 -3217 -1861 -1988
NM_002626 PFKL -1,769 0,078 0,233 972 1478 2059 -1970 -1843 -1729
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Supplementary Table 1: Normalised screen data and treatment effect per gene
The genes with positive t-statistics mediate epidoxorubicin cytotoxicity; the gene products with negative t-statistics inhibit epidoxorubicin cytotoxicity
Accession Number Gene Symbol t-statistic p-value FDR Untreated Treated
Screen 
1
Screen 
2
Screen 
3 
Screen 
1
Screen 
2
Screen 
3 
NM_000289 PFKM 0,109 0,914 0,953 3847 2791 2267 -1189 -2154 -2482
NM_002627 PFKP -1,155 0,249 0,466 1034 1356 933 -2908 -2570 -2782
NM_012395 PFTK1 -1,115 0,266 0,482 53 528 2157 -3684 -2307 -2935
NM_000291 PGK1 -1,135 0,257 0,475 1805 2622 3436 -1911 -1047 -802
NM_138733 PGK2 0,145 0,885 0,942 2890 2938 3910 -984 -1464 -2635
NM_002637 PHKA1 -0,951 0,343 0,562 1796 2592 1755 -2761 -1887 -1295
NM_000292 PHKA2 -1,155 0,249 0,466 2507 3034 1994 -241 -1928 -1867
NM_001031835 PHKB 0,926 0,355 0,575 4880 2591 4880 -913 -1928 -1590
NM_006213 PHKG1 -0,819 0,413 0,640 2448 1720 5015 -1342 -881 -989
NM_000294 PHKG2 -3,253 0,001 0,021 577 971 1501 505 -1390 -2356
NM_018323 PI4K2B -1,984 0,048 0,177 2038 1131 -464 -2855 -1987 -1938
NM_018425 PI4KII -2,415 0,016 0,089 403 1989 -329 -3031 -1416 -1889
NM_002645 PIK3C2A -1,964 0,051 0,181 -1142 1008 759 -3169 -2471 -3277
NM_002646 PIK3C2B -0,507 0,612 0,796 3104 1402 2586 -1860 -2411 -1829
NM_004570 PIK3C2G -0,345 0,731 0,867 2892 2316 2883 -2458 -1985 -1065
NM_002647 PIK3C3 -3,121 0,002 0,027 267 525 -1412 -2444 -1715 -3104
NM_006218 PIK3CA -2,822 0,005 0,041 -2833 278 -1343 -5231 -2543 -3442
NM_006219 PIK3CB -1,146 0,253 0,469 2683 2447 3223 -465 -1488 -1297
NM_005026 PIK3CD -1,800 0,073 0,221 144 1364 1140 -2167 -2820 -2336
NM_002649 PIK3CG -1,861 0,064 0,209 2361 2749 1881 16 -1833 -1002
NM_181504 PIK3R1 0,519 0,604 0,792 3099 2955 4447 -1090 -2618 -1548
NM_005027 PIK3R2 -4,775 3,11E-6 0,001 -3920 -1697 -3358 -4865 -3039 -3544
NM_003629 PIK3R3 -1,765 0,079 0,234 1442 725 1171 -1713 -2949 -2057
NM_014602 PIK3R4 -2,362 0,019 0,096 -187 1784 -760 -2705 -2616 -2382
NM_002650 PIK4CA -2,169 0,031 0,135 -28 1451 -802 -3561 -2631 -2212
NM_002651 PIK4CB -1,877 0,062 0,205 1038 1706 922 -1653 -2039 -2424
NM_002648 PIM1 -0,411 0,681 0,840 3174 2613 3877 -413 -1218 -2135
NM_006875 PIM2 -0,108 0,914 0,953 3308 1674 2526 -3003 -1667 -2011
NM_001001852 PIM3 1,149 0,252 0,468 4065 3204 4155 -1241 -1998 -2664
NM_032409 PINK1 0,001 0,999 0,999 3639 2568 3489 -1940 -1397 -1427
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Supplementary Table 1: Normalised screen data and treatment effect per gene
The genes with positive t-statistics mediate epidoxorubicin cytotoxicity; the gene products with negative t-statistics inhibit epidoxorubicin cytotoxicity
Accession Number Gene Symbol t-statistic p-value FDR Untreated Treated
Screen 
1
Screen 
2
Screen 
3 
Screen 
1
Screen 
2
Screen 
3 
NM_003557 PIP5K1A -1,988 0,048 0,176 10 1856 2241 -2455 -2032 -876
NM_003558 PIP5K1B -1,896 0,059 0,201 1538 2226 576 -2053 -1766 -1568
NM_005028 PIP5K2A -1,376 0,170 0,382 3457 2921 145 -1561 -1528 -1380
NM_138687 PIP5K2B -1,246 0,214 0,439 4733 2034 775 -839 -938 -1984
NM_024779 PIP5K2C -2,486 0,014 0,080 2275 1760 -252 -1560 -1340 -1546
NM_152671 PIP5K3 -2,256 0,025 0,114 2682 2048 1034 -980 -1192 -892
NM_173492 PIP5KL1 -2,162 0,032 0,136 4175 1901 3391 1783 -1885 593
NM_181839 PKIA 0,162 0,871 0,935 5941 2629 4139 -713 -726 -719
NM_032471 PKIB -1,828 0,069 0,217 1946 991 1157 -2239 -1281 -2285
NM_181871 PKLR -1,069 0,286 0,505 4987 2118 2435 699 -1358 -1558
NM_002654 PKM2 -1,031 0,304 0,521 3567 1136 1611 -2195 -1132 -2231
NM_004203 PKMYT1 -0,964 0,336 0,556 4394 1625 3089 -607 -1274 -1050
NM_013355 PKN3 -1,425 0,156 0,360 2167 1842 3580 -1275 -1576 -457
NM_005030 PLK1 -3,926 0,000 0,005 -2797 -1538 -2660 -5165 -2770 -3676
NM_006622 PLK2 -0,305 0,761 0,880 3248 3455 5223 -892 -985 106
NM_004073 PLK3 -1,223 0,222 0,445 2181 361 3461 -2140 -1158 -2080
NM_014264 PLK4 -2,421 0,016 0,088 439 1184 2477 -1937 -1275 -1092
NM_006556 PMVK -0,190 0,850 0,921 4523 2366 2284 -1080 -1353 -2376
NM_198452 PNCK -1,684 0,094 0,259 2553 676 1999 -874 -1486 -2652
NM_007254 PNKP -1,803 0,073 0,221 1448 730 3152 -1882 -664 -2058
NM_002715 PPP2CA -3,838 0,000 0,006 -1124 -1292 -572 -3594 -1857 -2413
NM_004156 PPP2CB -2,086 0,038 0,153 3876 964 2465 -1190 -788 68
NM_002720 PPP4C -2,395 0,017 0,091 1987 266 3397 -2038 -451 -277
NM_006251 PRKAA1 -1,616 0,107 0,281 2279 442 2340 -2003 -1058 -2290
NM_006252 PRKAA2 -0,587 0,558 0,757 4211 2703 5600 -580 -323 433
NM_207518 PRKACA -0,500 0,617 0,797 2619 1863 4957 -1326 -1668 -766
NM_207578 PRKACB -1,066 0,287 0,506 2854 2088 5327 -130 -1109 -263
NM_002732 PRKACG -2,298 0,022 0,107 721 1109 -789 -3314 -1265 -3070
NM_002733 PRKAG1 -2,889 0,004 0,037 -1071 705 -1191 -3913 -1375 -3456
NM_017431 PRKAG3 -3,071 0,002 0,028 525 -534 -910 -3781 -1470 -2428
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Supplementary Table 1: Normalised screen data and treatment effect per gene
The genes with positive t-statistics mediate epidoxorubicin cytotoxicity; the gene products with negative t-statistics inhibit epidoxorubicin cytotoxicity
Accession Number Gene Symbol t-statistic p-value FDR Untreated Treated
Screen 
1
Screen 
2
Screen 
3 
Screen 
1
Screen 
2
Screen 
3 
NM_002734 PRKAR1A -1,892 0,060 0,202 2081 -56 1750 -1484 -1938 -2525
NM_004157 PRKAR2A -2,110 0,036 0,149 2089 286 1295 -2663 -1425 -1422
NM_002736 PRKAR2B -1,411 0,159 0,367 2143 2853 3341 -1246 -1885 548
NM_002737 PRKCA -1,674 0,095 0,261 1669 458 4264 -2038 -1509 -278
NM_212535 PRKCB1 -0,142 0,887 0,942 4215 2117 3087 -1272 -797 -2614
NM_212539 PRKCD -0,620 0,536 0,739 2123 2428 3377 -1653 -1493 -1840
NM_005400 PRKCE -0,857 0,392 0,621 3037 1799 4081 -1098 -1592 -707
NM_002739 PRKCG -2,054 0,041 0,158 268 83 3715 -1841 -1290 -2062
NM_006255 PRKCH -1,855 0,065 0,209 964 -597 2909 -2300 -2121 -2088
NM_002740 PRKCI -0,246 0,806 0,899 3348 1462 5090 -1405 -1571 -963
NM_213560 PRKCL1 -1,870 0,063 0,206 2940 -238 785 -2877 -1917 -1466
NM_006256 PRKCL2 -2,274 0,024 0,112 3067 401 -241 -3056 -1273 -1149
NM_002742 PRKCM -4,079 6,15E-5 0,004 224 352 -56 -2125 -1330 -300
NM_005813 PRKCN -1,931 0,055 0,189 3347 2947 2659 -1178 -11 503
NM_006257 PRKCQ -1,295 0,196 0,413 3964 848 2011 -1660 -1012 -1706
NM_001001329 PRKCSH -3,204 0,002 0,023 115 -156 -690 -3641 -1554 -1979
NM_001033582 PRKCZ -1,303 0,194 0,410 2701 1845 3804 -1843 -736 -265
NM_016457 PRKD2 -0,851 0,396 0,622 2506 1050 3745 -1743 -1729 -1553
NM_006904 PRKDC -1,192 0,235 0,455 553 372 2428 -3052 -2066 -3003
NM_006258 PRKG1 -0,172 0,864 0,931 4143 964 6087 -857 -1208 -761
NM_006259 PRKG2 -2,880 0,004 0,037 1029 446 880 -2658 -1244 -1011
NM_002759 PRKR -0,933 0,352 0,571 4509 2733 1761 -633 -1716 -763
NM_018979 PRKWNK1 -0,655 0,513 0,724 1664 -451 2097 -4778 -2183 -2533
NM_006648 PRKWNK2 -0,195 0,846 0,920 3932 2684 2851 -1568 -1026 -1911
NM_001002838 PRKWNK3 -1,885 0,061 0,203 3779 253 388 -1197 -1695 -2375
NM_005044 PRKX -2,025 0,044 0,165 2713 444 3039 -2736 -922 528
XM_497470 PRKXP1 0,328 0,744 0,871 1867 1687 4328 -2793 -2044 -2562
NM_002760 PRKY -1,466 0,144 0,343 913 596 4303 -1873 -1823 -1238
NM_176800 PRPF4B -1,814 0,071 0,220 836 3048 1058 -2675 -1667 -614
NM_002764 PRPS1 -2,368 0,019 0,095 2041 1961 2297 -1426 -936 109
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Supplementary Table 1: Normalised screen data and treatment effect per gene
The genes with positive t-statistics mediate epidoxorubicin cytotoxicity; the gene products with negative t-statistics inhibit epidoxorubicin cytotoxicity
Accession Number Gene Symbol t-statistic p-value FDR Untreated Treated
Screen 
1
Screen 
2
Screen 
3 
Screen 
1
Screen 
2
Screen 
3 
NM_175886 PRPS1L1 -0,339 0,735 0,868 3118 2905 3901 -668 -1163 -1859
NM_002765 PRPS2 -1,083 0,280 0,495 2254 3602 2748 -1283 -1534 -334
NM_002766 PRPSAP1 -0,243 0,808 0,899 2877 2050 3591 -2285 -1181 -1867
NM_002767 PRPSAP2 -0,269 0,788 0,896 4029 1367 2270 -2362 -1221 -2534
NM_006742 PSKH1 -1,094 0,275 0,490 1956 21 2650 -2484 -2059 -2545
NM_033126 PSKH2 -2,497 0,013 0,079 1486 264 2745 -2217 -1113 -360
NM_005607 PTK2 -2,494 0,013 0,079 -181 1220 2096 -1864 -1567 -1655
NM_173175 PTK2B -1,369 0,172 0,383 2397 2444 1571 -1541 -1427 -1669
NM_005975 PTK6 -2,954 0,003 0,034 -596 209 -655 -4063 -1788 -2252
NM_152881 PTK7 -2,353 0,019 0,097 2844 1877 1132 -917 -1317 -495
NM_002822 PTK9 -0,198 0,843 0,920 1378 2661 2406 -2490 -2104 -2925
NM_007284 PTK9L -3,877 0,000 0,006 -3022 -922 -2711 -4926 -2935 -3519
NM_002843 PTPRJ -0,326 0,745 0,871 2007 2095 3708 -1260 -1867 -2705
NM_130846 PTPRR -1,805 0,072 0,221 2388 -859 1680 -2903 -1482 -2312
NM_017771 PXK -0,397 0,692 0,844 2290 153 3057 -2302 -2235 -3424
NM_001017423 PYCS 0,008 0,994 0,999 -62 2545 2502 -2778 -2744 -3972
NM_006908 RAC1 -0,772 0,441 0,663 742 1121 4327 -2141 -2353 -1823
NM_002880 RAF1 -0,796 0,427 0,649 1655 597 3659 -2389 -2087 -2071
NM_014226 RAGE -2,575 0,011 0,069 513 -641 1053 -2602 -1946 -2556
NM_006909 RASGRF2 -0,943 0,347 0,566 1705 1027 4150 -2525 -2052 -618
NM_022128 RBKS -2,904 0,004 0,036 2514 1562 664 -2264 -712 567
NM_020630 RET 0,355 0,723 0,864 3870 1890 2089 -1606 -3088 -2805
NM_018339 RFK 1,211 0,227 0,446 2826 3841 2754 -1033 -2631 -4426
NM_030950 RFP -0,075 0,940 0,970 3028 1082 2420 -1984 -2244 -3513
NM_153005 RIOK1 1,473 0,142 0,341 2001 4232 4707 -1759 -2018 -3449
NM_018343 RIOK2 0,529 0,598 0,786 1671 2940 2830 -2593 -1217 -4540
NM_003831 RIOK3 0,831 0,407 0,632 4114 3367 5333 255 -534 -3474
NM_003804 RIPK1 1,118 0,265 0,482 3648 4962 2960 -900 -1888 -2904
NM_003821 RIPK2 -0,096 0,923 0,959 3091 2507 1685 -2064 -2028 -2843
NM_006871 RIPK3 1,131 0,259 0,477 2570 4513 4324 -1064 -1374 -3460
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Supplementary Table 1: Normalised screen data and treatment effect per gene
The genes with positive t-statistics mediate epidoxorubicin cytotoxicity; the gene products with negative t-statistics inhibit epidoxorubicin cytotoxicity
Accession Number Gene Symbol t-statistic p-value FDR Untreated Treated
Screen 
1
Screen 
2
Screen 
3 
Screen 
1
Screen 
2
Screen 
3 
NM_021133 RNASEL 1,051 0,294 0,509 4490 3770 7116 271 -1660 -353
NM_005406 ROCK1 0,339 0,735 0,868 2843 3957 3065 -1296 -763 -3386
NM_004850 ROCK2 0,773 0,440 0,663 5494 4229 5053 1407 -663 -2383
NM_005012 ROR1 0,659 0,511 0,724 3398 2130 2858 -980 -2342 -4412
NM_004560 ROR2 -0,264 0,792 0,896 3687 2236 4793 866 -1708 -2234
NM_002944 ROS1 -0,508 0,612 0,796 2827 1976 2689 -527 -1515 -3646
NM_016542 RP6-213H19.1 -0,791 0,430 0,650 3347 1370 1769 -967 -2149 -2873
NM_001006665 RPS6KA1 0,414 0,679 0,839 2595 2664 1681 -1666 -2848 -4041
NM_001006932 RPS6KA2 -0,335 0,738 0,868 2679 4982 1946 -918 -1146 -1944
NM_004586 RPS6KA3 -1,354 0,177 0,389 3080 680 541 -1160 -1468 -4098
NM_001006944 RPS6KA4 -1,387 0,167 0,377 3510 2685 2027 -94 -817 -1855
NM_182398 RPS6KA5 1,241 0,216 0,440 4707 6029 3288 -139 -1496 -1921
NM_014496 RPS6KA6 0,646 0,519 0,728 3831 3078 6190 358 -1586 -1765
NM_003161 RPS6KB1 -1,101 0,272 0,487 3133 591 2534 233 -1697 -3930
NM_001007071 RPS6KB2 0,125 0,901 0,947 4929 3793 5581 1353 -595 -1229
NM_012424 RPS6KC1 -1,462 0,145 0,343 3339 1491 3327 561 -662 -2511
NM_031464 RPS6KL1 -1,054 0,293 0,509 1750 1534 1695 -1687 -1351 -3801
NM_002958 RYK -0,816 0,415 0,641 1023 2641 4116 -2249 -473 -1898
NM_014975 SAST -2,992 0,003 0,032 724 186 221 -1768 -1979 -2133
NM_001024401 SBK1 -2,264 0,024 0,114 437 2301 -914 -1529 -1432 -3937
NM_003726 SCAP1 -1,870 0,063 0,206 1833 643 250 -1014 -2431 -3590
NM_003930 SCAP2 -0,776 0,438 0,662 4119 2360 2338 -136 -949 -2605
NM_020680 SCYL1 -0,740 0,460 0,683 2877 1336 886 -644 -2324 -4513
NM_005627 SGK -2,229 0,027 0,122 510 -363 -1642 -2742 -3188 -4436
NM_170693 SGK2 -0,548 0,584 0,782 2165 1424 1796 -1892 -2309 -3504
NM_170709 SGKL -0,302 0,763 0,882 2220 2324 1200 -1882 -2799 -3280
NM_183001 SHC1 -1,881 0,061 0,203 852 1461 -999 -3159 -1597 -3655
NM_015191 SIK2 -0,865 0,388 0,615 2387 1498 2096 -1019 -1899 -3392
NM_014720 SLK -0,291 0,772 0,887 4054 4349 7594 442 1435 394
NM_015092 SMG1 -1,349 0,179 0,390 3225 3111 2560 -810 -1761 382
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Supplementary Table 1: Normalised screen data and treatment effect per gene
The genes with positive t-statistics mediate epidoxorubicin cytotoxicity; the gene products with negative t-statistics inhibit epidoxorubicin cytotoxicity
Accession Number Gene Symbol t-statistic p-value FDR Untreated Treated
Screen 
1
Screen 
2
Screen 
3 
Screen 
1
Screen 
2
Screen 
3 
NM_030952 SNARK -0,682 0,496 0,714 3962 3094 2830 -467 -1546 -858
NM_173354 SNF1LK -1,019 0,309 0,526 1542 2508 3473 -254 -1970 -2156
NM_017719 SNRK 0,395 0,693 0,844 3920 1769 4334 -1018 -1248 -3165
NM_017425 SPA17 -1,427 0,155 0,360 -1112 -753 868 -3549 -3006 -5315
NM_021972 SPHK1 -1,255 0,211 0,433 872 1262 1098 -1679 -2344 -4061
NM_020126 SPHK2 -1,637 0,103 0,274 284 992 -301 -2726 -2531 -4134
NM_198291 SRC 1,444 0,150 0,353 2445 4145 4535 -1877 -2743 -2327
NM_080823 SRMS -1,827 0,069 0,217 1132 867 3720 -1442 -1256 -1450
NM_006947 SRP72 -0,181 0,857 0,926 1928 873 4027 -1524 -2676 -2975
NM_003137 SRPK1 0,486 0,628 0,804 4456 2984 3245 -1125 -1953 -1908
NM_182692 SRPK2 0,295 0,768 0,886 3401 3629 5176 -968 -931 -1091
NM_032037 SSTK -1,569 0,118 0,298 2646 1543 1929 -3343 -1389 354
NM_005990 STK10 1,212 0,227 0,446 2943 1977 5378 -1409 -2138 -3683
NM_000455 STK11 1,057 0,292 0,509 2077 1635 4747 -2976 -2184 -3503
NM_001008910 STK16 -1,205 0,229 0,447 918 435 953 -3424 -1732 -3980
NM_004760 STK17A -0,168 0,867 0,933 2344 1686 3194 -1165 -1928 -3720
NM_004226 STK17B 0,846 0,398 0,622 3493 1730 2857 -2871 -1373 -4265
NM_004197 STK19 -0,933 0,352 0,571 406 1385 2230 -2222 -1968 -3907
NM_053006 STK22B 0,060 0,952 0,975 3578 2434 2101 -2098 -2068 -2329
NM_052841 STK22C -0,848 0,398 0,622 2562 1072 3070 -1311 -2370 -1953
NM_032028 STK22D -2,946 0,004 0,034 636 1952 1511 -1284 -952 -779
NM_014370 STK23 0,312 0,755 0,877 3770 1839 2329 -2363 -2384 -2553
NM_003576 STK24 -1,363 0,174 0,385 3802 3521 2754 -1119 58 79
NM_006374 STK25 -0,063 0,949 0,975 3872 2919 3286 -480 -1682 -2061
NM_003957 STK29 1,007 0,315 0,533 2524 2135 1024 -4048 -3298 -3942
NM_006281 STK3 -2,139 0,033 0,141 408 1101 -781 -2805 -1554 -3999
NM_031414 STK31 -0,711 0,478 0,702 3122 3399 1901 -455 -1371 -2429
NM_145001 STK32A -0,498 0,619 0,798 2778 1451 3023 -915 -1315 -3722
NM_018401 STK32B -0,058 0,954 0,975 3705 3971 784 -486 -1782 -3582
NM_173575 STK32C 0,114 0,910 0,951 4131 3598 1224 -1613 -1264 -2915
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Supplementary Table 1: Normalised screen data and treatment effect per gene
The genes with positive t-statistics mediate epidoxorubicin cytotoxicity; the gene products with negative t-statistics inhibit epidoxorubicin cytotoxicity
Accession Number Gene Symbol t-statistic p-value FDR Untreated Treated
Screen 
1
Screen 
2
Screen 
3 
Screen 
1
Screen 
2
Screen 
3 
NM_030906 STK33 -0,403 0,687 0,843 3675 2486 2492 -344 -783 -3660
NM_080836 STK35 -1,032 0,303 0,521 445 2219 492 -2965 -1568 -4173
NM_015690 STK36 -1,348 0,179 0,390 3224 3086 -1153 -1119 -1692 -3040
NM_007271 STK38 -1,352 0,178 0,389 2803 3230 -303 -1713 -1713 -1888
NM_015000 STK38L 0,642 0,521 0,728 3580 4565 2874 -1631 -86 -3342
NM_013233 STK39 0,148 0,883 0,942 3794 2011 1032 -1462 -1844 -4690
NM_006282 STK4 -0,992 0,322 0,541 633 2872 -1412 -2345 -2466 -5018
NM_018423 STYK1 -0,797 0,426 0,649 3184 1820 1058 -1584 -2136 -2682
NM_003177 SYK -0,979 0,328 0,548 1912 -136 425 -2561 -2756 -4483
NM_138923 TAF1 -0,893 0,373 0,600 2055 3042 249 -1756 -1412 -3691
NM_153809 TAF1L -1,135 0,258 0,475 3035 4875 2567 -89 -1448 405
NM_004783 TAO1 0,085 0,932 0,964 3985 2723 3716 -1080 -2274 -893
NM_013254 TBK1 -1,631 0,104 0,276 1799 3039 2506 -1632 -2397 1032
NM_199122 TBRG4 -1,197 0,232 0,452 3664 2866 1740 -1622 -1623 57
NM_003215 TEC 0,188 0,851 0,921 4381 4498 3060 -1682 -1475 166
NM_000459 TEK -2,526 0,012 0,078 4255 -17 1207 -73 -1745 -771
NM_006285 TESK1 -1,900 0,059 0,201 1031 182 1910 -2464 -2386 -1740
NM_007170 TESK2 -1,237 0,217 0,442 2105 2536 1283 -2408 -2020 -1017
NM_003236 TGFA -2,611 0,010 0,065 1339 1641 719 -1875 -2262 -85
NM_004612 TGFBR1 -2,983 0,003 0,033 4395 292 1572 -88 -1528 1020
NM_003242 TGFBR2 -3,415 0,001 0,015 2223 -211 1725 -1094 -2621 1710
NM_024838 THNSL1 -2,974 0,003 0,033 1505 1141 2057 -501 -2183 384
NM_005424 TIE -2,057 0,041 0,158 4240 1590 1693 -780 -2411 1500
NM_201629 TJP2 -2,811 0,005 0,042 3755 1141 1434 -877 -1961 1870
NM_003258 TK1 -4,049 6,92E-5 0,004 1333 -751 -71 -2191 -2211 686
NM_004614 TK2 -2,394 0,017 0,091 3791 1776 2990 -673 -2073 2988
NM_012290 TLK1 -0,994 0,321 0,541 1585 2059 1612 -2752 -2768 -1200
NM_015028 TLK2 -1,949 0,053 0,184 3703 680 552 -1139 -2747 -704
NM_003985 TNIK -0,667 0,505 0,723 4072 5846 3864 389 -998 1610
NM_001010938 TNK1 -1,848 0,066 0,210 1974 1894 1903 -2049 -2003 -12
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Supplementary Table 1: Normalised screen data and treatment effect per gene
The genes with positive t-statistics mediate epidoxorubicin cytotoxicity; the gene products with negative t-statistics inhibit epidoxorubicin cytotoxicity
Accession Number Gene Symbol t-statistic p-value FDR Untreated Treated
Screen 
1
Screen 
2
Screen 
3 
Screen 
1
Screen 
2
Screen 
3 
NM_015978 TNK2 -1,097 0,274 0,489 5031 -223 3435 -2411 -1823 859
NM_018492 TNNI3K -0,701 0,484 0,706 3509 2194 1528 -3348 -1823 -289
NM_033550 TOPK -0,011 0,992 0,999 3926 3873 5408 -275 -1020 69
NM_022445 TP53RK -2,851 0,005 0,039 1344 1021 282 -2758 -2056 170
NM_025195 TPK1 -1,815 0,071 0,220 -1243 1585 578 -3667 -3065 -2244
NM_021643 TRIB1 -2,648 0,009 0,060 3701 -110 1153 -1678 -2483 1235
NM_021158 TRIB2 -2,768 0,006 0,046 2927 1940 293 -980 -2249 939
NM_007118 TRIB3 -3,089 0,002 0,027 1565 2264 517 -1900 -2828 2582
NM_017662 TRIO -1,153 0,250 0,467 3481 2360 1477 -691 -2722 -833
NM_017672 TRPM6 -1,633 0,104 0,276 5528 2144 2321 1114 -855 -584
NM_032538 TRPM7 -2,337 0,020 0,099 1909 1374 580 -1902 -670 -2184
NM_173500 TTBK1 -3,258 0,001 0,021 392 1910 469 -2729 -755 -7
NM_003318 TTBK2 -2,176 0,031 0,135 1248 485 2049 -2635 -2358 -218
NM_133379 TTK -1,599 0,111 0,288 437 1329 20 -3978 -1849 -2842
NM_003328 TTN -0,251 0,802 0,899 4655 1871 4309 -1139 -1537 -315
NM_003331 TXK -2,428 0,016 0,088 3247 1239 3730 -760 -1498 2192
NM_006293 TYK2 -3,057 0,002 0,029 1854 2253 1026 -1509 -1480 1364
NM_031432 TYRO3 -1,159 0,248 0,466 1857 2124 1048 -1915 -2387 -2240
NM_175866 UCK1 -2,517 0,012 0,079 2251 1826 -356 -468 -2758 -1165
NM_003565 UHMK1 -1,689 0,092 0,257 3615 1293 2579 -216 -2124 -386
NM_014683 ULK1 -3,290 0,001 0,021 -638 -1833 189 -3997 -2827 -1652
XM_929989 ULK2 0,047 0,962 0,981 3823 1438 2525 -1771 -1241 -3780
NM_016308 ULK4 -1,730 0,085 0,247 1529 2390 2831 -1422 -1204 -769
NM_012474 UMP-CMPK -0,039 0,969 0,982 3454 2164 3279 -2599 -1382 -1482
NM_006852 UMPK -3,094 0,002 0,027 660 -712 -553 -2832 -2839 -1664
NM_017859 URKL1 -4,061 6,61E-5 0,004 -397 357 337 -1556 -2114 -348
NM_025054 VCPIP1 -1,063 0,289 0,507 4281 1410 2826 -838 -625 -1807
NM_018046 VG5Q 2,033 0,043 0,163 3501 3830 6143 -3495 -694 -1936
NM_003384 VRK1 -0,957 0,339 0,559 3260 1217 1453 -2214 -2552 -1365
NM_006296 VRK2 -1,853 0,065 0,209 1730 1060 1680 -2500 -2216 -642
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Supplementary Table 1: Normalised screen data and treatment effect per gene
The genes with positive t-statistics mediate epidoxorubicin cytotoxicity; the gene products with negative t-statistics inhibit epidoxorubicin cytotoxicity
Accession Number Gene Symbol t-statistic p-value FDR Untreated Treated
Screen 
1
Screen 
2
Screen 
3 
Screen 
1
Screen 
2
Screen 
3 
NM_001025778 VRK3 -2,009 0,046 0,170 1672 306 810 -2430 -2162 -2070
NM_003390 WEE1 -4,487 1,12E-5 0,001 -3868 -2513 -3498 -5390 -3019 -4679
NM_007191 WIF1 -2,606 0,010 0,065 698 -292 131 -3079 -2907 -1425
NM_032387 WNK4 -1,886 0,061 0,203 3646 794 -531 -1200 -2231 -2334
NM_005108 XYLB -0,307 0,759 0,880 4935 2074 1969 -1215 -1446 -2047
NM_005433 YES1 -1,860 0,064 0,209 1251 1591 -548 -3066 -1043 -3374
NM_016653 ZAK -1,236 0,218 0,442 3544 1174 363 -2442 -2184 -1641
NM_207519 ZAP70 -1,581 0,115 0,293 2701 158 1988 -1694 -2200 -1754
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CHAPTER 7
WHAT IS THE BENEfIT of TREATmENT 
WITH muLTIPLE LINES of 
CHEmoTHERAPY foR PATIENTS WITH 
mETASTATIC BREAST CANCER? 
– A RETRoSPECTIvE CoHoRT STuDY
Published in Cancer Epidemiology, 2015. December;39(6):848-53
Janine L. Bakker, Karen Wever, Jan H. van Waesberghe, Aart Beeker, Hanne meijers-Heijboer, 
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ABSTRACT
Background 
Despite the extensive clinical experience, it is still under debate to what extent patients 
with metastatic breast cancer (MBC) benefit from multiple lines of chemotherapy beyond 
standard first or second line treatment. Selection of patients with MBC who will benefit from 
treatment is crucial to improve outcome and reduce unnecessary toxicity. In this retrospective 
study, systemic treatment outcome for patients with MBC is being evaluated. We evaluated to 
what extent the clinical benefit of prior chemotherapy can predict the success of a subsequent 
treatment line. 
Methods 
Ninety-one patients treated with chemotherapy for MBC between January 2005 and January 
2009 were included in this study. Clinical characteristics of patients, choices of chemotherapy 
and response at first evaluation of every treatment line was evaluated based on radiologic and 
clinical data. 
Results 
Patients received multiple systemic cytotoxic and biological (combination) therapies. 30% 
of these patients received more than five consecutive systemic (combination) treatments. 
First line chemotherapy was mostly anthracycline-based, followed by taxanes, capecitabine 
and vinorelbine. The response rate (RR, complete response plus partial response according 
to RECIST 1.1) decreased from 20% (95% CI 11-28 %) upon first line of treatment to 0% 
upon the fourth line. The clinical benefit rate (combining RR and stable disease) decreased 
from 85% (95% CI 78-93%) in the first to 54% (95% CI 26-67) upon the fourth line. 
24% of the patients with clinical benefit at first evaluation did not receive a subsequent 
line of treatment when progressive disease occurred, while sixty-one percent of the patients 
with progressive disease at first evaluation of a treatment did not receive a subsequent line of 
chemotherapy. When applied, the efficacy of a subsequent line of treatment was similar for 
patients independent of previous treatment benefit. 
Conclusion
The clinical benefit at first evaluation from systemic treatment in MBC does not predict for 
subsequent treatment benefit in this retrospective analysis. The fact that 61% of patients did 
not receive subsequent treatment after previous treatment failure suggests that either clinical 
judgement is of critical value in selection of patients to prevent them from unnecessary 
toxicity or, alternatively indicates that based on the assumption that prior treatment failure 
predicts for lack of benefit undertreatment of patients occurs. Therefore, a more adequate 
clinical judgement tool or predictive biomarkers for response are urgently needed to improve 
treatment outcome.
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Introduction
Metastatic breast cancer (MBC) is the leading cause of death in the Western world among 
women with cancer. Approximately 20%-40% of patients initially diagnosed with localized 
disease will develop recurrent or metastatic breast cancer within 5 years.1 For women with 
MBC whose disease has become endocrine-resistant, or with extensive visceral localisations 
or life-threatening disease, chemotherapy is the only remaining therapeutic option. There 
are a number of chemotherapeutic agents that are being used in MBC. Treatment choices 
are guided by several factors, like the HER2 status of the tumor, duration of relapse-
free interval since primary diagnosis, localisation and extent of metastases, patient’s 
symptoms and preferences, anticipated side effects and the effect of previous treatment(s). 
Clear evidence for treatment recommendations beyond second line of chemotherapy are 
limited. Several options as third to fifth line therapy are available, including vinorelbine, 
capecitabine and/or the combination of gemcitabine and carboplatin, while the combination 
of CMF (cyclophosphamide, 5-fluorouracil and methotrexate) is also incidentally being 
used.2 Eribulin is a novel non-taxane microtubule inhibitor and seems to be a meaningful 
additional treatment option beyond the second line. In a phase 3 trial in heavily pretreated 
patients, eribulin improved overall survival when compared to a treatment of physician’s 
choice.3 In addition, trastuzumab emtansine is a new antibody-drug conjugate consisting 
of the monoclonal antibody trastuzumab conjugated to a cytotoxic agent mertansine 
(DM1), which is being released intracellularly and is a microtubule binder. This agent 
improved overall survival when compared to lapatinib-capecitabine combination treatment 
and provides an additional treatment option for MBC.4 The first international consensus 
guidelines for advanced breast cancer (ABC1) recommend anthracycline- and taxane-based 
regimes, preferably as single agent, as first line chemotherapy. Capecitabine is the preferred 
choice after anthracyclines and taxanes.5 The number of regimes should be tailored to each 
individual patient. In literature, it is even suggested that the ‘optimal’ treatment strategy 
should probably be to use as many therapeutic options as possible, considering MBC as a 
chronic disease.6 In a review of Palumbo, a very nice overview on the ongoing debate to what 
extent multiple lines of systemic treatment in MBC is beneficial for patients was provided5. 
They concluded that it is very hard to discriminate whether predictive and prognostic factors 
play a role in the currently available literature on systemic treatment in MBC after the second 
line. In addition, Palumbo et all claimed that better designed prospective clinical trials should 
provide us with necessary information in this matter, but that for now patients should be 
treated with as many agents as possible while balancing between efficacy and toxicity of 
treatment.
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We hypothesized that in daily clinical practice most patients receive as many treatment 
lines regardless of the potential benefit for an individual patient leading to overtreatment of 
patients who are intrinsically resistant. Therefore, the benefit of palliative chemotherapy for 
MBC in a retrospective cohort of 91 patients with MBC was assessed. The current practice 
in chemotherapeutic regimes in the setting of advanced breast cancer were described and the 
response at first evaluation of every chemotherapeutic line were determined in this study. We 
hypothesized that early progression of the disease at first evaluation was a strong negative 
clinical predictor of response to a subsequent chemotherapy line and evaluated to what extent 
the clinical benefit at first evaluation of prior chemotherapy can predict the success of a 
subsequent treatment line. 
Patients and methods
Inclusion criteria
All patients treated with one or more lines of chemotherapy for MBC in the VU University 
Medical Center (VUMC) or the “Spaarne Ziekenhuis” (SZ) in the Netherlands between 
January 2005 and January 2009 were retrospectively analyzed. All patients with breast cancer 
and chemotherapy were selected based on diagnosis and treatment codes and after reading 
medical files patients were selected with advanced breast cancer. We included patients with 
visceral, locoregional and/or lymphogenic metastases and followed the patients until death, 
except for one patient with a complete response for 91 months. Patients with solely bone 
metastasis were excluded for analysis. Adjuvant chemotherapeutic treatment was not included 
in our analysis as a chemotherapeutic treatment line. Some patients received consolidation 
with endocrine or HER2-direceted therapy in between subsequent chemotherapy lines, but 
this was not included in our analysis. 
Evaluation of response
Clinical response of patients was evaluated in retrospect in the period 2011-2012 according 
to RECIST 1.1 criteria.7 8 Clinical response of non-target lesions was categorized as: complete 
response (CR) based on disappearance of all lesions and normalization of tumor marker; 
progressive disease (PD) based on appearance of one or more new lesions and/or unequivocal 
progression of existing non-target lesions or tumor marker; or no CR/no PD (SD). In 
retrospect, Computed Tomography (CT) scans were all centrally evaluated and scored for 
RECIST criteria independently by a radiologist or a medical oncologist. Baseline CT scan 
(maximum 4 weeks before start chemotherapy) were compared with the CT scan of the 
first evaluation (after 3-4 months or 3 cycles of chemotherapy). If there was no radiological 
evaluation, clinical evaluation was based on tumor markers or guided by the judgement of 
the clinical physician. If the first 3 cycles of chemotherapy were not finished due to clinical 
progression this was defined as progressive disease (PD) at first evaluation. Twelve percent of 
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the response evaluations were missing for a certain treatment line, mostly cause patients were 
treated in other hospitals. 256 response evaluations were available, of these 207 evaluations 
were based on radiological data (almost all CT scans) and 40 evaluations were based on clinical 
judgements of the oncologist without radiological data. Of the 207 radiological evaluations, 
108 (52%) evaluations were assessed with target lesions. For the other evaluations, the 
target lesions were too small or non-measurable and evaluation were performed according 
to RECIST 1.1 for non-target lesions. There were no evaluations solely based on tumor 
markers. In case of pleuritis or peritonitis carcinomatosis, tumormarker levels in combination 
with CT scans were used to evaluate response to treatment. If the response was based on 
radiological evaluation without target lesions, difficult to interpreted and therefore guided 
by the clinical interpretation, stable disease was the best possible response. For nine patients, 
the evaluations were not possible because therapy was stopped due to toxicity. In patients 
with HER2 positive diseases, consolidation therapy with trastuzumab was not included as a 
separate treatment line. The clinical benefit rate (CB) was defined as the percentage of patient 
with complete response, partial response and stable disease based on RECIST and clinical 
criteria as described above. The response rate (RR) was defined as the percentage of patients 
with a complete or partial response based on RECIST criteria or complete response based on 
disappearance of non-target lesions and normalization of tumor marker level.
Statistical analysis
A Fisher exact test, Two sample T-test and Chi-Square test were used to compare different 
groups, with a value of p<0,05 considered to be statistically significant. In case of multiple 
testing, a Bonferroni correction was performed. All comparisons were two-tailed. A Kaplan-
Meier method was used to predict survival. Survival was defined as the interval between date 
of start of palliative chemotherapy and breast cancer related death. There were no non-breast 
cancer related deaths. Differences in survival were analyzed using a log-rank test. Statistical 
analysis was performed using the statistical program SPSS (IBM SPSS Statistics, version 19).
Results
Patient and tumor characteristics
91 patients treated with palliative chemotherapy for MBC were analyzed. Thirteen percent of 
the patients had metastatic disease at first diagnosis. Ninety-six percent of the patient without 
metastases (and complete tumor histology data) had an unfavourable prognosis at initial 
presentation with T2 or high grade tumor (grade >1) or regional lymph node metastases. In 
Table 1 patient characteristics at initial diagnosis are shown. At VUMC, the 42 patients were 
significantly younger compared to the 49 patients of SZ and also had more triple negative 
(8,2 % versus 219 %, p=0,126) and HER2 positive tumors (10,2 % versus 18 %, p<0,001). 
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In addition, there were more patients with brain metastases at first presentation of metastatic 
disease in VUMC (p=0,001). These differences in patient characteristics are mainly caused 
by referral to the academic center for a second opinion and for participating in a clinical 
trial with lapatinib and SU14813.9  10 In the period 2005-2011, in both hospitals, patients 
were included in a study with bevacizumab.11 The difference in patient population between 
VUMC and SZ is reflected by the survival data where patients of VUmc have a significant 
worse survival compared to patients of SZ (Log rank test, p=0.02). The median survival after 
start of palliative chemotherapy was 24.0 months (95% CI 20.3-27.7). In supplemental 
figure 1 an overview of the survival of the retrospective cohort and subgroups of the cohort 
are shown. Complete follow-up data was gathered in 91.2% (83 out of 91), with seven cases 
lost-to-follow-up and one case with ongoing complete remission of disease after 91 months. 
Chemotherapeutic treatment 
54% (49 out of 91) of patients received more than two lines of chemotherapeutic treatment 
and 30% of patients five lines or more. Table 2 gives an overview of the chemotherapeutic 
treatment of these 91 patients with MBC. In this table subgroups of anthracycline-
based, taxane-based and capecitabine-based chemotherapy are shown. In all 91 patients 
anthracyclines were the most frequently used agents in first line, independent of their use in 
the adjuvant setting. Second line treatment was mostly taxane-based and in 85% of the cases 
paclitaxel or docetaxel was administered as monotherapy. Capecitabine was mostly prescribed 
in third and vinorelbine mostly in the fourth line. Beyond administration of these four agents 
in the palliative setting, the variety of other prescribed agents included CMF, gemcitabine 
and methotrexate. Besides trastuzumab, other targeted agents like lapatinib, bevacizumab 
and sunitinib were used in combination with chemotherapeutic agents in clinical trials in 
6% of the treatments applied. 
All patients with HER2-positive disease received anti-HER2 therapy, although in the 
early years of our cohort an anthracycline-based regimen like FEC (5-fluorouracil (5FU), 
epirubicin and cyclophosphamide) was sometimes preferred above a combination with 
paclitaxel and trastuzumab when patients were chemotherapy naïve and trastuzumab was not 
yet always continued beyond clinical progression. In Supplementary Table 2 an overview of 
the systemic therapy in de patients with HER2 positive disease is given. 
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Table 1. Patient and tumor characteristics.
SZ
N=49
n (%)
VUMC
N=42
n (%)
P-value
Mean age at diagnosis of metastasis 63.2 55.5  <0,001a 
TNM classification at first diagnosis
Tumor 
T1 21 (42,8) 8 (19,0) 0,202b
T2 18(36,7) 19 (45,2)
T3 2 (4,1) 3 (7,1)
T4 7 (14,3) 4 (9,5)
Unknown 1 (2,0) 8 (19,0)
Lymphnodes 
N0 16 (33,3) 14 (33,3) 0,302 b
N1 19 (38,7) 18 (42,9)
N2 9 (18,4,6) 2 (4,8)
N3 4 (8,1) 4 (9,5)
Unknown 1 (2,0) 4(9,5)
Metastasis 
M0 41 (83,7) 33 (78,6) 0,883 b
M1 8 (16,3) 7 (16,7)
Unknown 2 (4,8)
Primary site of metastasis
Lymphnodes 4 (8,2) 3 (7,1) 0,811 b
Locoregional 4 (8,2) 6 (14,3)
Visceral
 Liver
 Lungs
 Cerebrum
 Peritoneum 
41 (83,7)
24 (49,0)
17 (40,5)
0 (0)
4 (8,2)
33 (78,6)
21 (50,0)
17 (40,5)
8 (19,0)
2 (4,8)
Estrogen receptor status
Positive 39 (79,6) 21 (50,0) 0,003 b
Negative 10 (20,4) 21 (50,0)
Progesteron receptor status
Positive 31 (63,2) 10 (23 8) 0,001b
Negative 18 (36,7) 28 (66,7,8)
Unknown 4 (9,5)
HER2 status
Positive 6 (12,2) 19 (45,2) <0,001 b
Negative 40 (81,6) 23 (54,8)
a Two-sample T-test b Chi-square test
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Table 1. Patient and tumor characteristics.
SZ
N=49
n (%)
VUMC
N=42
n (%)
P-value
Unknown 3 (6,1) 0 (0)
Triple negative 4 (8,2) 8 (19,0) 0,126 b
Grade
1-2 14 (28,6) 4 (9,5) 0,040 b
3 13 (26,5) 16 (38,1) 
Unknown 22 (44,9) 22 (52,4)
a Two-sample T-test b Chi-square test
Evaluation of response in clinical practice
In Table 3, response rates of every treatment is described. CBR and RR are decreasing for 
subsequent treatments. The RR decreased from 20% (95% CI 11-28 %, n=91) in first line 
to 14% (95% CI 5-22 %, n=71), 11% (n=49) and 8% (n=26) in the second, third and 
fourth line, respectively. Beyond fourth line therapy no objective response was observed. 
CB rate (CBR) was 85% in first line therapy and decreased to 63% in the fourth line. In 
the fifth till the seventh line of therapy CB was still 54%. It was observed that most of 
the patients without CB at first evaluation did not receive a subsequent chemotherapy and 
finally deceased (43 out of 70 (61%)). In contrast, 24 percent of patients with CB did not 
receive a second line treatment. For every treatment line we analyzed whether there was a 
relation between the benefit in a prior to a subsequent line (Table 4). The differences were 
not statistically significant (Fisher’s exact test p-value all above 0.576). 
Discussion and Conclusion
We here evaluated the current clinical practice of systemic treatment in a cohort of 91 
patients with MBC. It is of clinical importance to gain more insight in which patients with 
MBC will benefit from multiple lines of treatment. Evaluation of response at first evaluation 
showed that the response rate measured with RECIST decreased upon each subsequent 
line of therapy. The RR decreased from 20% in first to 0% beyond the fourth line of 
chemotherapy. If CBR was used as endpoint, 54% of the patients who received chemotherapy 
still do benefit from this palliative treatment after the fourth line. This observation was in 
agreement with data of a French cohort (year 2000-2004); they noted that after the third line 
of chemotherapy clinical benefit as defined by response or stable disease after 3 cycles was 
acquired in 66% in the third line, declining to 61%, 46% and 53% after the fourth, fifth, 
sixth line (n=106,n=60,n=39, n=18, resp.). All patients with MBC receiving at least one 
systemic treatment beyond second line were included in this study indicative for a significant 
bias of patient selection, while in our retrospective analysis, all patients with MBC receiving 
systemic chemotherapy were included.12 In an older cohort of Planchat et al. with patients 
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included between 1993 and 2007, CBR was between 29% and 35% beyond the third line.13 
We are convinced as also demonstrated by Gueth et al.14 that the use of newer agents and 
regimens in the treatment of MBC was associated with improved survival over time. The 
two most commonly used chemotherapeutics in every line in our data are comparable to the 
data of the French cohort with 162 patients with MBC treated with palliative chemotherapy 
between 2000 and 2004. The choice of treatment shifts from anthracycline in the first line 
to taxanes, 5FU and vinkaloids in second, third and fourth line. In the cohort of Planchat et 
al, 5FU was less frequently prescribed, possibly due to the older age of this cohort (patients 
started chemotherapy between 1993-2007). This difference in treatment regimens may have 
influenced the CBR. A summary of all the available retrospective cohorts of chemotherapy 
treatment in MBC are shown in Supplementary Table 1.
A large cohort of patients from four French cancer centers of Dufresne et all. is the only 
report in which the time of disease control (TDC) with respect to the number of previous lines 
was evaluated. The TDC was defined as interval between time of first treatment administration 
and date of the second progressive disease or death. If there was progression at first evaluation 
there was no time of disease control. In search for factors related to this TDC, the duration of 
disease control of the previous line showed to significantly influence the duration of disease 
control in every following line15. It was our hypothesis that a potential strong negative clinical 
predictor of response could be the lack of benefit a at the first evaluation of a previous line 
of chemotherapy. We hypothesised that patients with early progression will not benefit of 
subsequent chemotherapy line. We retrospectively analyzed whether such a relation would 
exist. Indeed, patients who had progression at first evaluation tended to do worse on follow 
up. However, 61 % of these patients did not receive a next chemotherapeutic line, while the 
other 39 % of patients who did receive a subsequent chemotherapeutic line did not have a 
significantly worse outcome compared to patient with CBR in previous line (Table 4). This 
might suggest that clinical judgement to select patients for subsequent treatment prevents 
a worse outcome compared to patients with clinical benefit from previous treatment. This 
judgement is probably based on selecting of patients with a minimal tumor burden, less 
comorbidity or better physical condition for subsequent antitumor therapy, but these data 
were not readily available for retrospective analysis and should be prospectively evaluated. 
The main factors on which clinicians do judge whether a patient should receive a subsequent 
treatment line most likely include the condition of a patient (WHO I or II), no important 
organ failures, the aggressiveness of the tumor, the burden of toxicity a patient suffered 
during prior treatment and the personal motivation of a patient2  5. We hypothesize that 
clinical judgement whether a patient will benefit from palliative treatment will stay as one 
of the main criteria for treatment guiding in the developing era of personalized medicine16. 
The clinical judgement might be a confounding factor when we analyzed whether there was 
a relation between the benefit in a prior to a subsequent line, cause clinicians selected a better 
subgroup for further palliative treatment. Alternatively, the reduced number of patients that 
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will receive subsequent systemic treatment after prior progressive disease may also cause 
undertreatment of patients who might have had clinical benefit as is observed with the group 
that still received subsequent treatment and showed similar beneficial outcome. This problem 
clearly needs to be adequately studied in a prospective trial. 
In our retrospective analysis we focussed on clinical benefit and response rates at the 
first evaluation (after approximately 3-4 months) of the chemotherapy. This evaluation 
focused on patients with early progression after start of chemotherapy. This might lead to 
an underestimation of the real response and benefit of chemotherapy, cause some patients 
might have had a partial response at the 6 month evaluation. Other endpoints, like time to 
progression or time to a new chemotherapy could give more insight into long-term benefit 
of the chemotherapy. 
The data as presented here are hypothesis generating and need further studies in which we 
will prospectively analyse in a larger cohort of patients with MBC which criteria determine 
clinical judgement for subsequent treatment. It is of crucial importance for patients with MBC 
to improve prediction of treatment outcome and reduce unnecessary toxicity. Although in 
this group of patients there was a clear difference in age, tumor type and outcome of patients 
being treated in an academic versus a peripheral medical center, these did not influence the 
outcome of responses and clinical benefit (data not shown). 
We are convinced that relying solely on clinical factors will be insufficient to adequately 
predict response in patients, emphasizing the need for biomarker analysis of tumor tissues to 
further improve outcome. More knowledge should be gained about the biology of the tumor 
related to the response to chemotherapy in metastatic setting.14  15 
In summary, in this study we have retrospectively analyzed the outcome of 91 patients 
with MBC treated with up to 7 lines of chemotherapy. Our retrospective analysis suggests 
that the benefit of the treatment is independent from prior chemotherapy treatment outcome 
at the first evaluation. Further prospective evaluation is needed on how clinicians select 
patients for a subsequent treatment line and which clinical and biological factors predict the 
response to a subsequent chemotherapy to further improve the treatment outcome and the 
quality of life of patients with MBC.
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Table 2. Overview of chemotherapeutic agents. 
Palliative chemotherapeutic line
1 2 3 4 5-7**
Chemotherapy regime* Anthracycline n(%) 45(49) 6(8) 2(4) 2(7) 3(11)
Taxanes n(%) 25(27) 26(36) 12(24) 4(15) 7(26)
Capecitabine n(%) 16(18) 27(38) 14(29) 5(19) 3(11)
Vinorelbine n(%) 4(4) 5(7) 16(33) 10(39) 2(7)
CMF n(%) 0(0) 3(4) 0(0) 1(4) 3(11)
Other agents n(%) 1(1) 5(7) 5(10) 4(15) 9(33)
Total patients n(%) 91 (100) 72 (100) 49 (100) 26(100) 27(100)
Combined with targeted agent Trastuzumab n(%) 16(18) 8(11) 5(10) 3(12) 2(7)
Other n(%) 8(9) 4(6) 3(6) 1(4) 0(0)
* Chemotherapy regimens with anthracycline and taxanes were included in the anthracycline group. Chemotherapy regimens with 
taxanes and capecitabine were included in the taxanes group 
* Numer of patients 5-7 th line: 18, 6, and 4 respectively
Table 3. Evaluation of Response at first evaluation.
Palliative chemotherapeutic line
1 2 3 4 5-7
Number of patients 91 72 49 26 27
Patients assessable for response with RECIST* 82 64 47 26 26
Objective response**
 CR n (%) 2 (2) 2(3) 2 (4) 0 0
 PR n (%) 14 (17) 7 (11) 3 (6) 2 (8) 0
 SD n (%) 54 (66) 37(58) 28 (60) 13 (50) 14 (54)
 PD n (%) 12 (15) 18 (28) 14 (30) 11 (42) 12(46)
 CBR (CR +PR +SD) % (95% CI) 85 (78-93) 72 (61-83) 70 (57-84) 58 (37-78) 54 (26-67)
 RR (CR+ PR) % (95% CI) 20 (11-28) 14 (5-22) 11 (15-20) 8 (0-19) 0
* Unassessable patients: No data available or stop chemotherapy for other reasons than clinical progression 
**CR, complete response; PR, Partial remission; SD, stable disease; PD, progressive disease; CBR, clinical benefit rate; 
RR, Response rate, 95% CI= 95% confidence interval
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Table 4. Clinical benefit in relation to response at first evaluation in prior treatment line.
CBR following benefit CBR following progression P-value* 
Line 1 compared to 2 (n=59) 73.1 % 71.4 % 1
Line 2 compared to 3 (n=43) 71.4 % 62.5 % 0.681
Line 3 compared to 4 (n=24) 57.1 % 33.3 % 0.576
Line 4 compared to 5 (n=17) 45.5 % 50,00% 1
Line 5 compared to 6 (n=5) 75.0 % 100% 1
Line 6 compared to 7 (n=3) 0,00% 0,00% n.a. 
CBR = Clinical benefit rate at 3-4 months evaluation 
* Fisher exact test with Bonferroni correction (statistically significant when p<0.007)
p= 0,459
ER positive (n=56)
HER2 positive (n=21)
Triple negative (n=14)
Time (months)
Spaarne ZH (n=49)
VUmc (n=42)
p= 0,020
Time (months)Time (months)
Ov
er
all
 Su
rv
iva
l
Supplementary figure 1. A Overall survival in the complete cohort after start of chemotherapy.  B Survival of ER positive, HER2 
positive and Triple negative (ER and HER2 negative) subtype. C Survival in VU University Medical Center 
(VUmc) and the Spaarne Ziekenhuis (Spaarne ZH).
Supplementary table 1. Overview of recent retrospective reports of metastatic breast cancer patients.
Country Author Cases Year of 
treatment
Outcome* Distribution 
of 
chemotherapy 
described
Additional 
information 
Switzerland Gueth et al (ref. 14) 96 1990-2006 OS no
France Vauleon et al. (ref. 12) 162 2000-2004 CBR, OS yes
Patients 
received at 
least 3 lines
France Dufresne et al. (ref. 15) 934 1999-2002 TDC, OS no
France Planhat et al. (ref. 13) 529 1993-2007
CBR, OR, 
OS
yes
Response in 
patients >3 
lines CT** 
(n=226)
A B C
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Part 1: Breast cancer genes
Breast cancer is the most common cancer among women worldwide.1  Both genetic and 
non-genetic factors contribute to the etiology of breast cancer. Twin studies estimate that 
around 27% of breast cancer is due to genetic factors. These genetic factors can be reflected 
in a family history of breast cancer, although shared life style factors might also be involved 
in this family history. Hereditary factors play a far greater role in women with early onset 
breast cancer and woman with relatives that are also affected compared to women with breast 
cancer at older age. Approximately, 10-15 percent of the breast cancer patients have a history 
of familial breast cancer.2  
Patients carrying a high risk allele like a BRCA1 or BRCA2 mutation, have five to more 
than 20 fold increased risk of getting breast cancer3 . In the general population the life-time 
breast cancer incidence is approximately 1 in 8 women.4  Monoallelic germline mutations 
in another group of genes, such as ATM, CHEK2 and PALB2, give rise to a moderately 
increased breast cancer risk (2-3 fold). ATM and CHEK2 both act in the same DNA damage 
response pathway and have been linked to the regulation of p53-dependent apoptosis in the 
response to double-stranded DNA breaks.3  The proteins encoded by PALB2 as well as those 
encoded by the high risk genes BRCA1 and BRCA2 are involved in the FA/BRCA pathway, 
a DNA-repair pathway required for resistance to DNA interstrand cross-linking agents.5  
More recently, more than 90 single-nucleotide polymorphisms have been identified each 
conferring a low increased risk to breast cancer. The relative risk conferred by these alleles is 
1.3 or less and the underlying causative mechanism is mostly unknown. It is estimated that 
the currently known low risk variants, and the moderate and high risk genes together explain 
approximately 35% of the familial breast cancer risk.3 6 
It is now well established that monoallelic germline mutations in some of the FA/BRCA 
pathway members predispose to breast cancer. Biallelic mutations in FA/BRCA genes cause 
Fanconi anemia (FA), a rare predominantly recessive disorder characterized by chromosomal 
instability, developmental abnormalities, bone marrow failure, and a high incidence of 
cancer.5  In chapter 2, we examined the role of SLX4, a novel FA gene also known as FANCQ, 
in hereditary breast cancer. The SLX4 gene was sequenced in 729 BRCA1/BRCA2-negative 
familial breast cancer cases and one truncating splice site mutation was identified. Four 
possible pathogenic missense mutations were selected for functional testing and appeared 
to be indistinguishable from wild-type. So far, in addition to our study, five other studies 
analyzed the entire SLX4 gene in familial breast cancer cases.7 8 9 10 11 12  Combining the six 
studies, in total three clear loss-of-function mutations were detected in 2,625 cases (0.1%). 
Two other studies also genotyped possible pathogenic missense variants in controls but could 
not significantly associate them to familial breast cancer. In one study, 10 rare variants were 
found once in 96 cases of familial breast cancer and subsequently genotyped in 285 control 
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cases. These rare variants were between one and four times in controls.12 In a second study, 
four novel possible pathogenic missense substitutions were detected in 52 familial breast 
cancer cases. Next, these variants were genotyped in 965 sporadic breast cancer cases and 
985 healthy female controls. Only one of the variants (p.R237Q ) was detected in additional 
patients. This glutamine allele was detected 12/933 cases (1.3%) and 7/928 controls (0.7%) 
(p=0.21).8   There is no information about co-segregation in families with respect to the loss-
of-function mutations. Overall, clear loss-of-function mutations in SLX4 might be associated 
with breast cancer in a very small proportion of cases, but significant evidence is lacking. 
The breast cancer susceptibility gene BRCA2 (FANCD1) is a known FA gene. In chapter 
3, we identified a novel mutation in the splice donor site of intron 1, close to non-coding exon 
1, of BRCA2 in a Japanese FA family. Functional analysis using a mouse embryonic stem cell-
based assay confirmed that the mutation caused aberrant splicing, reduced transcript levels 
and hypersensitivity to DNA damaging agents, suggesting that it is likely to be pathogenic. 
Screening for such splice site mutation close to the BRCA1/2 non-coding exons in a Dutch 
cohort of familial breast cancer cases did not reveal similar pathogenic variants. Although 
we did not observe breast cancer cases with such splice site mutations, an increased breast/
ovarian cancer risk as a consequence of such mutations cannot be excluded. We therefore 
recommend analyzing these splice sites of non-coding exons of BRCA1 and BRCA2 in the 
process of screening of familial breast and ovarian cancer cases.
Data indicate that germline mutations in SLX4, nor germline splice-site mutations in 
the non-coding exons of BRCA1 and BRCA2, have a significant contribution to familial 
breast cancer. Recently, next-generation sequencing techniques like whole genome and whole 
exome sequencing revealed additional FA and other DNA repair genes with rare variants in 
familial breast cancer patients but again significant evidence is lacking with respect to the 
association of these variants/genes with breast cancer. 6 13  Collaboration of research groups 
and genotyping of a very large number of cases and controls is necessary to assess the risk 
and possibly confirm these associations. In this light, functional experiments are of growing 
importance to obtain additional evidence that certain variants are pathogenic and might 
therefore be more likely to predispose to breast cancer. Still, the question remains how one 
can explain the ‘missing heritability’ in breast cancer. Possibly, a combination of gene-gene 
interactions, gene-environment interactions, additional rare mutations in moderate and high 
risk genes can explain (part of ) this missing heritability. For example, it has been shown that 
environmental factors and common low risk alleles modify the absolute breast cancer risk in 
carriers of BRCA1 and BRCA2 mutations.14 15  
  It is known that the CHEK2*1100delC mutation is associated with a two-fold 
increased risk of breast cancer. Familial cases with bi-allelic CHEK2*1100delC mutations are 
very rare and it has therefore been difficult to accurately estimate the life time breast cancer 
risk for these patients. It is striking that these patients suffer from a high incidence of multiple 
primary tumors.16  In chapter 4, a unique set of cell lines derived from women homozygous 
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Processed on: 1-12-2017 PDF page: 175
175
for the CHEK2*1100delC mutation is used to investigate the cellular role of CHEK2. 
Analyses of the cell cycle, aneuploidy, and sensitivity to DNA damaging agents revealed 
that CHEK2-deficient lymphoblasts are resistant to alkylating agents. Both anthracycline 
and fluorouracil (5FU) have alkylating properties and are the backbone of the adjuvant 
chemotherapy regimen in breast cancer. This might explain the increased risk of breast cancer 
specific death in women with a CHEK2*1100delC mutation.17  The observed resistance to 
alkylating agents could be related to an ineffective apoptotic pathway or ineffective cell cycle 
arrest but future studies are necessary to explore the underlying mechanism. This knowledge 
can help to obtain a better understanding of the role of CHEK2 in the etiology of breast 
cancer. 
Interestingly, CHEK2-wild type first-degree relatives of CHEK2*1100delC carriers with 
bilateral breast cancer still have a cumulative life time breast cancer risk of 23.8% by age 80 
years compared to 7.9 % in the general population.18  This suggests that CHEK2 interacts 
with other low- or moderate- penetrance genes in a polygenic model in these families. On 
the other hand, the CHEK2*1100delC variant confers no increased cancer risk in carriers 
of BRCA1 or BRCA2 mutations.19  This suggests that CHEK2 acts in the same pathway as 
BRCA1/2. It would be interesting to explore genome wide genetic data of a big cohort of 
CHEK2*1100delC carriers and determine how other moderate risk genes or low risk alleles 
affect the breast cancer risk.
CHEK2*1100delC is prevalent in The Netherlands and approximately 2.9 % of the 
Dutch breast cancer population carriers this mutation.20  More insights in the function of 
CHEK2 and genetic interactions with the CHEK2 gene in breast cancer might help to 
develop targeted agents for this subgroup of patients and improve their outcome. Further 
research strategies can be screening for synthetic lethal interactions or sensitizing drug 
compounds in CHEK2-deficient patient (breast cancer) cell lines. Analyses of somatic changes 
in tumors of CHEK2*1100delC carriers might also give more insight in specifically activated 
and deactivated pathways in these tumors.  Analysis of copy number and gene expression 
profiles of CHEK2*1100delC breast cancer samples by Massink et al. (n=14) and Muranen 
et al. (n=32) revealed a common copy number loss on chromosome 1p but no overlapping 
differentially expressed genes in the two studies.21 22  Compared to BRCA1/2 tumors the 
CHEK2*1100delC breast tumors are heterogeneous and lack specific copy number changes 
and cluster within the larger group of tumors with a luminal intrinsic subtype. However, 
the currently published studies21 23 made use of limited numbers of tumors and therefore, 
analyzing a larger number of tumors with newer techniques might reveal specific somatic 
changes in CHEK2*1100delC tumors. This will reveal which molecular pathways are 
involved in the oncogenesis of breast tumors with a CHEK2*1100delC mutation and might 
eventually help improving therapy of breast cancer for CHEK2 carriers. 
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Part 2: Breast cancer therapy
Early detection and adjuvant treatment led to decreased mortality rates in most Western 
countries since the early 1990s.24  Breast cancer is a heterogeneous disease with respect to 
histology and clinical outcome, and these differences have served as the basis for disease 
classification. Tumors can be classified by immunohistochemical staining of the estrogen 
receptor (ER), progesteron receptor (PR) and HER2 receptor. An even more precise 
classification of tumors can be based on their gene expression patterns and can accurately 
distinguish the different intrinsic subtypes (luminal A/B, HER2, and basal). Tumors of the 
basal subtype displayed extensive genomic instability and harbored the majority of BRCA1-
mutated tumors. It is suggested that the basal tumors might have the same etiology as BRCA1-
mutated tumors and share underlying defects in the FA/BRCA pathway.25  Although somatic 
BRCA1 mutations are not frequently identified in breast tumors26 27 , promoter methylation 
and decreased protein expression has been reported in a subset of basal-like breast tumors.28 
In chapter 5, we investigated the FA/BRCA pathway in a set of 40 breast cancer cell lines 
(luminal and basal). We identified 5 non-BRCA1/2-mutated luminal breast cancer cell lines 
and no non-BRCA1/2-mutated basal tumors with elevated levels of mitomycin C (MMC)-
induced chromosomal breakage. MMC-induced chromosomal breakage a hallmark of FA/
BRCA defective cells. These five MMC-sensitive cell lines showed normal RAD51 focus 
formation and MMC-induced FANCD2 monoubiquitination, and no clear pathogenic 
mutations were detected in DNA-repair genes. Unexpectedly, one of the MMC-sensitive 
cell lines had a focal amplification of the helicase RECQL5 on the HER2 amplicon which 
appeared responsible for the MMC sensitivity. This could be a future marker for chemotherapy 
in HER2 positive breast cancer. These findings show that mechanisms other than defects in 
the FA/BRCA pathway are involved in this hypersensitivity to cross-linking agents and this 
could be also true for the additional four MMC-sensitive cell lines in which no molecular 
cause was identified. Potentially, the MMC-induced breaks are a reflection of forced cell cycle 
progression due to a defective cell cycle checkpoint, or a combination of milder variants in 
DNA repair genes. 
Currently, cross-linking agents like MMC, cisplatin and carboplatin are not routinely 
used in breast cancer therapy. Carboplatin is sometimes used to treat advanced-stage breast 
cancer. Functional ex vivo assays, whereby breast tumors are irradiated and tested for 
DNA-repair capacity by visualization of RAD51 foci, will only detect cross-linker sensitive 
tumors with a defect in homologous recombination.29  So, this assay will detect tumors with 
germline or somatically acquired mutations in genes such as BRCA1, BRCA2 and RAD51(or 
its paralogs) but not in other genes in or linked to the FA/BRCA pathway like FANCQ 
or FANCM. It would be of interest to develop an ex vivo MMC-chromosomal breakage 
assay, or MMC-growth inhibition assay. In this way, tumors might be selected for cross-
linker therapy and further research of this phenotype can lead to better understanding of the 
515504-L-bw-Bakker
Processed on: 1-12-2017 PDF page: 177
177
hypersensitivity to cross-linking agents. In addition, it will be useful to screen for BRCA1 and 
BRCA2 mutations in the tumors which are triple negative and in tumors of patients with an 
early onset breast cancer because these patients have a higher probability of testing positive. 
It should be investigated if cross-linker therapy or treatment with PARP-inhibitors improves 
treatment outcome in these patients. Rapid BRCA1/2 mutation screening can also influence 
the choice of surgery as BRCA1/2 mutation carriers may want to choose for total mastectomy 
and immediate reconstruction. 
 Tumors with basal (no expression of ER/PR or HER2) or HER2 subtype have a 
worse prognosis compared to other tumors.25  In recent years new HER2-targeted therapies 
dramatically improved the outcome in both the early-stage and metastatic settings.30  No 
targeted treatment is available for the basal breast cancer subtype and current adjuvant 
anthracycline chemotherapy regimens are demanding for patients. In order to identify 
potential molecular targets involved in anthracycline sensitivity and viability in a BRCA1-
deficient triple negative breast cancer we performed a RNAi screen of the human tyrosine 
kinome with and without epidoxorubicin. In chapter 6, this screen identified some interesting 
candidates possibly involved in the viability of this BRCA1-deficient triple negative breast 
cancer cell line. Follow up studies are needed to validate and further explore these candidates. 
For instance, it has to be explored if the putatively lethal effect of specific hits can be attributed 
to the histological subtype, a synthetic lethality interaction with BRCA1 or other pathways 
in the tumor cells. Screens described in literature in breast cancer cell lines identified new 
candidates involved in chemosensitivity and viability of breast cancer31 32 . Translations into 
general clinical practice is difficult since specific protein or gene targeting agents have to 
be developed and tested in preclinical models where the microenvironment, combination 
treatments, and longer treatment duration have a role. Thereafter identifying sufficient 
numbers of patients for targeted agents for clinical trials is challenging. Neoadjuvant trials are 
a good opportunity for drug development because pathological response rates are a surrogate 
marker for later clinical endpoints. Our screen suggests that inhibition of tyrosine kinases 
does not have a major impact on sensitization for anthracycline therapy in this cell line. 
It would be interesting to see if this is related to all tumors with a triple negative breast 
cancer subtype. Based on gene expression profiling studies it is suggested that the triple 
negative subtype is a heterogeneous group, which can be separated in smaller subgroups, 
some enriched for elevated expression of genes involved in the cell cycle-related and in DNA-
damage repair pathways, and another group with high expression of growth factor signaling 
pathways.33  These features should be taken into account when analyzing clinical data and in 
setting up future siRNA screens.  
The last chapter of this thesis (chapter 7), the systemic treatment regime and outcome 
for patients with metastatic breast cancer is being evaluated in clinical practice. Patients 
received multiple systemic cytotoxic and biological (combination) therapies of whom 30% 
received more than 5  different types of chemotherapy. Clinical judgement is of critical value 
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in the selection of patients for a subsequent new chemotherapeutic treatment line. A clinical 
judgement is made based on observation of the patient in combination with his medical data. 
A more adequate clinical judgement tool and predictive biomarkers for response are urgently 
needed to select patients and improve treatment outcome. 
In this thesis DNA sequencing and next generation sequencing techniques have been used 
to explore the genome of patients and breast tumor cell lines. Overall, the cost of sequencing 
is declining and the use of gene panels, whole exome and genome sequencing is more easily 
available. This might be useful for a more precise estimation of clinical breast cancer risk 
in women with a family history of breast cancer but will also lead to the identification of 
variants with unknown clinical significance. Genetic testing should be easily available for 
these women and therefore a future oncologist with adequate education should be able to 
do pre-test counselling and offer genetic testing for breast and ovarian cancer patients. If the 
tests turn out positive, the patient should be referred to a clinical geneticist to address future 
issues for the patient and implications for the family. This information can also change the 
management by the oncologist. For example, radical surgery can be more appropriate, and 
the choice of chemotherapy might be different.34  Integrating genetic testing into the clinical 
practice of a medical oncologist would be more time and cost effective35 , but it remains 
important to collect genetic and clinical data in order to further optimize risk estimations for 
patients with genetic variants of unkown clinical significance.
 New sequencing techniques can also be used to gain information on the etiology of 
tumors. Whole genome sequencing of the tumor and germ line DNA of the same individual 
can give information about somatic changes in gene sequences, copy number alterations, and 
translocations. Specific changes might be targeted by drugs; examples of these are mutant 
forms of EGFR, ALK, HER2 and BCR-ABL. However, tumors harbour many somatic 
mutations and it is often difficult to select the driver mutations from the passenger mutations. 
If driver mutations have been identified in a research setting the next hurdle is to find out 
which of the driver mutations are clinically useful. Therefore, after identification of (putative) 
driver mutations it is important to understand how these mutations influence regulatory 
pathways and potentially alter the outcome of therapy. To translate this into clinical practice 
as soon as possible, genetic information should be obtained of sufficient numbers of patients 
and their tumors. In my opinion, the best next step to realize this is by offering cheaper multi-
gene panels that include genes which are known to, or have been suggested to, harbor driver 
mutations, as well as genes in which somatic alterations result in drug resistance or sensitivity. 
In this way sufficient numbers of patients can be obtained for clinical trials. For rare events 
it might be an option to include different tumor types with mutations in the same gene or 
alternatively to group patients with driver mutations in different genes that act in the same 
pathway. In addition to the somatic driver mutations, pathogenic germ line variants in genes 
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causing cancer-related syndromes, e.g. CHEK2, ATM and FA/BRCA genes should also be 
taken into account since (some of ) these have therapeutic relevance as well. 
In conclusion, whole genome, whole exome and multi-gene panel sequencing should 
be introduced more broadly in clinical practice for the development of ‘precision medicine’ 
and concurrently functional studies are necessary to improve our understanding of the role 
of somatic and germline mutations in breast cancer. In the end, this should lead to improved 
treatment of patients with hereditary and non-hereditary breast cancer. 
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515504-L-bw-Bakker
Processed on: 1-12-2017 PDF page: 186
186
515504-L-bw-Bakker
Processed on: 1-12-2017 PDF page: 187
187
Borstkanker is de meest voorkomende vorm van kanker bij vrouwen wereldwijd. Erfelijke en 
niet-erfelijke factoren (zoals hormonen en leefstijl) zijn verantwoordelijk voor het ontstaan 
van borstkanker. In West-Europa krijgen jaarlijks 89,3 van de 100.000 vrouwen borstkanker. 
Dankzij vroege opsporing van borstkanker en verbeterde behandeling met chemotherapie 
daalden het aantal sterftegevallen als gevolg van borstkanker in de afgelopen decennia. Het 
onderwerp van dit proefschrift is erfelijke borstkanker, waarbij er in het eerste deel aandacht 
wordt besteed aan het vinden van nieuwe genen/mutaties die betrokken zijn bij erfelijke 
borstkanker en het begrijpen van de functie van het borstkankergen CHEK2. Het tweede 
deel van het proefschrift richt zich op de therapie van erfelijke en niet-erfelijke borstkanker, 
waarbij de aandacht uitgaat naar het verbeteren van de gevoeligheid voor chemotherapie 
en het herkennen van genetische veranderingen die de gevoeligheid voor chemotherapie 
bepalen. In onderstaande twee secties wordt een samenvatting gegeven van de twee delen van 
het proefschrift. 
Deel 1: Borstkanker genen
Genetische veranderingen in bepaalde genen (ook wel DNA mutaties genoemd) kunnen 
bijdragen aan het ontstaan van borstkanker. Een belangrijk voorbeeld van een borstkankergen 
waarin mutaties voorkomen is BRCA1 (‘breast cancer 1’ gen). Een mutatie in dit gen kan 
leiden tot een niet functionerend BRCA1 eiwit, dat hierdoor niet meer in staat is breuken 
in het DNA te repareren. Bij een patiënte leidt dit uiteindelijk tot mutaties in genen die het 
proces van celvermeerdering controleren en derhalve het ontstaan van kanker. Draagsters van 
een mutatie in BRCA1 of BRCA2, hebben in de loop van hun leven een risico van ongeveer 
60 procent op het ontstaan van borstkanker. De borstkankergenen BRCA1 en BRAC2 
worden dan ook hoog risicogenen genoemd. Er zijn ook matig risicogenen, mutaties in deze 
genen geven een 20-30 procent ‘life-time’ risico op borstkanker. Er zijn ook variaties in het 
genoom welke een zeer laag extra risico geven op borstkanker. Deze genetische variaties geven 
een extra ‘life-time’ risico van minder dan 3% boven het algemene risico in de populatie van 
11% op het ontstaan van borstkanker. Op dit moment kunnen de bekende hoog, matig en 
laag risicogenen samen ongeveer 35% van het borstkankerrisico verklaren. 
BRCA1 is samen met BRCA2 en andere DNA reparatie eiwitten onderdeel van het 
Fanconi anemie(FA)/BRCA pad en (mede) verantwoordelijk voor het repareren van DNA 
breuken en DNA cross-links. DNA cross-links zijn onnatuurlijke verbindingen tussen de 
twee DNA strengen. Mutaties in sommige van de FA DNA reparatie genen zoals BRCA1, 
BRCA2, en PALB2 kunnen leiden tot een verhoogd borstkankerrisico. Er is echter een 
opvallende overlap met de ziekte Fanconi anemie. Het verhoogd risico op borstkanker is het 
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gevolg van een heterozygote mutatie in FA/BRCA genen. Indien er twee mutaties aanwezig 
zijn in een FA/BRCA gen (dus één in elke kopie van het gen) dan leidt dit tot het ernstige 
syndroom Fanconi anemie waarbij er sprake is van aangeboren skelet afwijkingen, beenmerg 
falen en een zeer hoog risico op het ontwikkelen van leukemie en hoofd-hals kanker op jonge 
leeftijd. In hoofdstuk 2 werd daarom onderzocht of het nieuw ontdekte FA gen SLX4 ook 
betrokken is bij erfelijke borstkanker. Het DNA van 729 familiaire borstkanker patiënten 
zonder BRCA1/2 mutatie werd onderzocht en slechts één truncerende mutatie in SLX4 werd 
gevonden (bij een truncerende mutatie wordt  maar een deel van het eiwit gevormd). Tevens 
werden vier mogelijk pathogene missense varianten gevonden. Dit zijn veranderingen in het 
DNA waarbij het eiwit er iets anders uitziet maar meestal wel in zijn geheel gevormd wordt. 
Uit functionele testen blijken deze SLX4 eiwitten niet afwijkend te functioneren en het is dus 
niet waarschijnlijk dat deze veranderingen betrokken zijn bij het ontstaan van borstkanker. 
Omdat de pathogene truncerende mutatie in SLX4 maar een keer gevonden is, lijkt deze geen 
belangrijke bijdrage te leveren aan het borstkankerrisico in de populatie. 
In hoofdstuk 3 wordt een bijzondere mutatie beschreven in het borstkankergen BRCA2 
die gevonden is in een Japanse FA patiënt. Deze mutatie ligt in het niet voor eiwit coderende 
gebied aan het begin van het BRCA2 gen en resulteert in een alternatieve en verminderde 
vorming van het messenger RNA. Deze mutatie is nagemaakt in embryonale muizencellen en 
deze cellen laten een hypergevoeligheid zien voor DNA schade. Dit laat zien dat de mutatie 
resulteert in afwezigheid van (voldoende) functioneel BRCA2 eiwit. Hiermee hebben we 
aangetoond dat deze mutatie de oorzaak is van FA bij deze patiënt. Nader onderzoek in 
borstkankerfamilies laat zien dat deze mutatie niet frequent betrokken is bij erfelijke 
borstkanker. Wel lijkt het zinvol ook deze niet coderende gebieden van BRCA1 en BRCA2 te 
onderzoeken bij de diagnostiek van borstkanker. 
In hoofdstuk 4 wordt er nader onderzoek gedaan naar de functie van het borstkankergen 
CHEK2. De CHEK2*1100delC mutatie is geassocieerd met een twee maal verhoogd risico 
op borstkanker. Er zijn in Nederland ook enkele patiënten beschreven met homozygote 
CHEK2*1100delC mutaties en deze patiënten lijken een nog hoger risico te hebben op 
borstkanker. Uit de literatuur weten we dat CHEK2 een multifunctionele rol heeft bij 
geprogrammeerde celdood (apoptose) en het reguleren van de celcyclus na DNA schade. 
Er werden unieke cellijnen verkregen van deze patiënten om de rol van het borstkankergen 
CHEK2 in humane cellen te onderzoeken. Hierbij lieten proeven zien dat het missen 
van CHEK2 in deze cellen leidt tot resistentie voor alkylerende stoffen (een vorm van 
chemotherapie). Het onderliggende mechanisme hiervan moet verder worden onderzocht; 
het zou interessant zijn om er achter te komen of dit fenotype een relatie heeft met de 
mogelijke slechtere respons van CHEK2*1100delC mutatie draagsters op chemotherapie. 
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Deel 2: Borstkanker therapie
Borstkanker is een heterogene ziekte, waarmee wordt bedoeld dat borsttumoren er 
histologisch (onder de microscoop) en genetisch verschillend uit zien en zich anders gedragen 
met betrekking tot respons op therapie. We maken onderscheid in hormonaal gevoelige en 
ongevoelige tumoren, maar met genetische expressie profielen kunnen we meer subtypen 
onderscheiden: luminal A/B, HER2 en basaal. Het ‘basaal’ of ‘triple negatieve’ subtype heeft 
de meeste genetische veranderingen en het meest agressieve gedrag en BRCA1-gemuteerde 
tumoren vallen voornamelijk binnen deze subgroep. Er is een hypothese dat de niet BRCA1-
gemuteerde “triple negatieve” tumoren ook onderliggende defecten hebben in het FA/BRCA 
pad. Tumoren met defecten in het FA/BRCA pad kenmerken zich door een verhoogde 
hoeveelheid chromosoombreuken na behandeling met de DNA-crosslinker mitomycine 
C (MMC). In hoofdstuk 5 werden 40 borstkankercellijnen onderzocht en 4 BRCA1-
gemuteerde ‘triple negatieve’ en 5 niet BRCA1/2 gemuteerde luminale cellijnen gevonden 
met een grote hoeveelheid chromosoombreuken na behandeling met MMC. Het FA/BRCA 
fenotype lijkt dus niet alleen bij het ‘triple negatieve subtype’ voor te komen. Het voor eiwit 
coderende gedeelte van het genoom werd bekeken in de 5 niet-BRCA1/2- gemuteerde 
borstkanker cellijnen, maar er werden geen duidelijke pathogene mutaties gevonden in DNA 
reparatie genen. Wel werd een amplificatie van het RECQL5-gen gevonden in één van de 
cellijnen en deze bleek verantwoordelijk voor het fenotype. Deze amplificatie is een potentiële 
marker voor gevoeligheid voor DNA beschadigende stoffen en komt voor in een deel van de 
HER2 positieve borsttumoren. Mogelijk speelt het niet goed functioneren ‘checkpoints’ van 
de celcyclus, betrokken bij het herstel van DNA schade, een rol in de andere 4 cellijnen. 
Een andere mogelijkheid is dat de combinatie van mildere veranderingen in meerdere DNA 
reparatiegenen een rol speelt. 
Om potentiële doelgerichte therapieën voor ‘triple negatieve’ borstkanker te 
vinden, werd een siRNA screen verricht in een ‘triple negatieve’ BRCA1-gemuteerde 
borstkankercellijn (hoofdstuk 6). Hierbij werden 715 kinases uitgeschakeld en gekeken naar 
het effect op anthracycline gevoeligheid en levensvatbaarheid in deze cellijn. Anthracycline 
is een belangrijk chemotherapeuticum in de behandeling van borstkanker. Kinases zijn een 
verzameling van eiwitten welke middels fosforylering andere eiwitten kunnen activeren of 
inactiveren en vormen een belangrijke bron van signaaloverdracht in de cel. Uit onze screen 
blijkt dat de uitschakeling van  geen van de kinases de gevoeligheid voor anthracycline in 
deze cellijn verhoogt. Er werden wel meerdere kinases ontdekt die leiden tot verminderde 
levensvatbaarheid van deze borstkanker cellijn. In het laatste hoofdstuk (hoofdstuk 7) van dit 
proefschrift wordt een cohort beschreven van 93 patiënten met gemetastaseerde borstkanker 
die behandeling met chemotherapie hebben ondergaan. Dit retrospectieve onderzoek laat 
zien dat deze patiënten in de praktijk vaak een veelvoud aan verschillende systemische 
cytotoxische en gerichte therapieën krijgen; bij 30% van de patiënten zijn er meer dan vijf 
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verschillende middelen gegeven. Onze hypothese was dat patiënten met een snel progressieve 
ziekte (na ongeveer drie maanden chemotherapie) ook een slechtere respons hebben op 
een andere soort chemotherapie. Dit blijkt niet zo te zijn. Echter niet alle patiënten met 
een snelle progressieve ziekte worden behandeld met een andere soort chemotherapie. In 
een deel van de patiënten wordt de behandeling met palliatieve chemotherapie definitief 
gestaakt. De vraag is hoe de klinische selectie van patiënten voor een volgende therapie, op 
basis van bijvoorbeeld factoren als  de algemene toestand en uitgebreidheid van de ziekte, 
geoptimaliseerd kan worden om het uiteindelijke effect van de volgende chemotherapie 
beter te voorspellen. Toekomstig onderzoek moet hierin meer inzicht geven, waarbij ook 
biologische factoren meegenomen dienen te worden. 
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Dankwoord
Het tot stand komen van dit proefschrift was als een lange fietstocht op de racefiets door de 
bergen en langs de kust van Kreta. Soms met de wind in de rug als er een nieuw Fanconi 
gen werd gevonden op de afdeling en ik hier wat mee kon doen. Daarna weer ploeteren en 
zweten om de berg op de komen. De volgende dag, een leuk vissersdorp  ontdekken dat niet 
in de toeristische boekjes stond. Trots ben ik stiekem toch dat ik echt zelf RECQL5 heb 
gevonden! De tocht was soms ook echt lang, maar aan het einde van de dag kon ik altijd 
even nabeschouwen onder het genot van koud biertje en waren er altijd mensen om mee te 
relativeren. Er waren ook momenten aan het einde van de dag dat relativeren lastig is als de 
pijn in je benen te hevig was en er nog steeds geen leuke slaapplek was gevonden. Maar in 
het vliegtuig terug was dit allang vergeten en keek ik terug op een mooie en leerzame reis. 
Alleen had ik dit proefschrift nooit kunnen maken en ik ben erg dankbaar voor alle mensen 
die mij onderweg hebben geholpen!
Mijn co-promotor Quinten: Zonder jouw eeuwige geduld en oneindige feedback was dit 
proefschrift er niet geweest. Dank dat ik door jou kritisch heb leren beschouwen en de wereld 
van het basale onderzoek heb leren kennen.
Johan: Jouw enthousiasme voor onderzoek werkte aanstekelijk. Jammer dat je er niet meer 
bij bent.
Promotor Hanne: Onze gesprekken over onderzoek en het ziekenhuisleven waren altijd 
interessant. Dank voor je vertrouwen.
Promotor Henk: Bij jou op de kamer was er ondanks de stapels dossiers altijd rust en onze 
maandelijkse afspraken gaven mij structuur. Dank daarvoor. 
Leescommissieleden Victor, Ruud, Inge en Hein: Dank voor de tijd die jullie in het lezen van 
mijn proefschrift hebben gestopt. 
Paranimf Saskia: Dank voor al je interesse, steun,  structuur en werk als vaste analist van onze 
groep. Ben blij dat je mijn paranimf wilt zijn!
Promotie genoten Chantal, Berber, Anneke H., Monique, Muriel, Stephanie, Atiq, Kash en 
Irsan: Al onze koffie, thee en pizza momenten, gezamenlijk cellen kweken, werkbesprekingen, 
maar ook de ‘pipet puntjes vul’ momenten waren waardevol. Super leuk om het doen van 
onderzoek met jullie gedeeld te kunnen hebben! Iedereen is onderwijl zijn eigen weg gegaan, 
maar ik blijf graag op de hoogte van jullie wegen. 
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Kamergenoot Maarten: Soms voelde ik me de echte nerd ten op zichte van jou. Dank voor 
je ondersteuning met interpreteren van next gen sequencing en array data. Zonder jou was 
dit echt niet gelukt!
Martin, Jesper, Anneke O., Davy, Yne, Jurgen  en Dominique: Dank voor jullie 
chromosoombreuktesten, western blots, transfecties, organiserende mailtjes en zo meer. Jullie 
inzet is en was belangrijk voor de continuïteit van het onderzoek bij Oncogenetica. 
Alle andere onderzoekers  Job, Najim, Sheba, Rob, Henri, Josephine, John Martens: Dank 
voor alle samenwerking.
Victor en Ida: Het optimaliseren en inzetten van de screen was een hele klus. Dank voor jullie 
ondersteuning. 
Studenten Sumira en Else: Door jullie inzet  in het laboratorium was er meer voortgang in 
mijn onderzoek, maar het was vooral leuk jullie te begeleiden! 
Alle collega’s in de VU en het Spaarne: Het combineren van opleiding en afronden van 
onderzoek was soms best tijdrovend. Maar dankzij collegialiteit, borrels, ski-uitjes, humor 
en gezellige koffie momenten een fantastische tijd. Alex (opleider Spaarne): Dank ook voor 
de extra tijd die ik kreeg tijdens mijn poli jaar om aan mijn promotieonderzoek te werken.
Aart, Anita, Bart en Jolande (oncologen Spaarne): Door jullie betrokken rol bij patiënten 
werd ook ik enthousiast voor de oncologie en rolde ik nietsvermoedend het onderzoek in.
Paranimf Robert: Eerst had ik de eer om jouw paranimf te zijn. Intussen zijn we alweer meer 
dan 4 jaar verder en  zijn de rollen omgedraaid. Je bent zeer ambitieus jouw weg gegaan bij de 
marine en nu anesthesie. Ik hoop dat we nog lang onze interesse in en buiten de geneeskunde 
kunnen delen. 
Jeroen: Hopelijk snel weer wat meer ruimte voor borrels en etentjes samen in Amsterdam na 
het afronden van dit proefschrift.  
Lieve vriendinnen Annerieke, Carolien, Daniëlle, Jitske, Laura, Liset en Yolande: Ook al 
snapten jullie af en toe echt niet waar ik nou op dat lab mee bezig was, er was altijd interesse 
en jullie probeerden zelfs mijn artikelen te lezen! Dank voor de vriendschap. 
Trudy en Laurens: Fijn dat wij nu bij jullie  in de buurt wonen en jullie kunnen meegenieten 
van ons gezin. Dank voor alle oppasmomenten! 
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Paps en Mams: Jullie hebben een enorme bijdrage geleverd aan hoe ik nu ben, maar ben 
natuurlijk ook mijn eigen weg gegaan. Het is grappig dat de wegen natuurlijkerwijs nu 
weer meer naar elkaar toe leiden. Dank voor jullie liefde en alle oppasmomenten voor Gijs. 
Hierdoor ben ik goed in staat mijn werk te doen en kon ik mijn proefschrift afronden! 
Lieve Maarten: Dit wordt natuurlijk een cliché einde van het dankwoord! Jouw oneindige 
liefde en directheid helpt mij staande te blijven in het drukke leven. Samen met jou en Gijs 
geniet ik van alle kleine en grote momenten. Ik hoop dat we samen nog heel veel (fiets)
tochten gaan maken! Ik hou van je. 
Janine
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